Title: Glymphatic flow resistance in humans measured by multifrequency impedance dispersion
Authors: Paul Dagum, MD, PhD<sup>1</sup>; Laurent Giovangrandi, PhD<sup>1</sup>; Swati Rane Levendovszky,
PhD<sup>2</sup>; Jake J. Winebaum<sup>1</sup>; Tarandeep Singh, MS<sup>1</sup>; Yeilim Cho, MD<sup>3</sup>; Robert M. Kaplan, PhD<sup>4</sup>;
Michael S. Jaffee, MD<sup>5</sup>; Miranda M. Lim, MD, PhD<sup>6,7,8</sup>; Carla Vandeweerd<sup>9,10</sup>, PhD; Jeffrey J.
Iliff, PhD<sup>3,11,12</sup>

7

Affiliations: <sup>1</sup>Applied Cognition Inc, Redwood City, CA; <sup>2</sup>Department of Radiology, University of 8 9 Washington School of Medicine, Seattle, WA; <sup>3</sup>VISN 20 NW Mental Illness Research, Education 10 and Clinical Center, VA Puget Sound Healthcare System, Seattle, WA; <sup>4</sup>Clinical Excellence Research Center, Stanford University School of Medicine, Stanford, CA;<sup>5</sup> Department of 11 Neurology, University of Florida Health, Gainesville, FL; <sup>6</sup>VISN 20 Northwest Mental Illness 12 13 Research, Education and Clinical Center (MIRECC), VA Portland Health Care System, 14 Portland, OR; <sup>7</sup>Neurology Service, Research Service, VA Portland Health Care System, Portland, OR: <sup>8</sup>Department of Neurology, Oregon Alzheimer's Disease Research Center, 15 16 Oregon Health & Science University, Portland, OR; <sup>9</sup>University of Florida Health Precision 17 Health Research Center, Clinical and Translational Science Institute, University of Florida, 18 Gainesville, FL; <sup>10</sup>Health Outcomes and Biomedical Informatics, College of Medicine, University 19 of Florida, Gainesville, FL; <sup>11</sup>Department of Psychiatry and Behavioral Science, University of Washington School of Medicine, Seattle, WA: <sup>12</sup>Department of Neurology, University of 20 21 Washington School of Medicine, Seattle, WA; 22

- 23 Corresponding Author:
- 24 Paul Dagum, MD, PhD
- 25 Applied Cognition Inc
- 26 1629 Main St.
- 27 Redwood City, CA 94063
- 28 paul@appliedcognition.com
- 29 Ph: (415) 378-5456
- 30

# 31 ABSTRACT

32 Glymphatic function in animal models supports the clearance of brain proteins whose mis-33 aggregation is implicated in neurodegenerative conditions including Alzheimer's and 34 Parkinson's disease. The measurement of glymphatic function in the human brain has been 35 elusive, limiting its potential in translational research. Here we described a non-invasive 36 multimodal device for the first-in-human continuous measurement of sleep-active glymphatic 37 flow resistance using repeated electrical impedance spectroscopy measurements through two 38 separate clinical validation studies. Device measurements successfully (i) paralleled sleep-39 associated changes in extracellular volume that regulate glymphatic function, (ii) replicated 40 preclinical findings showing glymphatic function is increased with increasing sleep EEG delta 41 power, and is decreased with increasing sleep EEG beta power and heart rate, and (iii) 42 predicted glymphatic solute exchange measured by contrast-enhanced MRI. The present 43 investigational device permits the continuous and time-resolved assessment of glymphatic flow 44 resistance in naturalistic settings necessary to determine the contribution of glymphatic 45 impairment to risk and progression of Alzheimer's disease, and to enable target-engagement 46 studies that modulate glymphatic function in humans. 47 Words 11957 48 Without methods 5467 49 50 51

# 53 INTRODUCTION

54 The glymphatic system is a brain-wide network of perivascular pathways along which the 55 cerebrospinal fluid (CSF) surrounding the brain exchanges with brain interstitial fluid, supporting 56 nutrient distribution and waste clearance (Figure 1a-b). In animal models, glymphatic function 57 supports the clearance of amyloid beta<sup>1,2</sup>, tau<sup>3-5</sup>, and alpha synuclein<sup>6,7</sup>, whose mis-aggregation 58 is implicated in the pathogenesis of neurodegenerative conditions including Alzheimer's and 59 Parkinson's disease. Glymphatic function is further postulated to be a mechanism for volume 60 transmission of the neurotransmitters acetylcholine, serotonin and norepinephrine, and of 61 neurohormones regulating brain-body homeostasis<sup>8</sup>. While this system is foundational to brain 62 health and disease, measurement of glymphatic function in the human brain, principally by 63 magnetic resonance imaging (MRI), is conducted in only a handful of academic neuroimaging 64 centers<sup>9</sup>. Without a consistent, reproducible and accessible way of measuring this important 65 neurobiology in humans, the promise of developing therapeutic interventions that target 66 glymphatic function to treat and prevent neurological and psychiatric diseases remains elusive. 67

68 Studies in rodents have demonstrated that glymphatic function is more rapid during sleep 69 compared to the awake state<sup>2,10</sup>. During periods of wakefulness, the interstitial space is narrow 70 and tortuous, forming a high-resistance pathway that suppresses glymphatic flow, while during 71 sleep fluid shifts from the intracellular compartment into the extracellular (interstitial) space, 72 widening these pathways, and enhancing glymphatic function by ~60% (Figure 1c-d). 73 Measuring glymphatic function across a range of physiological conditions demonstrated that 74 faster glymphatic exchange is associated with increased electroencephalogram (EEG) delta band power, decreased EEG beta power, and reduced heart rate<sup>11</sup>. Studies utilizing contrast-75 76 enhanced (CE)-MRI to measure solute exchange between the CSF and brain interstitial 77 compartments have confirmed in human participants more rapid glymphatic function during sleep<sup>12</sup>, although the poor temporal resolution of this approach<sup>13-15</sup> has not permitted the 78

relationship between EEG or cardiovascular features and glymphatic function to be defined inthe human brain.

81

82 Electrical impedance spectroscopy (EIS) is widely used in medicine for body composition analysis and for monitoring cellular changes in settings including tumors and edema<sup>16-19</sup>. When 83 84 alternating current is injected into tissue, at low frequencies the voltage drop depends primarily 85 on the resistive pathway of the extracellular (interstitial) fluid, while at high frequencies cell 86 membranes behave like capacitors allowing current to also pass relatively freely through the 87 intracellular space (**Figure 1c-e**). This frequency dependence is the  $\beta$ -dielectric dispersion of 88 the underlying tissue and its repeated measurement permits the detection of shifts in the 89 extracellular and intracellular distribution of water within tissue<sup>17,20</sup>.

90

91 We propose that the biophysics of EIS can be leveraged to measure the fluid shift that occurs 92 with changes in sleep-active glymphatic function. Because intracranial volume is constant, any 93 change in this frequency dependence across repeated EIS measures reflects changes in the 94 resistance of the extracellular space, which is inversely proportional to the extracellular fluid 95 volume (Figure 1c-e). Within the brain, the extracellular compartment includes the brain 96 interstitial space (~16% of total volume) and a combination of CSF (~10%) and blood plasma 97 (~6%)<sup>21</sup>. Small diurnal fluctuations occur in blood volume and in the CSF compartments, 98 however these changes are small and offset one another across physiological states<sup>22,23</sup>. In 99 contrast, sleep-wake differences in glymphatic function are associated with much larger shifts in 100 the intracellular and particularly interstitial volumes<sup>2</sup>. Thus, sleep-wake changes in EIS 101 measures will be sensitized to changes in brain intracellular and interstitial volume, and EIS-102 based measures of parenchymal resistance (R<sub>P</sub>) may represent a novel approach to track 103 sleep-active glymphatic function.



105

106 Figure 1. Detection of sleep-wake changes in glymphatic flow resistance by impedance 107 spectroscopy. a, Glymphatic function involves the influx of cerebrospinal fluid (CSF) influx along 108 perivascular spaces (PVSs) surrounding penetrating arteries (center). Glymphatic flow is driven by 109 arterial pulsations and vasomotor oscillations (right). Astrocytic endfoot processes create the barrier 110 between the PVS and the brain parenchyma, with gaps allowing CSF to exchange through the brain 111 interstitial space. The endfoot processes are studded with perivascular aguaporin-4 water channels 112 that also enable water to move into the astrocytes and out to the interstitial space. b, Data from 113 physiological studies in rodents suggest that glymphatic function is increased in conditions of 114 reduced heart rate, increased vasomotor pulsations, reduced EEG beta power, and increased EEG 115 delta power (Hablitz et al. 2019). c, The interstitial space is dynamically regulated. Under conditions 116 of low EEG delta power and high EEG beta power common to the awake state, it is narrow and 117 tortuous, forming a high-resistance pathway that suppresses glymphatic function. When alternating 118 current is injected into the brain parenchyma, at low frequencies the current cannot penetrate the 119 capacitive cell membranes and its propagation depends primarily on the resistive pathway of the 120 interstitial fluid. At high current frequencies, the current readily penetrates the capacitive cell 121 membranes and its propagation depends on the resistance of the total tissue volume. This frequency 122 difference is the  $\beta$ -dielectric dispersion of the underlying tissue. If the intracranial volume is constant, 123 a change in the dielectric dispersion reflects a change in the low-frequency resistance pathway of 124 the interstitial fluid. d, Under high EEG delta power and low EEG beta power common to the sleep 125 state, fluid shifts from the intracellular compartment into the interstitial space, enhancing glymphatic 126 function by ~60% in rodent studies (Xie et al. 2013). This widening of interstitial pathways reduces 127 the current resistance at low-frequencies which reduces the measured dielectric dispersion. e, An 128 impedance-frequency graph shows the change in dielectric dispersion between the two sleep/wake 129 EEG states. The change in glymphatic flow resistance between these two states is inversely 130 proportional to the relative change in the dielectric dispersion. f. Contrast-enhanced MRI following 131 intravenous gadolinium-based contrast agent (GBCA) injection shows vascular regions that enhance 132 immediately (t=30 min) upon GBCA injection (red), and CSF and brain parenchymal regions that 133 enhance late (t=3 hrs) after leakage of GBCA first into the CSF and thence into the brain interstitium 134 (green). A given MRI voxel includes GBCA within the blood, CSF and brain interstitial fluid 135 compartments.

136

137

138 We developed a wearable investigational device (Figure 2a-f) that overcomes several technical 139 challenges surrounding the implementation of EIS as a measure of glymphatic flow resistance. 140 To define the dynamic relationship between R<sub>P</sub>, sleep EEG features, and cardiovascular 141 parameters through the course of an overnight period, EIS measurements must be made with 142 high accuracy and temporal resolution. The investigational device performs measurements at 143 frequencies between 1kHz and 256kHz and has a  $\sim$ 3% measurement error in R<sub>P</sub> 144 (Supplemental 4) enabling it to detect small changes in dispersion between repeated 145 measures. It is important to ensure that device measurements are not affected by changes in 146 electrode impedances that can occur over time, including those caused by the effects of motion 147 on the electrode-skin interface. A non-traditional four-electrode impedance configuration was 148 used with multiple excitation and sense configurations in combination with low-impedance, non-149 polarizable electrodes. This ensured high-fidelity measurements including at low frequencies 150 due to the reduced sensitivity to motion artifacts, low noise, and stability of the skin-gel-151 electrode interface. A signal processing approach enabled identification of signal from noise 152 using the real and imaginary parts of the impedance to establish if the measured response is 153 related to the excitation signal or has been distorted by artifact. The device further integrated 154 shielded cables to reduce effects of electromagnetic interferences, both external and internal to 155 the device, and the design minimized stray capacitances affecting higher frequencies. The 156 device is described in more detail in **Methods** and **Supplemental Information** including 157 Supplemental Figure 2, Supplemental Figure 3 and Supplemental Tables 7 – 12. We note 158 that glymphatic flow is determined by the parenchymal resistance to flow and the motive force 159 driving CSF along the perivascular spaces (PVS) into the interstitial compartment. The 160 resistance measured by the device is transcranial with a high temporal resolution of changes in 161 global intracellular to interstitial fluid shifts.

162



163

# 164 **Figure 2. Technical schematic of investigational device and its output signals.** Data for

this study was acquired with a non-invasive multimodal skin-interfaced wireless device for

166 continuous measurement of brain parenchymal resistance using repeated electrical impedance

- 167 spectroscopy EIS time-multiplexed with EEG and cardiovascular measurements. EEG 168 differential measurements were made between the two in-ear electrodes and a left mastoid was
- 169 used to drive the common mode. These electrodes were shared with the EIS and the two
- 170 measurements were time-multiplexed with a pair of analog multiplexers that decoupled EEG

and EIS. The transcranial multi-frequency alternating current injections created an electric field

172 through the brain and orthogonal equipotential surfaces. a, Each in-ear electronics housed PPG

- and IMU sensors. **b**, Data from the sensors were stored on the device's FLASH memory and
- transferred via a USB port to a cloud signal processing pipeline for offline analysis. Data from a
- participant visit is shown, which includes the device EEG periodogram and hypnogram. c, The
   EIS resistance and reactance frequency plots for this participant reveal an approximate 2000
- 176 EIS resistance and reactance frequency plots for this participant reveal an approximate 2000 177 mOhm change in the dielectric dispersion during the sleep visit. **d**, The IPG respiratory and
- cardiac impedance variations are 120 m $\Omega$  and 50 m $\Omega$ , respectively. **e**, Cardiac ejection of blood
- 179 is detected by the in-ear IMUs in the ballistocardiogram. The J peak of the ballistocardiogram
- 180 marks the aortic valve opening. **f**, Time delay between the ballistocardiogram and in-ear PPG

181 measures the pulse-transit time (PTT) to the that ear.

- 182
- 183

# 184 **RESULTS**

185 Data were acquired using the investigational medical device developed by Applied Cognition 186  $Inc^{24,25}$ . Transcranial impedance dispersion is estimated from each EIS measure using a 187 dielectric relaxation model. In addition to EIS measurements, the device measures EEG, 188 photoplethysmogram (PPG), impedance plethysmogram (IPG) and head motion (Figure 2a-f). 189 We propose that the change in transcranial impedance dispersion, which we will henceforth 190 term parenchymal resistance  $R_P (R_P = R_0 - R_{\infty})$ , reflects shifts in brain intracellular and 191 interstitial compartment fluid volumes that underlie changes in glymphatic function (Figure 1c-192 e). Supplemental 3 contains an intuitive justification of the physiological connection between 193 EIS change and changes in glymphatic function. To test this, we evaluated whether  $R_P$ 194 measured with this device in human participants aligned with the central features of glymphatic 195 function described in rodent models<sup>2,11</sup>.

196

# 197 Study Design

198 We conducted two clinical studies (denoted as "Benchmarking Study" and "Replication Study") 199 to validate the performance of the device's R<sub>P</sub> measure as a surrogate of glymphatic flow 200 resistance during sleep and wake (Figure 3, top). Both studies were cross-over trials where 201 participants wearing the investigational device were subjected to one night of natural sleep and 202 one night spent awake, separated by two or more weeks. The Benchmarking Study was 203 conducted in The Villages® community, an active-lifestyle senior living community in Central 204 Florida where the University of Florida maintains a satellite academic research center, The 205 University of Florida Health Precision Health Research Center (UF Health PHRC). The 206 Benchmarking Study was designed to define the effect of sleep on overnight R<sub>P</sub> measurements. 207 as well as the relationship between  $R_P$  and glymphatic function. It included overnight device 208 recordings, overnight gold-standard polysomnography (PSG), and morning contrast-enhanced 209 magnetic resonance imaging (CE-MRI) following intravenous gadolinium-based contrast agent

210 (GBCA) administration as a measure of glymphatic function. During the morning period, 211 following pre-contrast MRI scanning, GBCA injection, and immediate post-contrast MRI 212 scanning (totaling 2.5 hours spent awake), participants that were sleep deprived overnight were 213 provided a 1.5 hr sleep opportunity prior to the final MRI scan, while those that slept normally 214 overnight were kept awake during the 1.5 hr period (Figure 3, top). We evaluated whether, as 215 predicted from prior rodent studies on the sleep-modulation of glymphatic function<sup>2,11</sup>, **a**)  $\mathbb{R}_{P}$  is 216 reduced in sleeping compared to awake participants, **b**) whether reduced  $R_P$  is associated with 217 more rapid CSF-brain interstitial solute exchange measured by CE-MRI. c) whether  $R_P$  is 218 associated with increasing sleep EEG delta power and decreasing sleep EEG beta power, and 219 d) whether reduced  $R_P$  is associated with decreasing heart rate. The Replication Study 220 conducted at the University of Washington did not include overnight PSG or morning CE-MRI 221 and had as a primary outcome confirming the effect of sleep state on device-measured R<sub>P</sub>, and 222 secondary outcomes confirming the associations between  $R_P$  and sleep stages, heart rate, and 223 EEG spectral band power. As noted in the detailed study description in the Methods section, 224 these studies also evaluated novel non-contrast MRI measures of glymphatic function, sleep-225 sensitive changes in cognitive function, and sleep-sensitive changes in plasma Alzheimer's 226 disease biomarkers across a range of physiological sleep conditions. Those findings will be 227 reported elsewhere.

228

#### 229 Inclusion and Exclusion Criteria

230 All studies were performed between October 2022 – June 2023 and were reviewed and

approved by University of Florida Institutional Review Board (IRB No. 202201364,

232 Benchmarking Study) and Western Institutional Review Board (IRB No. 20225818, Replication

233 Study). The studies have been registered at ClinicalTrials.gov

234 (https://clinicaltrials.gov/study/NCT06222385 and https://clinicaltrials.gov/study/NCT06060054 ).

235 Written informed consent was obtained from all study participants during a screening visit, prior



240 morning device recordings, overnight and morning gold-standard polysomnography (PSG), and morning 241 contrast-enhanced magnetic resonance imaging (CE-MRI) following intravenous gadolinium-based 242 contrast agent (GBCA) administration as a measure of glymphatic function. Primary and secondary 243 outcome data not reported here included blood analysis of amyloid  $\beta$  and tau levels, cognitive 244 assessment, and non-contrast MRI. b, The Replication Study conducted at the University of Washington 245 had a primary outcome of confirming the effect of sleep state on device-measured R<sub>P</sub>, and secondary 246 outcomes of confirming the associations between R<sub>P</sub> and sleep stages, heart rate, and EEG spectral 247 band power. The Replication Study also included secondary outcomes on blood analyses for amyloid  $\beta$ 248 and tau levels, cognitive assessment and non-contrast MRI. c, The Benchmarking Study enrolled 34 249 participants of which 30 completed both visits. Three were censored due to changes in device data 250 collection and sensor locations. One withdrew following the first MRI scan. Of the 30 that completed the 251 study, 5 overnight sleep visits and 8 overnight wake visits failed the data quality control (QC) criteria to 252 provide sufficient artifact free data to yield results. This resulted in 25 sleep and 22 wake device, PSG 253 and MRI complete data sets. Of these, 20 sleep and 21 wake device participants had complete data from 254 both the overnight and morning sleep/wake periods. The Replication Study enrolled 14 participants. All 14 255 completed the study, of which 3 wake visits failed the data QC criteria and no sleep visit failed. (sleep op,

256 sleep opportunity)

236 237

238

257 to any study activities. Studies were carried out in accordance with the principles of the Belmont Report. The Benchmarking Study enrolled 34 healthy participants 56-66 years of age. The 258 259 Replication Study enrolled 14 healthy participants 49-63 years of age. Participants were 260 excluded if they had cognitive impairment or clinical depression. Cognitive impairment was assessed using the Montreal Cognitive Assessment<sup>26</sup> (MoCA, 28.1 +/- 1.2; range 26, 30) and 261 262 depression was evaluated using the 15-item Geriatric Depression Scale<sup>27</sup> (GDS, 0.7 +/- 1.1; 263 range 0, 4). Participants with a self-reported history of diabetes, hypertension, coronary artery 264 disease, pulmonary disease, neurological disease, depression or anxiety were also excluded 265 from the study, as were participants planning travel to alternate time zones within two weeks of 266 study participation. Participant demographics, MoCA and GDS scores are listed for each study, 267 and for the combined dataset in Supplemental Table 1.

268

269 A Consolidated Standards of Reporting Trials (CONSORT) diagram for the Benchmarking Study 270 and Replication Study is provided in Figure 3 (bottom). Within the Benchmarking Study, the first 271 three participants were removed from analysis because of a design change in the 272 investigational device sensor positions. One participant was unable to complete the first MRI 273 session and withdrew from the study. Of the remaining 30 participants ( $61.8 \pm 2.7$  years of age; 274 14 female, 16 male) that completed the Benchmarking Study, five overnight sleep studies and 275 eight overnight wake studies failed data quality control due to excessive artifacts in the 276 recordings, leaving 25 overnight sleep studies and 22 overnight wake studies in the 277 Benchmarking Study with complete device, PSG and MRI data. Excessive movement artifacts 278 during the morning recording periods resulted in the exclusion of data from five additional 279 morning wake and one additional morning sleep opportunity periods, leaving 20 overnight 280 sleep/morning wake and 21 overnight wake/morning sleep opportunity datasets with complete 281 overnight and morning data. All participants enrolled in the Replication Study (55.6  $\pm$  4.6 years

of age; 7 female, 7 male) completed the protocol. All overnight sleep data were usable, but three overnight wake studies were removed, two because of excessive artifact and one because of non-compliance with the wake protocol. The higher number of quality control failures in the Benchmarking Study was largely due to the physical challenges caused by simultaneous data acquisition from both PSG and investigational device on the same night. Note that when the investigational device was used in the absence of PSG in the Replication Study, quality control failures were less frequent and restricted to motion artifacts in the awake condition.

289

# 290 Assessment of sleep and wake changes in parenchymal resistance

291 Study participants underwent one night of normal sleep and one night of sleep deprivation 292 separated by 2-4 weeks. Sleep/wake or wake/sleep visit order was determined by random 293 assignment following informed consent. In the Benchmarking Study, sleep and wake status was 294 confirmed by PSG with anticipated differences in rapid eve movement (REM), and non-REM 295 (NREM: N1, N2, N3) sleep stages observed between sleep and wake conditions. Similar 296 differences were observed in the Replication Study, in which investigational device-based EEG 297 was used to evaluate sleep parameters. EEG was assessed with the investigational device in 298 both the Benchmarking and Replication Studies; these measures were used when combining 299 EEG parameters between both studies. Averaged hypnograms showing sleep stage distribution 300 throughout the overnight sleep period for the Benchmarking and Replication Studies are shown 301 in **Figure 4a-b** (top), respectively. The averaged hypnogram for the overnight and morning 302 periods for the Benchmarking study participants with complete data during both periods is 303 shown in Figure 4c (left).

304

305 During the overnight period R<sub>P</sub> was continuously monitored. The results from the Benchmarking
 306 Study are provided in Figure 4a (bottom), which depicts the mean and standard errors of
 307 overnight R<sub>P</sub>. Each participant's R<sub>P</sub> was normalized to the R<sub>P</sub> at onset of the observation period,

308 and linear interpolation was used for missing R<sub>P</sub> values within each participant. Compared to the 309 wake condition, overall R<sub>P</sub> during sleep was reduced by 8% (Wake 1.00  $\pm$  0.06, Sleep 0.92  $\pm$ 310 0.06, T-test p < 0.001). When evaluated through the course of the overnight period, the  $R_P$ 311 during the wake period remained largely constant. In contrast, during the sleep period the mean 312  $R_P$  decreased monotonically, reaching at the end of the sleep period a nadir ~20% lower than at 313 onset or under the awake condition. Similar results were observed the Replication Study 314 (Figure 4b, bottom). Within the Benchmarking study, participants that were sleep deprived 315 overnight received a 1.5 hr sleep opportunity in the morning. Over this period, R<sub>P</sub> began at a 316 higher value (resulting from overnight sleep deprivation) but declined over the 1.5 hr sleep 317 opportunity (Figure 4c, right). Among participants that slept overnight but were kept awake in 318 the morning,  $R_P$  during the morning period began at a low value (resulting from overnight sleep) 319 but increased over the 1.5 hr period of wakefulness. These data demonstrate across two study 320 populations that  $R_P$  remains constant or increases during periods of waking but declines steadily 321 through periods of sleep.

322

# 323 Association between sleep parameters and glymphatic function

324 Following the overnight sleep periods, participants in the Benchmarking Study underwent CE-325 MRI for the assessment of glymphatic function. Beginning at 7am, participants underwent a pre-326 contrast T1-weighted MRI scan, received intravenous GBCA (Gadavist, 0.1 mmol/kg), followed 327 by T1-weighted MRI scans at 7-10 min ( $T_{10}$ ) and 240 min ( $T_{240}$ ) post-injection. We evaluated 328 contrast enhancement in eight regions of interest (ROIs): frontal cortical gray and white matter, 329 parietal cortical gray and white matter, temporal cortical gray and white matter, and occipital 330 gray and white matter. Contrast enhancement at the  $T_{10}$  time point primarily reflects GBCA 331 within the blood column, while enhancement at the  $T_{240}$  time point reflects GBCA leakage into 332 the cerebrospinal fluid (CSF) and into the brain interstitial compartments<sup>14,15</sup>. Glymphatic 333 function was defined by measuring brain parenchymal contrast enhancement, the % change in



**Overnight EEG and Parenchymal Resistance** 

Overnight + Morning EEG and Parenchymal Resistance: Benchmarking Study



334

335 Figure 4. Brain parenchymal resistance is reduced periods of sleep. a. Averaged EEG hypnograms 336 from the sleep condition are shown for the overnight period of the Benchmarking Study with WASO 337 excluded in both the hypnograms and sleep  $R_P$  (top). Over that period, parenchymal resistance ( $R_P$ , 338 bottom) remained constant during the awake state (red) but declined gradually in the sleep state (green). 339 b. Similar trends were observed in the Replication Study. c. During the morning period of the 340 Benchmarking Study, participants underwent a 1.5 hr sleep opportunity or period of wakefulness. 341 Averaged EEG hypnograms for the overnight and morning periods are shown at left. At right, during the 342 morning awake period, R<sub>P</sub> increased gradually (dashed red), while it declined gradually during the sleep 343 state (dashed green). Parenchymal resistances  $R_P$  shown (a), (b) and (c) are the average across the 344 participants after normalizing each participant's RP measurements by their value at onset of the sleep or 345 wake period.  $R_P$  in (c) for morning wake is plotted starting at the ending value of overnight  $R_P$  for 346 illustration purposes. Standard error of the means are shown for each plot in light grey. The combined 347 overnight and morning Benchmarking Study (c) includes participants who's overnight and morning data 348 passed quality controls.

T1-weighted signal intensity between 10-240 min post-GBCA injection ( $100\% * (T_{240}-T_{10})/T_0$ ) within each ROI.

352

353 To evaluate different sleep-related contributions to glymphatic function, we developed a general 354 random intercept mixed model with eight ROI groups fit to the T<sub>10</sub>-T<sub>240</sub> change in brain 355 parenchymal enhancement. Our null hypothesis was that parenchymal contrast, including 356 contrast in the interstitial compartment, was not influenced by sleep variables. Glymphatic 357 function supports the movement of solutes into and out of the brain interstitial compartment, yet 358 brain parenchymal enhancement includes contrast signal from the blood compartment (the 359 initial source of the GBCA) and the CSF compartment (the intermediate space linking the blood 360 and brain interstitium) in addition to the interstitial compartment (Figure 1f). Thus, we defined 361 the **null model** to include regressors for vascular and CSF contrast in the mixed model: the  $T_{10}$ -362 T<sub>240</sub> change in blood signal within the internal carotid artery, and the T<sub>10</sub>-T<sub>240</sub> change in CSF 363 signal within the cerebral lateral ventricles. We also included the confounding biological 364 variables of age, gender, and APOE £4 status in the null model shown in Supplemental 365 (bottom). The analyses of EEG powerbands, heart rate and sleep staging were performed on 366 the overnight sleep period recordings. Pulse plethysmography and EEG were acquired 367 concurrently and heart rate, EEG powerbands, sleep stage durations (REM; N1, N2, N3 368 NREM), number of awakenings and wake after sleep onset (WASO) were computed and 369 included independently in the null model (Supplemental Table 2), and likelihood ratio tests 370 used to compare the individual predictor model with the null model. Relative EEG delta, theta, 371 alpha and beta powerbands were each expressed as the overnight mean of the powerband 372 normalized to the average powerband value of the first three sleep epochs. Higher EEG delta 373 power (mean 19.12, 95% CI 5.4819, 32.7599; P=0.0072), lower EEG alpha (mean -7.28, 95% 374 CI -12.2638, -2.2935; P=0.0052) and beta (mean -5.33, 95% CI -7.7859, -2.8728; P<0.001) 375 power were significantly associated with greater contrast enhancement. We next evaluated 376 EEG-derived sleep stages within individual mixed models. Neither number of awakenings during

377	the sleep period, nor wake after sleep onset (WASO) were associated with parenchymal
378	contrast enhancement. Lower N1 sleep time was significantly associated with greater
379	parenchymal contrast enhancement (mean -0.1274, 95% CI -0.2130, -0.0420; P=0.0043), while
380	N2, N3 and REM sleep time had no significant association with parenchymal enhancement
381	within these individual models (Supplemental Table 2). Thus, within individual mixed models,
382	increased overnight EEG delta band power, reduced alpha and beta band power, and reduced
383	time in N1 sleep are each associated with greater glymphatic function, each rejecting the null
384	hypothesis that parenchymal contrast was not influenced by sleep variables (Supplemental
385	Table 2).
386	
387	Direct association between parenchymal resistance and glymphatic function
388	The device $R_P$ values were computed repeatedly throughout the overnight sleep period from
389	each EIS scan. During sleep recordings, the $R_{\mbox{\tiny P}}$ was non-stationary, decreasing throughout the
390	night as shown in Figure 4a-c. We observed that lower overnight $R_P$ was significantly
391	associated with higher glymphatic contrast enhancement (mean -38.08, 95% CI -61.34805, -
392	14.8115; P=0.0018, <b>Supplemental Table 2</b> ).
393	
394	Combined effects of overnight parenchymal resistance, EEG spectral power, and heart
395	rate on glymphatic function
396	We next utilized a comprehensive mixed model to define the contributions of $R_P$ , EEG spectral
397	band power, and heart rate to parenchymal contrast enhancement. As in the individual mixed
398	models above, this comprehensive model extended the null model that contains only contrast
399	enhancement in the blood and cerebral ventricles as regressors, and age, APOE4 status, and
400	gender as confounding biological variables. We evaluated the relative delta, theta and beta
401	powerbands, omitting the alpha powerband to avoid multicollinearity in the model. We subjected
402	the model to a backward elimination algorithm with a Wald's p-value threshold of 0.05. Table 1

provides the full outputs of the analyses for each of the four intervention periods of overnight
sleep opportunity, morning sleep opportunity, overnight sleep deprivation and morning awake of
the study (Figure 3, top).

406

407 In reference to the models selected by backward elimination shown in **Table 1**, as expected,

408 both blood and ventricular CSF contrast enhancement were strongly associated with

409 parenchymal enhancement following the overnight sleep opportunity (blood mean 8.89; 95% CI

410 3.62, 14.16; P = 0.001; CSF mean 170.45; 95% CI 143.86, 197.04; P<0.001) and overnight

411 sleep deprivation (blood mean 13.09; 95% CI 7.09, 19.10; P < 0.001; CSF mean 162.36; 95%

412 CI 129.54, 195.19; P<0.001). For the overnight sleep opportunity, lower heart rate (mean -

413 54.48, 95% CI -79.51, -29.45; P<0.001) and lower  $R_P$  (mean -52.55, 95% CI -74.76, -33.33;

414 P<0.001) predicted greater contrast enhancement. Reduced EEG beta power predicted greater

415 parenchymal enhancement (mean -6.29, 95% CI -8.54, -4.05; P < 0.001), while neither delta nor

theta power exhibited significant associations within the multivariate model. In the overnight

417 sleep deprivation condition, reduced EEG delta power (mean -20.77, 95% CI -34.34, -7.20; P =

418 0.004) and increased theta power (mean 7.89, 95% CI 1.13, 14.64; P = 0.026) predicted greater

419 parenchymal enhancement, while neither beta power, heart rate nor R<sub>P</sub> showed significant

420 associations within the multivariate model.

421

## 422 Combined effects of morning parenchymal resistance, EEG spectral power, and heart

#### 423 rate on glymphatic function

424 As shown in the study schematic (Figure 3, top), between 7:10 am and 9:30am (140 min post-

425 injection, T<sub>140</sub>) participants underwent MRI scanning followed by instrumentation with the

426 investigational device and PSG for the morning sleep opportunity or awake intervention.

427 Because the mean terminal half-life of intravenous GBCA in adults with normal renal function is



429

430 **Figure 5. Effect of sleep stages on** R<sub>P</sub>. The mean first-order difference  $\Delta$ R<sub>P</sub> is shown by sleep 431 stage and study for the overnight sleep period with 95% confidence intervals. During N2, N3

432 and REM sleep  $\Delta R_P$  is negative for each study and when combined reaches significance.

- 433 Benchmarking N2 (mean -3.21, 95% CI -9.07, -0.33; P = 0.113), N3 (mean -9.07, 95% CI -434 17.04, -3.75; P = 0.005), REM (mean -8.01, 95% CI -25.64, -1.18; P = 0.133). Replication N2
- 435 (mean -12.46, 95% CI -34.94, -1.49; P = 0.115), N3 (mean -16.04, 95% CI -25.32, -5.32; P =
- 436 0.002), REM (mean -16.24, 95% CI -42.19, -4.65; P = 0.065). Combined N2 (mean -6.10, 95%
- 437 CI -14.78, -1.71; P = 0.04), N3 (mean -10.91, 95% CI -17.35, -5.93; P < 0.001), REM (mean -
- 438 10.75, 95% CI -23.86, -3.91; P = 0.023). Units of  $\Delta R_P$  are m $\Omega$ .
- 439
- 440

441	109 min <sup>28</sup> , the post-injection blood contrast during the morning recordings was 60% cleared by
442	$T_{140}$ and 80% cleared by $T_{240}.$ Glymphatic function in the period between $T_{140}$ and $T_{240},$ would
443	therefore dilute existing parenchymal contrast with CSF having 60% to 80% lower contrast
444	concentration, a process analogous to 'clearance' of interstitial contrast. Thus, we would expect
445	that an increase in glymphatic function during the period between $T_{140}$ and $T_{240}$ would be
446	reflected as reduced parenchymal contrast enhancement at $T_{240}$ (Supplemental Figure 1).
447	
448	In reference to the models selected by backward elimination in Table 1, once again both blood
449	and ventricular CSF contrast enhancement were strongly associated with parenchymal
450	enhancement following the morning sleep opportunity (blood mean 11.73; 95% CI 7.89, 15.57;
451	P < 0.001; CSF mean 145.25; 95% CI 125.08, 165.42; P<0.001) and awake intervention (blood
452	mean 9.83; 95% CI 5.37, 14.29; P < 0.001; CSF mean 232.52; 95% CI 210.27, 254.77;
453	P<0.001). During the morning sleep opportunity, $R_P$ begins to decrease ( <b>Figure 4c</b> ). Higher
454	EEG delta power (mean -35.94, 95% CI -44.10, -27.78; P < 0.001) and lower $R_{\rm P}$ (mean 55.35,
455	95% CI 33.01, 77.70; P < 0.001) predicted reduced parenchymal enhancement (greater
456	contrast clearance).
457	
458	During the morning awake period, $R_P$ increases from its overnight sleep ending level ( <b>Figure</b>
459	4c). During this intervention, higher EEG delta power (mean -20.98, 95% CI -30.19, -11.77; P <
460	0.001), theta power (mean -15.27, 95% CI -19.51, -11.03; P < 0.001) and beta power (mean -
461	21.38, 95% CI -24.34, -18.43; P < 0.001) predicted greater contrast clearance as did lower heart
462	rate (mean 235.70, 95% CI 201.64, 269.76; P < 0.001) and lower $R_{\rm P}$ (mean 29.38, 95% CI 5.63,
463	53.13; $P < 0.021$ ). These findings are similar to those observed for the morning sleep
464	opportunity and consistent with the explanation that an increase in glymphatic influx of CSF
465	during this period dilutes the ISF contrast concentration and reduces the $T_{240}$ MRI signal
466	intensity.

		Full Model			Selected Model			Bootstrap Analysis			
Predictor Period	Fixed Effect Predictors	Estimate	CI	р	Estimate	СІ	р	Bootstrap Inclusion Frequency (%)	RMSD Ratio	Relative Conditional Bias (%)	Bootstrap Median
	Blood CE	10.57	(4.89, 16.25)	<0.001	8.89	(3.62, 14.16)	0.001	100	1.00	-11.89	9.22
	CSF CE	169.37	(141.53, 197.22)	<0.001	170.45	(143.86, 197.04)	<0.001	100	0.96	0.70	171.06
	Age	0.50	(-0.03, 1.04)	0.071	-	_	-	29.8	1.40	63.40	0
	Male Sex	-6.10	(-9.89, -2.31)	0.002	-2.98	(-5.63, -0.34)	0.030	61.0	1.10	-29.97	-3.19
Overnight	APOE ε4	5.13	(1.89, 8.37)	0.003	4.29	(1.13, 7.46)	0.010	71.2	0.84	-1.90	4.08
Opportunity	R₽	-55.47	(-77.74, -33.20)	<0.001	-52.55	(-74.76, -30.33)	<0.001	70.2	1.03	2.38	-49.70
opportunity	Delta Power	12.69	(-1.93, 27.32)	0.098	-	-	-	28.0	1.25	-15.65	0
	Theta Power	-8.69	(-18.01, 0.63)	0.075	-	-	-	18.4	1.77	-9.60	0
	Beta Power	-5.21	(-8.11, -2.32)	0.001	-6.29	(-8.54, -4.05)	<0.001	98.4	1.03	14.11	-5.96
	Heart Rate	-81.28	(-112.92, -49.63)	<0.001	-54.48	(-79.51, -29.45)	<0.001	93.0	1.63	-26.68	-57.59
	Blood CE	10.76	6.24, 15.29	<0.001	11.73	(7.89, 15.57)	<0.001	99.6	0.89	3.26	11.30
	CSF CE	154.87	125.96,183.78	<0.001	145.25	(125.08, 165.42)	<0.001	100.0	1.02	-0.58	151.27
	Age	-1.38	-1.95, -0.81	<0.001	-1.26	(-1.74, -0.79)	<0.001	99.6	1.05	-1.70	-1.33
Manulau	Male Sex	-0.36	-2.75, 2.02	0.771	-	-	-	13.6	2.38	425.36	0
Morning	APOE ε4	-2.89	-6.31, 0.53	0.109	-3.94	(-6.74, -1.15)	0.007	53.6	1.17	58.42	-3.17
Opportunity	RP	56.58	32.87, 80.29	<0.001	55.35	(33.01, 77.70)	<0.001	98.6	1.03	-5.03	53.67
oppontanti	Delta Power	-39.36	-51.30, -27.42	<0.001	-35.94	(-44.10, -27.78)	<0.001	100.0	1.03	-2.48	-37.30
	Theta Power	9.01	-6.18, 24.20	0.259	-	-	-	40.0	1.26	74.24	0
	Beta Power	-2.68	-12.06, 6.70	0.585	-	-	-	24.0	1.85	190.46	0
	Heart Rate	72.92	44.23, 101.62	<0.001	77.55	(49.74, 105.35)	<0.001	100.0	0.88	5.61	77.21
	Blood CE	7.42	-0.407, 15.25	0.076	13.09	(7.09, 19.10)	<0.001	56.6	1.59	72.95	8.57
	CSF CE	199.82	152.77, 246.87	<0.001	162.36	(129.54, 195.19)	<0.001	100.0	1.81	-0.67	193.14
	Age	0.06	-0.60, 0.72	0.871	-	_	-	4.0	2.01	-118.25	0.
	Male Sex	-6.53	-10.37, -2.70	0.002	-4.81	(-8.05, -1.57)	0.005	90.8	0.96	1.08	-6.23
Overnight	APOE ε4	6.17	-0.71, 13.05	0.093	-	_	-	58.4	1.60	60.69	6.40
Sleep Deprivation	RP	12.37	-31.98, 56.71	0.600	-	_	-	8.8	1.31	199.07	0
	Delta Power	-31.79	-54.44, -9.13	0.009	-20.77	(-34.34, -7.20)	0.004	85.4	1.24	12.63	-30.78
	Theta Power	19.96	7.38, 32.53	0.003	7.89	(1.13, 14.64)	0.026	83.8	1.45	7.75	19.85
	Beta Power	-17.30	-32.72, -1.89	0.036	-	_	-	62.0	1.26	42.29	-17.71
	Heart Rate	-25.01	-63.14, 13.11	0.218	-	_	-	44.2	1.75	97.16	0
	Blood CE	10.58	5.67, 15.49	<0.001	9.83	(5.37, 14.29)	<0.001	98.0	0.86	-5.59	9.91
	CSF CE	232.82	210.603, 255.04	<0.001	232.52	(210.27, 254.77)	<0.001	100.0	1.07	0.84	233.00
	Age	-0.88	-1.72, -0.04	0.049	-0.72	(-1.43, -0.01)	0.057	63.8	1.14	28.44	-0.81
	Male Sex	0.96	-1.69, 3.61	0.495	-	-	-	20.2	2.18	223.65	0
Morning	APOE ε4	11.02	8.30,13.74	<0.001	10.54	(8.16, 12.92)	<0.001	100.0	1.63	-2.35	10.62
Awake	R₽	25.30	-0.93, 51.53	0.071	29.38	(5.63, 53.13)	0.021	64.0	1.15	51.96	30.70
	Delta Power	-22.53	-32.67, -12.39	<0.001	-20.98	(-30.19, -11.77)	<0.001	98.6	1.38	-5.75	-21.33
	Theta Power	-15.37	-19.62, -11.134	<0.001	-15.27	(-19.51, -11.03)	<0.001	100.0	1.15	-2.22	-15.00
	Beta Power	-21.09	-24.15, -18.04	<0.001	-21.38	(-24.34, -18.43)	<0.001	100.0	1.13	0.73	-21.42
	Heart Rate	230.91	194.43, 267.38	<0.001	235.70	(201.64, 269.76)	<0.001	100.0	1.19	0.74	234.67

# 467 Table 1. Multivariate models of brain parenchymal contrast enhancement using R<sub>p</sub>, HR and EEG power band predictors.

468 Parenchymal Resistance, R<sub>P</sub>; Heart Rate, HR; Contrast Enhancement, CE; 95% Confidence Interval, CI; Backward Elimination, BE;

469 Root-Mean Square Deviation, RMSD; within ROI variability,  $\sigma^2$ ; inter-ROI variability,  $\tau_{00 \text{ ROI}}$ . Bolded P values reflect significant

470 **associations at P < 0.05**. Shaded cells demark the **null model** that includes blood CE, CSF CE and potential biological

471 confounders.

472 We used bootstrap analysis of the backward elimination algorithm for stability investigations on 473 the impact of variable selection on bias and variance of the regression coefficient and bootstrap 474 inclusion frequencies. We estimated the multivariate model using the backward elimination 475 algorithm on 500 bootstrap data replicates with replacement for each intervention period (Table 476 1). The bootstrap inclusion frequency represents the percent of the 500 backward elimination 477 models that retained each variable, while the bootstrap median is the median estimate for that 478 variable. The relative conditional bias quantified the omitted variable selection bias of each 479 variable from inclusion/non-inclusion of other variables from the full model. In the overnight 480 sleep opportunity, in addition to vascular and CSF contrast enhancement (each with an 481 inclusion frequency of 100%),  $R_P$  (70.2%), EEG beta power (98.4%), and heart rate (93.0%) had 482 high bootstrap inclusion frequencies and bootstrap median estimates comparable to the 483 selected model estimates. Device-measured R<sub>P</sub> and ventricular contrast enhancement had the 484 lowest relative conditional bias, and therefore their predictions of parenchymal contrast uptake 485 were least affected by inclusion of the other variables. Findings in the morning sleep opportunity 486 also showed high inclusion frequencies of the variables retained in the backward elimination 487 algorithm on the full data set and bootstrap median estimates comparable to the selected model 488 estimates, with vascular contrast enhancement (99.6%), CSF contrast enhancement (100%), RP 489 (98.6%), EEG delta power (100%), and heart rate (100%). These regressors also had low 490 relative conditional bias. These analyses suggest high model stability to perturbations of the 491 data set<sup>29</sup>.

492

Lastly, we computed the percent of the residual variance of the null model that was explained by including EEG power band, heart rate and R<sub>P</sub> regressors for each intervention and computed the LRT between the null model and the intervention models. For the overnight sleep and sleep deprivation interventions, 24.5% and 12.7% of the residual null model variance was explained by including these regressors, respectively. The null hypothesis that parenchymal contrast

enhancement is not influenced by these variables was rejected for the overnight sleep model
(likelihood ratio 52.6, p-value < 0.001) and the sleep deprivation model (likelihood ratio 14.1, p-</li>
value = 0.015). Including the regressors in morning sleep and awake models explained 38.3%
and 74.8% of the residual null model variance, respectively. The null hypothesis that the
parenchymal contrast enhancement is not influenced by these variables during the morning
sleep (likelihood ratio 79.5, p-value < 0.001) and awake condition (likelihood ratio 149.6, p-value</li>
< 0.001) were also both rejected.</li>

505

# 506 **Combined effects of parenchymal resistance and sleep stages on glymphatic function**

507 We developed a second comprehensive mixed model to define the relationship among R<sub>P</sub>,

508 sleep stages, heart rate and parenchymal contrast enhancement. As above, this comprehensive

509 model extended the null model that contained contrast enhancement in the blood and cerebral

510 ventricles as regressors, and age, APOE4 status, and gender as confounding biological

511 variables. We evaluated WASO time, and time in N1, N2, N3 and REM sleep stages.

512 **Supplemental Table 3** provides the model output for the overnight sleep opportunity (top) and 513 the morning sleep opportunity (bottom). In the overnight sleep opportunity model selected by 514 backward elimination, as before lower R<sub>P</sub> was significantly associated with greater parenchymal 515 contrast enhancement (mean -67.17; 95% CI -87.78, -46.56; P<0.001). In this model, more time 516 in REM sleep (mean 0.16; 95% CI 0.09, 0.23; P<0.001), and less time in N1 (mean -0.32; 95% 517 CI -0.43, -0.21; P<0.001), N2 (mean -0.10; 95% CI -0.15, -0.06; P<0.001), N3 (mean -0.07; 95% 518 CI -0.12, 0.02; P=0.007) sleep and WASO (mean -0.07; 95% CI -0.12, -0.02; P=0.006) were 519 each associated with greater contrast enhancement. Bootstrap analysis showed that blood and 520 CSF contrast enhancement (each with an inclusion frequency of 100%), as well as  $R_{\rm P}$  (100%), 521 REM sleep time (99.0%), N1 sleep time (98.8%) and N2 sleep time (98.0%) were the most 522 stable elements of the model relating sleep stages to parenchymal glymphatic function, while 523 the RMSD ratio for N2 sleep time, N3 sleep time and WASO showed substantial variance

deflation following backward elimination (Supplemental Table 3) that is associated with weak
 or noise predictors.

526

- 527 In the morning sleep opportunity model selected by backward elimination, lower R<sub>P</sub> was
- 528 significantly associated with greater parenchymal contrast clearance (mean 34.42; 95% CI 5.25,
- 529 63.59; P = 0.025), similar to the EEG band power model for this intervention. In this model, less
- 530 time in REM sleep (mean 0.41; 95% CI 0.20, 0.62; P<0.001), and more time in N1 (mean -0.26;
- 531 95% CI -0.50, -0.02; P=0.04) and N3 (mean -0.17; 95% CI -0.33, -0.021; P=0.031) were
- 532 associated with less contrast enhancement, or greater contrast clearance. N3 sleep did not
- 533 survive bootstrap analysis while R<sub>P</sub>, REM and N1 sleep had inclusion frequencies of 65.4%,
- 534 88.2% and 61.6%, respectively (**Supplemental Table 3**).
- 535

### 536 Effects of sleep stages on brain parenchymal resistance

537 To understand if sleep stages had a differential effect on the overnight change in  $R_P$ , we

538 computed the mean of the first-order differences  $\Delta R_P$  for each sleep stage for the Benchmarking

and Replication studies separately and combined (**Figure 5**). The mean  $\Delta R_P$  was negative and

540 largest for N2, N3 and REM sleep stages reaching significance when the values for both studies

541 where pooled together. This suggests that  $R_P$  in **Figure 4a-c** decreases during N2, N3 and

542 REM sleep.

543

#### 544 Effects of large changes in EEG spectral power on brain parenchymal resistance

To define the relationships between sleep EEG powerbands, heart rate and  $R_P$ , we modeled the relationship between the first-order difference  $\Delta R_P$  and the difference in spectral band power ( $\Delta$ delta,  $\Delta$ theta,  $\Delta$ alpha,  $\Delta$ beta) and changes in heart rate  $\Delta$ HR, during NREM, REM and Wake (**Table 2**). We utilized threshold regression to model the relationships between  $\Delta R_P$  and large

- 549 changes in ( $\Delta$ ) band power or heart rate. A custom estimation procedure described in
- 550 **Supplemental Information** was used to jointly estimate the threshold regression for the full
- 551 positive and negative ranges of  $\Delta$  band power and  $\Delta$ HR. The full output of the threshold
- regression models is provided for the combined study data in **Table 2**. In both REM and NREM
- sleep, a large increase in  $\Delta$  delta was significantly associated with a decrease in  $\Delta R_P$  (Figure
- **6a**). In contrast during REM and NREM sleep, a large increase in ∆beta was significantly

# 555 Table 2. The change in parenchymal resistance resulting from large changes in EEG

# 556 band power and heart rate occurring during REM sleep, NREM sleep, wake, and at NREM-

557 **REM and sleep-wake transitions.** 

558

				Fixed Effe	cts	Threshold Model Parameters			
Study Condition	Period	Predictors	Estimate	CI	р	DF	Positive Threshold	Negative Threshold	Slope Ratio
	NREM	∆delta	-0.28	(-0.50, -0.058)	0.014	1380	1.5	-1.5	0.7
		∆theta	-0.08	(-0.23, 0.063)	0.265	1380	1.5	-0.98	0.5
		∆alpha	-0.14	(-0.30, 0.022)	0.091	1380	1.5	-1.25	0.65
		∆beta	0.04	(0.0022, 0.080)	0.039	1380	0.18	-1.5	2
		ΔHR	0.10	(-0.0033, 0.19)	0.059	1115	0.43	-0.43	0.5
		∆delta	-0.57	(-0.77, -0.37)	<0.001	319	1.5	-1.5	2
	REM	∆theta	-0.41	(-0.70, -0.13)	0.005	319	0	-1.5	0.5
Overnight		∆alpha	-0.09	(-0.21, 0.041)	0.189	319	1.45	0	2
Sleep Op		∆beta	0.45	(0.14, 0.77)	0.006	319	1.5	-1.3	0.5
		ΔHR	0.31	(-0.057, 0.68)	0.101	271	1.5	-1.15	0.5
	NREM to REM	∆delta	-0.29	(-0.82, 0.24)	0.293	67	1.5	-1.05	2
		∆beta	0.77	(0.04, 1.49)	0.046	67	0.6	-1.5	0.5
	REM to NREM	∆delta	-1.50	(-2.35, -0.66)	0.001	58	1	-1.5	0.5
		∆beta	-0.05	(-0.24, 0.14)	0.615	58	0.1	-1.5	1.85
	Sleep to	∆delta	0.03	(-0.34, 0.4)	0.885	66	1.5	-0.3	1.95
	Wake	∆beta	0.73	(0.13, 1.32)	0.021	66	0.35	-1.23	0.5
	Wake to	∆delta	-0.20	(-0.64, 0.25)	0.392	113	0.05	-1.35	0.6
	Sleep	∆beta	0.37	(-0.01, 0.76)	0.065	113	1.5	-1.05	2
	WAKE	∆delta	-0.06	(-0.15, 0.034)	0.216	1137	1.5	0	0.5
Overnight		∆theta	-0.07	(-0.17, 0.035)	0.198	1137	1.4	-1.45	2
Sleep		∆alpha	0.06	(-0.030, 0.14)	0.206	1137	1.15	0	0.73
Deprivation		∆beta	0.12	(0.0075, 0.23)	0.037	1137	1.5	-1.43	1.93
		ΔHR	-0.10	(-0.20, -0.011)	0.029	1002	0.25	-0.25	0.5

559 Rapid eye movement, REM; non-REM, NREM; Confidence Interval, CI; Degrees of Freedom,

560 DF; EEG band power predictor units in percent of total band power; HR predictor units beats-

561 per-minute. **Bolded P values reflect significant associations at P < 0.05**. Predictor and

562 parenchymal resistance values in regression models were scaled to zero mean and unit

563 standard deviation with coefficient estimates representing effect size in standard deviations.

564 Positive and negative thresholds are in units of predictor standard deviation. Models included

565 confounding biological variables age, gender, and APOE ε4 status.

567 associated with an increase in  $\Delta R_P$ . The threshold models for the significant estimated effects of 568  $\Delta$  band power on  $\Delta R_P$  are plotted in **Figure 6b**. The full output of the threshold regression model 569 is provided for each site individually in **Supplemental Table 4**. Because the variables were 570 standardized before model estimation, the regression estimates in **Table 2** and **Supplemental** 571 **Table 4** can be interpreted as standardized effect sizes. Note that because of the slope ratio r, 572 changes that exceed the positive change point  $t_p$  have effect sizes given by the regression 573 estimate multiplied by the slope ratio. The positive and negative thresholds are in units of 574 standard deviation.

575

576 The asymmetric effect of EEG band power changes on R<sub>P</sub> shown in Figure 5 accounts for the 577 progressive decline in R<sub>P</sub> that occurs through the course of the overnight sleep period, shown in 578 **Figure 4a-c.** In the overnight wake state,  $\Delta$  beta had a significant but small effect on  $\Delta R_P$ .  $\Delta HR$ 579 in NREM and wake had a small effect on  $\Delta R_P$  and a larger but non-significant effect in REM. 580 The threshold model findings in **Table 2** and plots in **Figure 6a** demonstrate that large changes 581 in spectral band power are needed to alter R<sub>P</sub>. Because such large changes in EEG 582 powerbands and HR occur at sleep stage transitions, we explored the associations between 583  $\Delta$ delta and  $\Delta$ beta and  $\Delta$ R<sub>P</sub> at NREM-REM and REM-NREM transitions, and at Sleep-Wake and 584 Wake-Sleep transitions. **Table 2** provides the full model output on sleep stage transitions for 585 data pooled from both study sites, while the significant estimated effects of  $\Delta$  delta and  $\Delta$  beta on 586  $\Delta R_{\rm P}$  are plotted in **Figure 6c**. The full output of the threshold regression model on sleep stage 587 transitions is provided for each site individually in **Supplemental Table 5**. During the NREM-588 REM, Wake-Sleep, and Sleep-Wake transitions, changes in EEG beta power and not EEG delta 589 power underlie the observed changes in  $\Delta R_{P}$ . In contrast, during the REM-NREM transition, 590 changes in EEG delta power and not beta power were associated with changes in  $\Delta R_P$ . In total,



596 error after differencing both  $R_P$  and powerband values to make data stationary, standardizing 597 the  $\Delta R_P$  and  $\Delta$  powerband values to zero mean and unit standard deviation, and adjusting for 598 site, age, gender, APOe4 and site-age interaction confounders. Units of  $\Delta R_P$  and  $\Delta$  powerband 599 are in standard deviations. Data in light blue are inside the change points and data in dark blue 600 are outside the change points. When delta and beta power changes between successive 601 measurements exceed 1.0 to 1.5 stand deviations, we observe significant changes in  $\Delta R_P$ , **b**.

602 95% CI of regression coefficients show that large changes in REM delta, theta and beta, and

603 NREM delta and beta are significant predictors of  $\Delta R_P$ . For a 1 standard deviation increase in  $\Delta$ 604 powerband, an increase (decrease) in  $\Delta R_P$  is illustrated in red (green) with units along the top in

605 standard deviation of  $\Delta R_{P}$  c, Large changes in beta and delta powerbands at sleep-wake and

606 NREM-REM transitions show significant effect on  $\Delta R_P$  consistent with the step change in beta

and delta power at these transitions. For a 1 standard deviation increase in  $\Delta$  powerband across

608 a sleep-wake or NREM-REM transition, an increase (decrease) in  $\Delta R_P$  is illustrated in red

609 (green) with units along the top in standard deviation of  $\Delta R_{P.}$ 

592 593

594

- 610
- 611

612 these data show that glymphatic function is enhanced by declining R<sub>P</sub>, and that R<sub>P</sub> in turn

- 613 declines with reduced EEG beta power and heart rate, and with increasing EEG delta power.
- 614

# 615 **DISCUSSION**

616 We have described a non-invasive multimodal skin-interfaced wireless device for continuous 617 measurement of brain parenchymal resistance R<sub>P</sub> using repeated EIS time-multiplexed with 618 EEG and cardiovascular measurements. Through two separate clinical validation studies, we 619 observe that brain  $R_P$  measured by the device faithfully captures sleep-active changes in 620 glymphatic flow resistance based on three complementary criteria established from studies in 621 the murine and human brain. Brain R<sub>P</sub> declines overnight, paralleling sleep-associated changes 622 in extracellular volume that regulate glymphatic function<sup>2</sup>. Brain R<sub>P</sub> is reduced with increasing 623 sleep EEG delta power, and is increased with increasing sleep EEG beta power and heart rate<sup>11</sup>. Lastly, brain R<sub>P</sub> is a robust predictor of glymphatic function, measured by CE-MRI<sup>12-15,30</sup>. 624 625 These findings demonstrate that this investigational device provides the first remote, non-626 invasive, and time-resolved measure of glymphatic flow resistance suitable for defining this 627 sleep-active biology in naturalistic settings.

628

Several technological advances have enabled this work. We have developed a technique for low-noise EIS measurements using multiple excitation and sense configurations to determine the brain parenchymal impedances accurately. A signal processing approach enabled the segregation of signal and noise, using the Kramers-Kronig relations<sup>31,32</sup> between the real and imaginary parts of the impedance to establish if the measured response is related to the excitation signal or has been distorted by noise or other artifact. Unlike applications of EIS to neurological conditions such as seizures, tumors or cerebral edema<sup>33-36</sup>, the rapid evolution of glymphatic function during sleep and its nightly variability make it suitable for monitoring with
longitudinal repeated assessments. Data collected under a variety of scenarios in benchtop
testing, agar phantom testing with biological interfaces and in-human testing indicate that this
system yields consistent, repeatable results and shows longitudinal stability of the measured
impedances.

641

642 A key first step in validating any potential measure of glymphatic function is assessing its 643 performance against established, principally contrast-based, measures of glymphatic exchange. 644 Initial studies characterizing glymphatic function in rodents utilized dynamic in vivo 645 fluorescence-based imaging<sup>1,2,37</sup>. More recent studies in rodents, and recently in human 646 participants, have utilized CE-MRI following either intrathecal or intravenous GBCA injection<sup>12,14,15,30,38</sup>. We evaluated whether device-based R<sub>P</sub> measures reflect glymphatic 647 648 function by measuring overnight and morning R<sub>P</sub>, EEG, and the movement of GBCA into brain 649 tissue over a four-hour timeframe. In the analysis, both overnight and morning R<sub>P</sub> emerged as 650 robust explanatory variables of net contrast movement, in a regression model that included CSF 651 and blood contrast levels, EEG neurophysiological parameters, age, gender and APOE e4 652 confounders. It is important to note that device-based R<sub>P</sub> measures are acquired with 2-minute 653 temporal resolution whereas CE-MRI captures overall glymphatic function over a 4-hour 654 window. This fine temporal resolution enabled translational validation of the physiological drivers 655 of glymphatic function in the human brain for the first time. It further revealed that while key 656 events during sleep were necessary to lower parenchymal resistance R<sub>P</sub>, low R<sub>P</sub> was sufficient 657 to enhance glymphatic function independent of sleep in the morning period. In addition, it 658 showed that sleep-related changes in RP do not shift with sleep-wake in a stepwise fashion, but 659 rather accumulate through the course of time spent sleeping or awake. These observations are 660 not inconsistent with prior studies in rodents that used real-time iontophoresis to measure sleepassociated increases in brain extracellular volume fraction<sup>2</sup>, as these observational studies did 661

not directly test the causal effect of these changes in extracellular volume on glymphatic
function, and did not monitor changes in extracellular volume fraction in a time-resolved manner
over extended period. Future studies of the determinants of glymphatic function in human sleep
will likely further refine existing conceptual models of sleep-wake regulation of glymphatic
function.

667

668 The physiological mechanisms regulating glymphatic function have been defined almost exclusively through experimental rodent studies<sup>1,2,10,11,30,37,39,40</sup>, due in large part to invasiveness 669 and poor temporal resolution of contrast-based measures of glymphatic function<sup>12-15,30</sup>. It is 670 671 noteworthy that these rodent studies are not all in agreement. While multiple studies have 672 reported more rapid glymphatic exchange under conditions of sleep, or under certain anesthetic regimes<sup>2,11,41-45</sup>, two studies<sup>46,47</sup> have reported apparently slower clearance during sleep or 673 674 under anesthesia. In the present human clinical studies, we demonstrate within-participant 675 longitudinal declines in brain  $R_P$  during overnight sleep, but not in awake participants. During 676 morning recovery sleep, we demonstrate within-participant longitudinal declines in brain  $R_P$  and 677 during morning wake we observe increases in brain R<sub>P</sub>. This pattern is consistent with sleep-678 wake changes in extracellular volume fraction measured in mice and reported by Xie et al.<sup>2</sup>. 679 Using overnight PSG followed by CE-MRI in human participants, we confirmed that glymphatic 680 function in the human brain is associated with lower EEG beta power and heart rate, and in a 681 simplified model with increasing EEG delta power. These findings sustain the physiological findings in mice from Hablitz et al.<sup>11</sup>. More broadly, these human CE-MRI-based imaging studies 682 683 demonstrate that glymphatic solute exchange is more rapid under conditions of natural sleep, at 684 least in human participants, and that these sleep-wake differences are regulated by sleep-685 related changes in R<sub>P</sub>, heart rate, and EEG spectral band power.

687 Linking changes in R<sub>P</sub> with sleep EEG features, we further demonstrate that the investigational 688 device-based measure of R<sub>P</sub> exhibits the same dependence upon EEG delta power, EEG beta 689 power, and heart rate during sleep. Conducting parallel time-resolved sleep EEG and R<sub>P</sub> 690 measurements, we observed that rapid changes in R<sub>P</sub> occurred at sleep stage transitions 691 between REM and NREM, and between sleep and wake. Transitions between REM and NREM 692 exhibit large changes in EEG delta and beta powerbands, and in HR, consistent with our 693 findings. Large changes in an EEG power within a frequency band can occur because of 694 sudden bursts of oscillatory activity within the band's frequency range. In rodents, recent 695 experiments support a role for such synchronized oscillatory activity as a mechanism driving 696 glymphatic flow by creating propagating ionic waves within the brain interstitium<sup>41</sup>. To our 697 knowledge, this is the first time that these physiological drivers of glymphatic function have been 698 confirmed in human participants, within an experimental setting permitting validation against 699 current benchmark CE-MRI-based measures of glymphatic function well established preclinical 700 features.

701

702 There are clear limitations both of the investigational device, and of the present study design. 703 Existing MRI-based measures of glymphatic function remain poorly time-resolved but provide 704 excellent cranium-wide anatomical resolution. In contrast, the present investigational device 705 captures a measure of global brain glymphatic flow resistance with high temporal resolution. 706 While finer anatomical resolution may have value in future iterations of the investigational 707 device, it is important to note that the present design was sufficient to capture sleep-wake 708 changes in glymphatic function, and to define novel neurophysiological drivers of these 709 processes in the human brain. Study methodological limitations include protocol differences 710 between the Benchmarking Study and Replication Study. The Benchmarking Study included 711 CE-MRI as part of the neuroimaging package and gold-standard PSG concurrent with the 712 device usage whereas the Replication Study did not include CE-MRI and used the device's

713 single-derivative EEG. Furthermore, the Benchmarking Study enrolled participants 55-65 years 714 old living in Florida whereas the Replication Study enrolled participants 50-65 years old living on 715 the West Coast. Despite these differences, after adjusting for age, study site and age-site 716 interaction effects, we confirmed that the device's single-derivative EEG showed good 717 agreement with the PSG of the Benchmarking Study. Additionally, the pooled analysis and 718 study-specific analyses of R<sub>P</sub>, EEG and HR were all in good agreement between studies. The 719 Benchmarking Study was powered to detect a low to moderate correlation between R<sub>P</sub> and CE-720 MRI measures of glymphatic function, which was confirmed. Quality control of the 721 investigational device filtered out measurements that did not satisfy the Kramers-Kronig 722 relations<sup>31,32</sup>. Failed measurements were more common in the Benchmarking Study, particularly 723 during the awake conditions. This is attributable to excessive motion, likely due to the technical 724 challenges associated with conducting concurrent PSG and device-based sleep EEG measures 725 in participants being kept awake by study staff. The low rate of quality-control failures in the 726 Replication Study that did not involve PSG instrumentation supports this conclusion. 727

728 The characterization of the glymphatic system in rodents beginning in 2012 has spurred a great 729 deal of interest into its potential mechanistic role linking sleep to cognitive performance, and 730 sleep disruption to a wide range of neurological and psychiatric conditions including Alzheimer's 731 disease, Parkinson's disease, chronic traumatic encephalopathy, stroke, traumatic brain injury, 732 headache and others<sup>42-45</sup>. Preclinical studies have demonstrated that glymphatic function is impaired in the setting of aging<sup>48</sup>, sleep disruption<sup>2</sup>, cerebrovascular injury<sup>49,50</sup>, and traumatic 733 734 brain injury<sup>3</sup>, all risk factors for neurodegenerative conditions including Alzheimer's disease. 735 Experimental impairment of glymphatic function is sufficient to promote the development of the amyloid beta<sup>51-53</sup> and tau pathology<sup>3-5</sup> characteristic of Alzheimer's disease. In clinical 736 737 populations, genetic and histological associations support a link between glymphatic dysfunction and the development of clinical disease<sup>52,54-56</sup>. Yet the technical challenges of real-time dynamic 738

739 measurements of glymphatic function in human clinical populations have proven a challenging 740 barrier to defining the causal role of glymphatic function and dysfunction in the development of 741 neurological and psychiatric conditions in these populations. Whether glymphatic dysfunction 742 contributes to development of conditions such as Alzheimer's disease remains to be directly 743 tested. The present investigational device may permit the continuous and time-resolved 744 assessment of glymphatic function in naturalistic settings necessary to define whether 745 glymphatic impairment contributes to risk and progression of Alzheimer's disease and its 746 underlying pathological processes. The ability to assess glymphatic function over short 747 timescales may enable target-engagement studies to identify and test pharmacological, device-748 based and lifestyle/behavioral interventions for modulating glymphatic function in humans. 749 Assessment of these processes may also permit the identification of clinical populations with 750 impaired glymphatic function, at risk for the development of Alzheimer's disease, and who would 751 thus be ideal candidates for therapeutic approaches targeting glymphatic clearance. Similar 752 avenues now remain open outside the realm of neurodegenerative conditions as glymphatic 753 dysfunction is implicated in an ever-increasing list of sleep-related neurological and psychiatric 754 conditions.

# 755 **METHODS**

#### 756 Investigational Device

757 System Architecture

The Applied Cognition device is a wearable multi-sensor acquisition system that uses an

- 759 STM32WB5MMG microcontroller (ST Microelectronics, NV). It consists of a primary module
- housing the main electronics board and a 430 mAh Li-ion battery, two earpieces each housing
- one electrode, one accelerometer and one photoplethysmogram sensor, and two separate
- 762 mastoid electrodes. A device schematic and visualization of signal outputs is provided in
- 763 **Figure 2a-f**. Sensor data is stored in on-board FLASH memory and is downloaded via a USB
- port for offline analysis. The relevant sub-systems are further described below.
- 765

#### 766 Electrical Impedance Spectroscopy

767 Electrical impedance spectroscopy (EIS) was used to measure electrical impedance using the

768 AFE4500 analog front-end (AFE) from Texas Instruments. Four electrodes – two in-ear and two

769 mastoid – were used to deliver the excitation current across the head and sense the resulting

voltage. The two mastoid current injection sources were initially co-located inside the ear next to

the Ag/AgCl sensors but because of salt-bridging were externalized to the mastoids. In a

departure from traditional four-electrode measurements, where excitation and sense electrodes

are fixed, the AFE4500 was programmed to implement a technique developed by Texas

174 Instruments where multiple excitation and sense configurations are used to determine the

contact impedance and body impedance accurately.

776

777 Measurements were successively performed at eighteen frequencies ranging from 1 kHz to

256 kHz following a logarithmic series, all with excitation current below 50 μA root-mean-square

- (rms). Frequencies were in alternating order from high-low to minimize any impact on
- impedance drift during each scan. Sensed voltages were quadrature-demodulated, filtered and

digitized internally by the AFE4500 to provide in-phase and out-of-phase components.

782 Measurement time for each frequency was adjusted to give consistent signal-to-noise ratio

across the frequency range, resulting in a scan time of 106 seconds.

784

785 Electroencephalogram

786 Electroencephalogram (EEG) was measured with an ADS1299-4 AFE from Texas Instruments,

587 between the two in-ear electrodes (differential measurement). A third electrode (left mastoid)

was used to drive the common mode. While these electrodes were shared with the EIS, the two

789 measurements were time-multiplexed and a pair of analog multiplexers (TMUX1136, Texas

790 Instruments, Inc.) effectively decoupled EEG and EIS sub-circuits and respective

791 measurements. For EEG, both in-ear electrodes were also buffered (OPA376, Texas

Instruments, Inc.) in the earpiece. These buffers were bypassed (analog multiplexer

793 TMUX1136, Texas Instruments, Inc.) for EIS or electrode impedance measurement.

794

795 The ADS1299-4 was programmed to have a sampling rate of 250 samples-per-second (24-bit 796 samples) and an input range of ±180 mV. The common mode drive was actively derived from 797 the in-ear electrodes. Both mastoid electrodes were also connected to an input channel so that 798 the low-frequency (31.25 Hz) impedance of each electrode could be measured using the 799 internal current source of the ADS1299-4. Such impedance measurements were performed 800 before starting a recording session, and then automatically between EEG periods and EIS. EEG 801 measurement periods were 170 seconds long, and the sequence EEG-EIS-Electrode 802 impedance repeated until the end of the recording session. A sample EEG spectrogram and 803 hypnogram, derived from the device EEG is shown in Figure 2b.

804

805 Impedance Plethysmogram

806 In addition to impedance spectroscopy, real-time bioimpedance was acquired simultaneously 807 with the EEG, using the MAX30001 AFE (Analog Devices, Inc.). The four-electrode 808 configuration shared electrodes with the EEG, with the two mastoid electrodes used for current 809 injection and the two in-ear electrodes for voltage sensing. A 96 µA current at 82 kHz was used 810 for excitation. Such high frequency excitation is effectively filtered by the ADS1299-4 and does 811 not corrupt the EEG signal. The MAX30001 built-in synchronous demodulator filtered and ADC 812 recovered the in-phase component of the sensed voltage and digitized it at 64 samples-per-813 second (20-bit resolution). The resulting impedance measurements had a noise floor of 3 m $\Omega$ 814 rms (100  $\Omega$  load), enabling the detection of blood pulsations. A sample trace from a study 815 participant, derived from the device IPG is shown in Figure 2d. Note that the impedance shifts 816 measured in either the respiratory or cardiac frequency bands range between 50 to 150 m $\Omega$ . In 817 contrast, impedance shifts detected by EIS were at least an order of magnitude greater. 818

819 Photoplethysmogram and Acceleration

820 In-ear reflective photoplethysmogram (PPG) was measured with two miniature, fully-integrated 821 optical sensors MAXM86161 (Analog Devices, Inc.) located in each earpiece, facing the anterior 822 wall of the ear canal. One side was programmed to use green light (530 nm), while the other 823 used alternatively red (660 nm) and infrared (880 nm) lights. To achieve a tight synchronization 824 with EEG samples, the sensors ran at 1024 Hz for each color, and the most recent samples 825 available at the time of the EEG read were averaged, resulting in a 250 Hz output rate and a 826 phase variation <1 ms. A sample trace of the left (red) and right PPG (green) from a study 827 participant is provided in Figure 2f.

828

In-ear acceleration (X,Y,Z) was measured using two miniature MEMS Inertial Measurement Unit
 (IMU) LSM6DSOX (ST Microelectronics, NV) located in each earpiece. Similar to the PPG, the

831 sensors were run at 833 Hz (each axis) and averaged to ensure tight time synchronization

832 between sensors. A noise floor of 1 mg rms enabled the resolution of cardiac/blood pulsations,

833 in addition to posture and activity. From these accelerometer data, a ballistocardiogram is

- derived, as shown for a study participant in **Figure 2e**.
- 835
- 836 Electrodes

837 In-ear electrodes were laser-cut from silver sheets 100 microns thick and 99.9% purity. The

838 electrodes were 4.5 mm diameter plates with a 1 mm-wide stem. The electrodes were abraded

and sonicated in distilled water, dip-coated with Ag/AgCl ink provided by Creative Materials Inc

840 (SKU EXP 2653-138-1) and cured at 100°C for 60 min. Following curing, they were sintered at

841 427°C for 60 minutes under low-flow argon gas.

842

Once fabricated, all electrodes were characterized according to the ANSI/AAMI EC12 standard for AC impedance<sup>57</sup>, DC offset voltage, combined offset instability and internal noise, and bias current tolerance (**Supplemental Table 7**). Pairs of electrodes were also connected to the earpiece circuits with clip-on wires and tested on an agar phantom as described in the *Device Testing* section.

848

849 Electrical Impedance Spectroscopy Validation

850 Measurement accuracy was first evaluated using a test fixture simulating the load and the four

electrodes (**Supplemental Figure 2**). The load was either purely resistive (R, 20-100  $\Omega$ ), or

slightly reactive (2*R1C*, 20-100  $\Omega$  in parallel with 470  $\Omega$  and 22 nF in series) to mimic the brain

- parenchyma. The electrodes were implemented as either (i) low impedance (270  $\Omega$  resistor in
- series with a 1 k $\Omega$  resistor and 180 nF capacitor in parallel), or (ii) high impedance (620  $\Omega$
- resistor in series with a 3.3 kΩ resistor and 82 nF capacitor in parallel), in order to simulate the
856 frequency-dependence of typical Ag/AgCl electrodes, but also to ensure a minimal impedance 857 at high frequencies. Two 10  $\Omega$  resistors were added between the electrodes connected to the 858 same side of the load to simulate the tissue impedance between these electrodes as well. 859 Supplemental Table 8 describes the benchtop tests performed and Supplemental Table 9 860 and **Supplemental Table 10** contain the results. 861 862 Device Testing 863 In addition to the EIS test fixture, stability and reproducibility of EIS measurements over twelve 864 hours were evaluated with an agar phantom. A slab (5-10 mm thick) of conductive agar was first 865 cast using a solution of 2.5% weight agar (Living Jin USA, Inc.), 0.64% weight NaCI (RND 866 Center, Inc.) and distilled water. Electrodes (mastoids and earpieces for the final testing) were 867 then coated with conductive gel (Electro-Gel, Electro-Cap International) to reduce the contact 868 resistance, and placed on the agar slab in a pattern geometrically similar to the electrode 869 location on the head. A 12-hour recording was performed, resulting in a total of 450 minutes of 870 EEG recording, 159 EIS cycles and 160 electrode impedance checks. The results of a 12 hr 871 agar phantom EEG test is shown in **Supplemental Figure 3**. 872 873 Signal Processing – Parenchymal Resistance 874 A python neuroprocessing pipeline developed by Applied Cognition performed the data analysis 875 of the signals captured by the investigational device. The neuroprocessing pipeline runs in the 876 Amazon Web Services cloud on a distributed architecture allowing for fast parallel execution of 877 participant device readings.

878

879 An EIS scan by the investigational device measured impedances  $Z(\omega)$  at 18 frequencies  $f(\omega =$ 

 $2\pi f$ ) ranging from 1,000 Hz to 256,000 Hz and took 106 seconds. The frequencies were

measured in the following permuted order for each scan (all in Hz): 2276, 102400, 1600, 64000,

4551, 51200, 12800, 85333, 3200, 25600, 1000, 32000, 6400, 8533, 128000, 204800, 256000.
During the EIS scan, all other device sensors were powered off except the left-in-ear IMU that
sampled at 1Hz to detect head motion and position. The EIS scans were duty-cycled throughout
the recording period with 165 second neurophysiology scans that captured data from the other
sensors: EEG, PPGs and IMUs. Four electrode impedance checks at 30Hz and lasting 7
seconds were performed during the neurophysiology scan and immediately preceding the EIS
scan.

889

The Cole-Cole model<sup>58-60</sup> is commonly used to analyze EIS data. The analysis is based on the four parameters contained in the Cole equation R<sub>0</sub>, R<sub>∞</sub>,  $\alpha$  and  $\tau$ .

892 
$$Z(\omega) = R_{\infty} + \frac{R_0 - R_{\infty}}{1 + (j\omega\tau)^{\alpha}}$$

As the excitation frequency  $\omega$  ( $\omega = 2\pi f$ ) increases to large values, the capacitive cell membranes are invisible to the excitation frequency and the impedance Z( $\omega$ ) approaches R<sub> $\infty$ </sub>. The four excitation and response electrodes are positioned trans-cranially and at large  $\omega$ measure total intracranial brain volume. As the excitation frequency  $\omega$  decreases approaching DC values, the capacitive cell membranes prevent any transmembrane conduction and the impedance Z( $\omega$ ) approaches R<sub>0</sub> the measure of electrical resistance through extracellular fluid.

The value of  $\tau$  in the Cole-Cole model is the inverse of tissue characteristic frequency  $2\pi f_c$ . The Cole-Cole  $\alpha$  describes the divergence of a measured dielectric dispersion from the ideal dispersion exhibited by a Debye type of dielectric relaxation, and is widely assumed to be related to a distribution of the relaxation times in the system involved. The value of  $\alpha$  ranges from 0.5 to 1 with a value of 1 reducing the Cole-Cole model to the Debye model. 905

906 For each EIS scan, the four parameters were estimated using a non-linear least-squares fit 907 (Python SciPy's least squares) with the Trust Region Reflective algorithm that is a robust 908 method suitable for large sparse problems with bounds. The  $\alpha$  parameter was found to be close 909 to one in the estimations and thereafter set to one, reducing the Cole-Cole model to the Debye 910 model. The remaining three parameters were estimated with bounds of 0 to 90 $\Omega$  for  $R_0$ , 0 to 70 $\Omega$ for  $R_{\infty}$  and bounds for  $\tau = \frac{1}{2\pi f_c}$  determined by requiring the characteristic frequency  $f_c$  to lie 911 912 between 16kHz and 160kHz. The parameter bounds where confirmed to encompass 913 neurophysiological values in all participants by plotting all EIS scan resistance (real values of 914 impedances  $Z(\omega)$ ) and reactance (imaginary values of impedance  $Z(\omega)$ ). Furthermore, no 915 parameter solutions lay on a boundary for each scan across the range of dynamic impedance 916 spectroscopy measurements for all participants. 917 918 Prior to fitting the Debye model to the EIS scan data, to compensate for stray capacitance, time 919 delay effects from signal transmission and electrical components, the impedances Z from each scan were rotated by multiplying by the factor  $e^{-j\omega T}$  with the value T chosen so that the 920

921 reactance at the highest frequency of the scan was zero<sup>59</sup>. This rotation was independently

922 validated using EIS scans recorded on the benchtop tests using known impedance loads

923 (Supplemental Table 10). The root-mean-squared-error (RMSE) of the Debye model fits to the

924 benchtop tests (Supplemental Table 8) are reported in Supplemental Table 11.

925

Each EIS scan measures  $R_P$  at a point in time and to evaluate glymphatic function the Debye model fits need to detect small changes in  $R_P$ . With the device time-multiplexing settings, the device completes approximately 84 scans over a 7-hour night of sleep. The statistical models require significance testing of the mean change in  $R_P$  between sleep and wake, and testing significance of predictors of  $R_P$  in linear mixed models. These tests depend on the SD of the

931 Debye model dispersion and the number of EIS scans (Supplemental Table 12). Details of
932 these analyses are found in Supplemental 4.

933

934 During EIS, tissue behaves as a linear, time-invariant and causal system allowing the use of 935 Kramers-Kronig relations to identify electrical impedance measures that are corrupted by 936 artifacts from motion, electrode impedances and other sources<sup>31,32</sup>. The Kramers-Kronig 937 transform allows the real part of the electrical impedance measure to be derived from the imaginary part and vice versa<sup>31</sup>. These relations are used as validity tests for measured 938 939 spectrums. When the real and imaginary impedance measures do not satisfy the Kramers-940 Kronig relation the measure is discarded. The Python PyEIS1.0.10 repository was used for 941 Kramers-Kronig impedance validation. The validation uses the method of Schönleber<sup>32</sup> to avoid 942 ambiguities in the linear Kramers-Kronig validity tests due to under- and over-fitting. 943 944 In addition to the Kramers-Kronig validity tests, EIS measures were discarded if for any of the 945 four electrode impedances, the difference across successive time measures exceeded  $1k\Omega$  or if 946 the EIS scan was collected during a wake interval on a participant randomized to sleep. The first 947 condition ensured that the electrode impedances were maintained within a narrow range during

the EIS scans and the second condition ensured that the EIS scans were representative of

sleep physiology for participants randomized to sleep.

950

#### 951 Signal Processing – Electroencephalography

The raw EEG tracings from the device and the commercial PSG (Philips Respironics Alice 6 LDx Diagnostic Sleep System) were time-synchronized by time-aligning a 100-ms square pulse generated by the device every 10 seconds and stored both in the device flash memory and in the PSG recording through as an unused auxiliary analog input channel. Each raw tracing was notch filtered at 60 Hz using a second-order infinite impulse response (IIR) notch digital filter (Python SciPy *iirnotch*). The digital filter was applied to the signal forward and backward with a
combined filter phase of zero (Python SciPy *filtfilt*). The signal was then bandpass filtered
between 0.3 Hz and 50 Hz using a finite impulse response (FIR) filter with a Hann window
(Python SciPy *firwin*). The length of the low-pass filter was 501 and the length of the high-pass
filter was 2,401.

962

963 During the observation periods, participants were not allowed to touch devices that were 964 plugged to power outlets. Other non-physiologic sources included excessive head motion that 965 led to signal artifacts from the electrode-skin interface. Physiologic sources of signal artifact 966 included electrooculogram, electrocardiogram and electromyogram. The signals where 967 partitioned into time-aligned 30- second epochs. Epochs containing one or more peak-to-peak 968 signal amplitude exceeding 350 µV or maximum power in the Welch power spectrum exceeding 969 1,000  $\mu$ V<sup>2</sup>/Hz were removed. In addition, the device left in-ear and right-in ear IMU signals were 970 used to filter excessive motion by filtering epochs with peak-to-peak values on an x-, y-, or z-971 axis on either ear that exceeded 100 milli-g during sleep and 200 milli-g during wake. 972 973 The power spectral density of each 30-second epoch was computed using Welch's method<sup>61</sup> 974 (Python Scipy welch) using 10-second segments and 50% overlap across successive 975 segments. Relative power bands were computed for delta power (1-4 Hz), theta power (4-8 Hz), 976 alpha power (8-12 Hz), sigma power (12-15 Hz), beta power (15-30 Hz) and low gamma power 977 (30-50 Hz), each normalized to the total power in the power spectral density. Simpson 978 integration of the power spectral density was used for computing the total power and respective 979 band powers. 980

Hypnogram staging of each 30-second epoch used automated scoring (Python yasa 0.6.3 *SleepStaging*) trained and validated on 3,000 nights of data from the National Sleep Research

990	Supplemental Table 6.
989	PSG and agreement between investigational device-based EEG and PSG are presented in
988	comparison to the device's transcranial in-ear derivative. The internal agreement of commercial
987	additional T3-T4 transcranial PSG derivative was used for hypnogram staging as another
986	separately. The PSG left EOG channel was used for commercial PSG hypnogram staging. An
985	commercial PSG, hypnogram staging using C3-A2 and C4-A1 derivatives were recorded
984	For device hypnogram staging the single in-ear transcranial derivative was used and for the
983	Resource <sup>62</sup> . The automated scoring uses a single EEG derivative and a single EOG channel.

991

#### 992 Signal Processing – Heart Rate

993 The photoplethysmography (PPG) left and right raw signals were bandpass filtered between 0.5 994 Hz and 10 Hz using a finite impulse response (FIR) filter with a Hann window (Python SciPy 995 firwin). Empirical mode decomposition was used to identify peaks in the raw signals (Python 996 emd 0.6.2) using a box-car rolling window of 100 observations<sup>63</sup>. Heart rate variability metrics 997 were computed after removing outliers, ectopic beats and interpolating missing values (Python 998 Aura-healthcare hrvanalysis). Both time-domain features (standard deviation (SD) of the inter-999 beat-interval of normal sinus beats, sdnn) and frequency-domain features using the Lomb-1000 Scargle periodogram [ref] (low-frequency signal power *If* between 0.04-0.15 Hz considered a 1001 mixture of sympathetic and parasympathetic activity, high-frequency signal power hf between 1002 0.15-0.4 Hz representing beat-to-beat changes from parasympathetic vagal activity, and the low-frequency to high-frequency ratio (*lf-hf-ratio*) were computed<sup>64</sup>. 1003 1004 The device inertial-measurement units (IMU) were located inside the left and right ear canal and

1004 The device inertial-measurement units (INO) were located inside the left and right ear canal and 1005 provided left and right cartesian coordinates of acceleration measured in milli-g where 1,000 1006 milli-g is the acceleration caused by earth's gravitational force. Each in-ear component from the 1007 device is uniquely and reproducibly oriented on account of the ellipsoidal shape of the human

- 1008 ear-canal and the matching shape of the in-ear component. From this orientation, head position
- and motion (acceleration) were resolved from each set of IMU samples that included gross
- 1010 positions such as *supine*, *reclined*, *upright*, *left* and *right*.
- 1011

#### 1012 Clinical Study Design

1013 The Investigational Device was evaluated in two studies, a Benchmarking Study conducted in 1014 The Villages community in Florida in partnership with the UF Health PHRC, and a Replication 1015 Study conducted at the University of Washington in Seattle. These studies were reviewed and 1016 approved by University of Florida Institutional Review Board (IRB No. 202201364) and Western 1017 Institutional Review Board (IRB No. 20225818), respectively. Written informed consent was

1018 obtained from all study participants during a screening visit, prior to any study activities.

1019

#### 1020 Participant Recruitment

1021 Following distribution of study flyers in public-facing locations in senior recreation and/or local 1022 medical centers, the Benchmarking Study enrolled 34 healthy participants 56-66 years of age 1023 and the Replication Study enrolled 14 healthy participants 49-63 years of age. Participants were 1024 cognitively intact and had no history of clinical depression, confirmed during screening using the 1025 Montreal Cognitive Assessment (MOCA) and Geriatric Depression Scale (GDS). Other 1026 exclusion criteria included a history of diabetes, hypertension, coronary artery disease, 1027 pulmonary disease, neurological disease, or anxiety. Participants planning travel to alternate 1028 time zones within two weeks of study participation were also excluded. Consolidated Standards 1029 of Reporting Trials (CONSORT) diagram for the Benchmarking Study and Replication Study is 1030 provided in **Figure 3** (bottom), and participant exclusions are detailed in the Results section. 1031 Demographic data including age, sex, APOE4 allele status, MOCA and GDS for the 1032 Benchmarking Study, Replication Study, and Combined Studies are provided in **Supplemental** 

1033 **Table 1**.

1	034	
	0.0	

#### 1035 Study Protocol

1036 As shown in the study schematic (Figure 3, top), this is a cross-over study in which participants

- 1037 took part in two overnight study visits, one undergoing normal sleep and the other undergoing
- 1038 overnight sleep deprivation, at a 2-4 week interval. Each overnight study visit consisted of three
- 1039 study periods beginning at 1900 hrs, 0700 hrs, 1330 hrs separated by two intervals an
- 1040 overnight interval (2300-0630 hrs), and a morning interval (0800-1130 hrs).

1041

1042 <u>Benchmarking Study:</u> Beginning with arrival to the study suite at 1900, participants underwent a

1043 blood draw for APOE genotyping and assessment of amyloid  $\beta$  and tau biomarkers (A $\beta_{1-40}$ , A $\beta_{1-1}$ 

1044 <sub>42</sub>, phospho-tau181, phosho-tau217, non-phospho-tau181, non-phospho-tau217; C<sub>2</sub>N

1045 Diagnostics<sup>65-67</sup>) and 60 min of non-contrast magnetic resonance imaging (MRI) scanning

1046 (sequences detailed below). On completion, participants were instrumented for commercial

1047 polysomnography (PSG, Philips Respironics Alice 6 LDx Diagnostic Sleep System) that

1048 included a 10-20 EEG montage with electro-oculogram (EOG) and submental electromyogram

1049 (EMG). Electrode impedances were required to be below 5 k $\Omega$ . Participants were last

1050 instrumented with the Investigational Device, and device electrode impedances required to be

1051 below 5 k $\Omega$ .

1052

The Overnight interval lasted from 2300-0630 hrs the following morning. To support study planning, participants were randomized to undergo either normal sleep or sleep deprivation for their initial overnight visit following completion of their informed consent, however this information was not shared with the participants. To reduce likelihood of preparation bias on the part of participants (i.e. altering sleep schedules or taking naps in anticipation of sleep deprivation visits) participants were not informed of their initial visit assignment until 4pm the

day of their arrival. Both PSG and Investigational Device recordings took place continuously
throughout the Overnight interval. Throughout the overnight period, sleep-assigned participants
were allowed to sleep normally without interruption. Participants assigned to the sleep
deprivation were monitored by study staff to ensure adherence to the sleep deprivation protocol.

1064 Between 0700-0745 hrs the next morning, all participants were administered a cognitive battery 1065 that included the 5-minute psychomotor vigilance test for sustained attention<sup>68,69</sup>, symbol-digit 1066 modality test of processing speed, trail making test part A and part B for assessing executive 1067 function<sup>70</sup>, and digit span forward test of working memory<sup>71</sup>. Following the cognitive battery, 1068 participants underwent a blood draw for amyloid  $\beta$  and tau biomarkers and a second non-1069 contrast MRI scanning session (denoted  $T_0$  in Results section). Immediately following the 1070 second non-contrast MRI scan, participants underwent intravenous gadolinium-based contrast 1071 agent (GBCA) injection (Gadavist, 0.1 mmol/kg), followed by T1- and T2-weighted contrast-1072 enhanced MRI scans 7-10 min after GBCA injection (denoted  $T_{10}$  in Results section).

1073

1074 Participants were escorted back to the study suite where they were re-instrumented with the 1075 commercial PSG and the Investigational Device. The Morning Interval ran from 0800 to 1130. 1076 Participants who assigned to the sleep condition in the Overnight Interval were required to 1077 remain awake and were monitored by study staff to ensure adherence: those assigned to the 1078 sleep deprivation condition in the Overnight were allowed to sleep. During this interval both the 1079 PSG and Interventional Device recorded data. The third assessment period commenced at the 1080 end of the Morning Interval. Participants underwent a final blood draw for amyloid  $\beta$  and tau 1081 biomarker assessment and then had a third MRI scanning session, including non-contrast 1082 sequences and T1- and T2-weighted contrast-enhanced sequences at approximately 4 hrs post-GBCA injection (denoted T<sub>240</sub> in Results section). 1083

1084

1107

1085	Replication Study: The Replication protocol was an abridged version of the Benchmarking
1086	protocol. The inclusion/exclusion criteria were identical to the Benchmarking study except for
1087	the lower age cut-off. Participants were similarly randomized to a night of sleep or a night of
1088	sleep deprivation on their first visit, with a crossover to the alternative sleep/sleep deprivation
1089	assignment on their second visit. The protocol for the Replication Study was identical to that of
1090	the Benchmarking Study excepting that 1) Participants did not undergo commercial PSG, sleep
1091	was assessed by Investigational Device EEG; 2) Participant sleep deprivation adherence in the
1092	Overnight Interval was assessed retrospectively using the sleep EEG; 3) The cognitive battery
1093	did not include the digits forward working memory test; 4) Participants underwent only non-
1094	contrast, and not contrast-enhanced MRI.
1095	
1096	Cognitive Assessments: The 5-minute PVT from Texas A&M University System CSE <sup>72</sup> and
1097	digits forward recall from Cambridge Cognition <sup>71</sup> were administered on an iPad. The paper-
1098	based SDMT from Western Psychological Services <sup>73</sup> , the TMT A and TMT B <sup>74</sup> , were
1099	administered by a clinical coordinator trained in administering these tests. The cognitive battery
1100	was administered in a quiet room with minimal distractions on the morning following sleep/wake
1101	and prior to the neuroimaging and phlebotomy. The administration of each test was preceded by
1102	the corresponding practice test. We have included a description of these tests within the overall
1103	protocol for completeness. The results of these cognitive tests, and their relationship to
1104	Investigational Device outputs, sleep parameters, fluid biomarkers, and MRI measures of
1105	glymphatic function will be reported elsewhere.
1106	

1108 analyzed using mass spectrometry by  $C_2N$  Diagnostics<sup>75</sup>. The sample collection procedure was

Plasma Biomarkers: The APOE genotyping, amyloid  $\beta$  and tau plasma biomarkers were

1109 provided by  $C_2N$  Diagnostics. Venipuncture and blood draw from the antecubital fossa were

1110 performed using a 22-gauge butterfly needle to minimize red blood cell hemolysis. A total of 10 1111 ml of blood was drawn into a K<sub>2</sub> EDTA Vacutainer. The blood was centrifuged for 15 min using a 1112 swinging bucket rotor at 500-700 x g with the brake on. Immediately after centrifugation, four 1.0 1113 mL plasma samples were aliquoted into four Sarstedt 2.0 ml Micro Tube without disrupting the 1114 plasma/cell interface when transferring plasma. A calibrated air-displacement hand-held pipette 1115 with a polypropylene pipette tip was used. After aliguoting plasma into the Sarstedt Micro 1116 Tubes, the tubes were immediately capped and frozen at -40°C. When the tubes were ready to 1117 be shipped to  $C_2N$  Diagnostics, they were packed into a plastic zip-lock bag with plenty of dry 1118 ice, placed in an absorbent towel and cryobox, and express couriered to  $C_2N$  Diagnostics 1119 priority overnight. In the present report, we utilize APOE4 allele status as a covariate in our 1120 analysis, and we have included a description of plasma biomarker assessment within the overall 1121 protocol for completeness. However, the fluid biomarker levels, and their relationship to 1122 Investigational Device outputs, sleep parameters, cognitive tests, and MRI measures of will be 1123 reported elsewhere.

1124

1125 Magnetic Resonance Imaging Approach

1126 MRI scanning at The Villages site was conducted on a 3T Siemens Vida system at Lake 1127 Medical Imaging, while scanning at the University of Washington site was conducted on a 3T 1128 Philips Ingenia Elition X at the Diagnostic Imaging Sciences Center. In the present report, to 1129 define the relationship between brain  $R_P$  and glymphatic function, we utilize CE-MRI from 1130 Benchmarking Study participants following the overnight sleep condition. We have included a 1131 description of the other MRI-based approaches within the overall protocol for completeness. 1132 However, the relationship between these different MRI measures of glymphatic function, 1133 Investigational Device outputs, sleep parameters, cognitive tests, and fluid biomarker levels will 1134 be reported elsewhere.

1136 Contrast-Enhanced MRI: Contrast-enhanced MRI involves intravenous administration of a 1137 Gadolinium chelate that shortens T1, T2, and T2\* relaxation parameters of the tissue it 1138 traverses through. Specifically, in this study, shortening of the T1 relaxation parameter 1139 enhances MRI signal that is proportional to the amount of Gadolinium and its characteristic 1140 relaxivity. Gadolinium passes quickly through the cerebral and peripheral vasculature within the first 5-30 minutes. A fraction of the contrast enters the CSF and ISF<sup>14,15</sup> over many hours and 1141 1142 finally almost 99% of the contrast exits the body by renal clearance. The passage of intravenous 1143 GBCA from the vasculature to the CSF and ISF was measured in terms of a delayed signal 1144 enhancement at approximately 4 hours after administration. Two prior studies have shown that 1145 delayed enhancement following contrast injection between 3 and 6 hours is indicative of solute (in this case, GBCA) transport via the CSF-ISF glymphatic exchange<sup>14,15</sup>. At the Villages®, we 1146 1147 performed 3D T1-weighted magnetization-prepared rapid acquisition with gradient echo (MPRAGE) with TR/TI/TE = 2300/900/2 ms, resolution =  $1 \times 1 \times 1$  mm<sup>3</sup>, field-of-view = 1148 1149  $256 \times 256 \times 208$  mm<sup>3</sup>, total acquisition time = 5:12 min before contrast injection. The post-contrast 1150 MRI image  $(T_{10})$  was acquired approximated 7-10 minutes after contrast injection and its 1151 acquisition was identical to the pre-contrast image. A second post-contrast scan was acquired 1152 about 4 hours  $(T_{240})$  later using identical imaging parameters.

1153

1154 <u>Structural MRI:</u> Structural T1 MRI was used for classifying the brain tissue into lobar gray 1155 matter, lobar white matter, and CSF as well as for segmenting regions-of-interests including the 1156 hippocampus, sagittal sinus, internal carotid arteries, lateral ventricle, and subarachnoid space. 1157 The T1 images were also used for registration purposes for all other imaging modalities. The T1 1158 images were used for determining PVS morphometry<sup>76,77</sup>. Scanning parameters for the 1159 Benchmarking Study are identical to the contrast-enhanced MRI. Scanning parameters for the 1160 Replication Study were TR/TI/TE = 12/1000/4.5 ms, resolution =  $0.8 \times 0.8 \times 0.8 \text{ mm}^3$ , field-of-view

1161	= 256×240×166 mm <sup>3</sup> , total acquisition time = 5:24 min. Since inclusion of T2 MRI significantly
1162	improves PVS detection, a T2 MRI with TR/TE = $3200/561$ ms, resolution = $0.8 \times 0.8 \times 0.8$ mm <sup>3</sup> ,
1163	field-of-view = $256 \times 240 \times 166$ mm <sup>3</sup> , total acquisition time = 4:32 min was also added.
1164	
1165	Intravoxel Incoherent Motion MRI: Intravoxel incoherent motion (IVIM) MRI is a multi-shell
1166	diffusion imaging approach to measure water movement at different scales of distance and time.
1167	Glymphatic transport includes movement of CSF in the subarachnoid space and the interstitium
1168	at a slow speed (~1 mm/s) over large distances (~100-200 um) <sup>1,30,40</sup> . This perivascular
1169	movement of CSF through the subarachnoid compartment is upstream of its exchange with the
1170	ISF along the penetrating intraparenchymal vasculature and hence could serve as an important
1171	correlate of glymphatic function <sup>78</sup> . The imaging parameters for the Benchmarking Study were:
1172	TR/TE = 5500/124 ms, resolution = $1 \times 1 \times 5$ mm <sup>3</sup> , field-of-view = $250 \times 250 \times 150$ mm <sup>3</sup> , parallel
1173	imaging factor = 2, multi-band factor = 3, fat suppression with Spectral Presaturation with
1174	Inversion Recovery (SPIR), b values = 0, 50, 100, 150, 200, 250, 300, 350, 400, 500, 700, 800,
1175	and1000 s/mm <sup>2</sup> , and total acquisition time = 7:01 min. The b = 0 s/mm <sup>2</sup> was acquired with
1176	reverse phase encoding to correct for field distortions. The imaging parameters for the
1177	Replication Study were TR/TE = 2978/90 ms, resolution = $1 \times 1 \times 5$ mm <sup>3</sup> , parallel imaging factor =
1178	2.2, field-of-view = $230 \times 196 \times 115$ mm <sup>3</sup> , fat suppression with SPIR, b values = 0,
1179	10,40,80,100,150,200, 300,500,700, 800, 900,1000 s/mm <sup>2</sup> , and total acquisition time = 8:08
1180	min. A Split echo (SPLICE) acquisition was used to eliminate the need for distortion correction.
1181	
1182	Multi-Echo, Multi-Delay Arterial Spin Labeling (ASL) MRI: Multi-echo, multi-delay ASL measures
1183	perfusion and time for exchange of water across the endothelium. This time metric is dependent
1184	on perfusion, endothelial permeability, and the glial vascular unit including the AQP4 water
1185	channels that are critical to the perivascular CSF-ISF exchange <sup>78,79</sup> . This protocol was

1186 implemented only for the Replication Study as a Hadamard-encoded ASL acquisition. TR/TE = 1187 5000 ms, resolution =  $1 \times 1 \times 5$  mm<sup>3</sup>, field-of-view =  $230 \times 196 \times 115$  mm<sup>3</sup>, post labeling delay = 650, 1188 950,1210,1510,2083,2383 ms with background suppression, label duration = 3400 ms, and TE 1189 = 0.40.80, 120 ms. Total acquisition time = 12:40 min. A conventional arterial spin labeling 1190 (ASL) protocol was implemented in the Benchmarking Study due to the lack of availability of the 1191 multi-echo component. The parameters were: TR/TE = 4420/22 ms, resolution =  $1.7 \times 1.7 \times 4$ 1192 mm<sup>3</sup>, field-of-view =  $220 \times 220 \times 96$  mm<sup>3</sup>, post labeling delay = 500, 1193 900,1000,1100,1200,1400,1600,1800, label duration = 1800 ms. Total acquisition time = 2:37 1194 min. The sequence was acquired twice. A reference M0 images was acquired in both studies 1195 with identical parameters but without background suppression or labeling. 1196 1197 Fast Functional MRI: A sub-second functional MRI sequence was implemented to separate and 1198 regress physiological noise (cardiac and respiratory signals) as well as to capture slow CSF 1199 oscillations in the ventricles<sup>80</sup>. The protocol for the Benchmarking Study was TR/TE = 400-1200 500/30 ms, resolution =  $3.6 \times 3.6 \times 3.6$  mm<sup>3</sup>, flip angle =  $70^{\circ}$ , multi-band factor = 4, field-of-view = 1201  $230 \times 2430 \times 101$  mm<sup>3</sup>, fat suppression, no. of volumes = 365 using SPIR, total acquisition time = 1202 2:37 min. Heart rate and respiration were monitored using the BIOPAC MR160 and 1203 synchronized with MRI acquisition. The Replication Study used a gradient-echo, echo planar imaging sequence with TR/TE = 400-500/30 ms, resolution =  $3 \times 3 \times 4$  mm<sup>3</sup>, flip angle =  $42^{\circ}$ , multi-1204 1205 band factor = 6, field-of-view =  $240 \times 240 \times 123$  mm<sup>3</sup>, slice gap = 0.4 mm, fat suppression using 1206 SPIR, no. of volumes = 450, total acquisition time = 3:00 min. Two single volume, spin echo 1207 acquisitions were also acquired with opposite phase encoding to allow for distortion correction. 1208 Heart rate and respiration were monitored using the sensors built into the Philips scanner and 1209 synchronized with MRI acquisition. Glymphatic CSF-ISF exchange is at least partly driven by 1210 vasomotion, which may be reflected by periodic motion in the CSF spaces. This CSF motion

1211 correlates well with sleep stages, with power of the slow CSF oscillation increasing from
1212 wakefulness to the N1 and finally to the N2 stage<sup>80</sup>.

1213

1214 Phase-Contrast MRI: The phase contrast MRI is used to quantify CSF efflux from the Aqueduct 1215 of Sylvius. The peristaltic motion of CSF at the Aqueduct is measured by gating the MRI signal 1216 to the participants and calculating the CSF motion into and out of the brain over a cardiac 1217 signal. Variations in CSF efflux velocity appear to follow the cardiac and respiratory signals and 1218 may impact glymphatic CSF-ISF exchange. The Benchmarking Study protocol for this MRI was 1219 the following: a single slice acquisition perpendicular to the Aqueduct of Sylvius, TR/TE = 21/6.6 ms, resolution =  $30.6 \times 0.6 \times 6$  mm<sup>3</sup>, flip angle =  $10^{\circ}$ , 40 phases per cardiac cycle, and velocity 1220 1221 encoding for 12 cm/s, total acquisition time: 2:00 min. The Replication Study protocol included 1222 the following: a single-slice acquisition perpendicular to the Aqueduct of Sylvius, TR/TE = 12/7.9 ms, resolution =  $30.6 \times 0.6 \times 4$  mm<sup>3</sup>, flip angle =  $10^{\circ}$ , 15 phases per cardiac cycle, and velocity 1223 1224 encoding for 12 cm/s, total acquisition time: 2:02 min

1225

1226 Statistical Approach

The Benchmarking study was designed to have 80% power at a significance level of 5% to detect a low-to-moderate correlation r (r=0.5) between the device measurements and CE-MRI measurement of glymphatic function. The Replication study was designed to have 80% power at a significance level of 20% to detect a low-to-moderate correlation r (r=0.5) between the device measurements and non-contrast MRI measurement of glymphatic function and to detect overnight sleep/wake differences in brain parenchymal resistance.

1233

1234 The parenchymal resistances R<sub>P</sub> computed from each EIS scan from the device were

1235 normalized to the sleep/wake onset values to allow comparison across visits and participants.

To reduce measurement variability of the sleep/wake onset value, the value was inferred from a linear regression to the initial R<sub>P</sub> values. The overnight change in R<sub>P</sub> per participant visit was taken as the average of the normalized values for that visit. For example, a value of 1 indicated that there was no overnight change from the onset value and a value of 0.8 indicated a 20% overnight reduction from onset. A Student's T-test group comparison between sleep/wake visits, group mean and SD were calculated.

1242

1243 Contrast-enhanced MRI of sleep-related glymphatic function was analyzed using a random 1244 intercept linear mixed effect model (R, Ime in the Imne package). Glymphatic function was 1245 defined by measuring brain parenchymal contrast enhancement, the % change in T1-weighted 1246 signal intensity between 10-240 min post-GBCA injection  $(100\% * (T_{240}-T_{10})/T_0)$  at each of eight 1247 regions of interest (ROIs): frontal cortical gray and white matter, parietal cortical gray and white 1248 matter, temporal cortical gray and white matter, and occipital gray and white matter. Only sleep 1249 visits were analyzed leading to a one level of grouping, the eight ROIs, for the participant sleep 1250 visit. All models included regressors in the mixed model for the  $T_{10}$ - $T_{240}$  change in blood signal 1251 within the internal carotid artery, and the  $T_{10}$ - $T_{240}$  change in CSF signal within the cerebral 1252 lateral ventricles to compensate for the influence of vascular and CSF contrast on parenchymal 1253 enhancement. Potentially confounding biological variables age, gender, and APOE ε4 status 1254 were also included in all models.

1255

To evaluate different sleep-related contributions to glymphatic function, overnight changes from sleep onset for each of the four recorded EEG relative band powers (delta, theta, alpha, beta) and for HR were computed. The recorded values were normalized to their respective value at sleep onset and a single statistic, the average of the overnight normalized values, computed per participant visit. The four hypnogram sleep stages (N1, N2, N3, REM) and WASO were each summed into single total sleep stage durations and total WASO duration per participant visit.

1262 The device R<sub>P</sub> normalization and averaging has been previously described. Models were run 1263 separately for each of the four EEG relative band powers (delta, theta, alpha, beta), for each of 1264 the four hypnogram sleep stages (N1, N2, N3, REM), for WASO, for HR and for device R<sub>P</sub>. Two 1265 full models were then fit to the data, with the EEG band power and the hypnogram sleep stages 1266 separated into distinct models because of collinearity across those predictors. The variance 1267 inflation factor (R 'vif' function from the 'car' package) was used to test for predictor collinearity 1268 using a threshold of 5. The EEG powerbands included were limited to delta, theta and beta 1269 because of collinearity among the four relative band powers. HR and the device  $R_P$  were 1270 included in both full models. Each full model was reduced to a selected model using backward 1271 elimination of predictors with a threshold Wald's p-value of 0.05. 1272 1273 Model selection stability, or robustness of the selected model to perturbations in the dataset, 1274 was tested using resampling-based multi-model inference<sup>29</sup>. The dataset was bootstrapped 1275 resampled with replacement to generate 500 bootstrapped datasets. For each of these datasets 1276 the two full models were estimated and reduced to a selected model using backward 1277 elimination. The bootstrap inclusion frequency (the percent of bootstrap datasets that included 1278 the predictor), the RMSD ratio (the RMSD of the predictor bootstrap estimate divided by the 1279 standard error of that coefficient in the full model and expressing the variance inflation or 1280 deflation caused by variable selection), the relative conditional bias (guantifying the variable-1281 selection-induced bias to expect if a predictor is selected) and the bootstrap median of each 1282 predictor coefficient were reported. 1283 1284 The analyses of device  $R_P$  values with EEG band powers, heart rate and hypnogram staging

1286 NREM sleep (N1, N2 and N3). The device resistances were computed repeatedly throughout

were performed on the overnight sleep recordings. Analyses were grouped into REM sleep and

1285

1287 the night from each EIS scan. During sleep recordings, these data were non-stationary. After

1288 normalization to sleep onset as previously described, first-order differences  $\Delta R_P$  and  $\Delta X$  for X 1289 one of the EEG band powers or HR were incorporated into individual random intercept linear 1290 mixed models to evaluate their relationship. Threshold regression models were used in the 1291 linear mixed model. A custom estimation procedure described in Supplemental Information 1292 was used to jointly estimate the threshold regression for the full positive and negative range of 1293 the predictors. The hinge threshold model was analytically reduced to estimation by linear 1294 regression which allowed it to be used in a random intercepts linear mixed effects regression 1295 model. The autocorrelation function and augmented Dickey Fuller tests were used to confirm 1296 stationarity of the differenced variables  $\Delta R_P$  and  $\Delta X$  and also of the fitted model residuals (R, 1297 acf and adf functions). 1298 1299 In addition to the analyses of  $\Delta R_P$  and  $\Delta X$  for X one of the EEG powerbands or HR during REM 1300 sleep and NREM sleep, these were analyzed at hypnogram transitions NREM to REM, REM to NREM, sleep to wake and wake to sleep. The analysis was similar, using threshold regression 1301 1302 models in a random intercept mixed linear model. 1303 1304 Univariate outliers were trimmed at the 0.5 and 99.5 percentile. For multivariate analysis, the 1305 Mahalonobis distance was computed and outliers trimmed at the 0.5 and 99.5 percentile of the 1306 Mahalonobis distance. All regressions were adjusted for potential confounding effects of age,

1307 sex and APOE genotype. All tests were considered significant at a 5% level if the 95%

1308 confidence interval (CI) did not contain the null hypothesis. All statistical analyses were

performed in R version 4.2.1 (2022-06-23) or Graphpad Prism 8.0.0.

1310

1311 We reported the pooled findings of the Benchmarking and Replication study for both the

1312 investigational device transcranial resistance measurements and EEG parameters.

1313

#### 1315 SUPPLEMENTAL INFORMATION

#### 1316 Supplemental 1: Analysis of device EEG and commercial polysomnography

- 1317 The single derivative device EEG was validated against the commercial PSG (Philips
- 1318 Respironics Alice 6 LDx Diagnostic Sleep System) in participants that underwent concurrent
- 1319 device and PSG sleep recording as part of the Benchmark study. Both hypnogram sleep staging
- 1320 and sleep parameters were validated using a confusion matrix between the device prediction
- and the PSG prediction both per participant and pooled across participants. Prediction metrics
- 1322 computed included sensitivity, specificity, precision, accuracy and F1 score. The device EEG
- 1323 with EOM and the PSG C3-A2, C4-A1 derivatives were individually input into the automated
- hypnogram scoring (Python yasa 0.6.3 *SleepStaging*). Manual scoring of the PSG by a sleep
- 1325 physician (YC) was used as the gold-standard. The results of these comparisons are provided

1326 in Supplemental Table 6.

1327

#### 1328 Supplemental 2: Threshold regression model and estimation

1329 Threshold regression models were fit on data that spanned the full positive and negative range 1330 of abscissa values. These models are defined by a positive turning point  $t_p \ge 0$  where for  $x \ge$ 1331  $t_p$  the regression line goes from f(x) = 0 to  $f(x) = m_p(x - t_p)$  and a negative turning point 1332  $t_n \le 0$  where for  $x \le t_n$  the regression line goes from f(x) = 0 to  $f(x) = m_n(x - t_n)$ . These 1333 models can be reduced to linear regression. First transform the data  $(x, y) \to (w, y)$  were

1334  
$$w = \begin{cases} x - t_n \text{ if } x \leq t_n \\ 0 \text{ if } t_n < x < t_p \\ r(x - t_p) \text{ if } x \geq t_p \end{cases}$$

For values of  $t_p$ ,  $t_n$  and r, a least squares estimator can be used to fit a linear model to the transformed data values (w, y). With  $r = \frac{m_n}{m_p}$ , the transformed data is linear, through the origin and has slope  $m_n$ . When r = 1 both slopes are identical; for  $r \neq 1$  the positive half-space slope equals the regression estimate multiplied by r. Hence, for r < 1 the positive half-space slope is

1339 less than the negative half-space slope and for r > 1 the positive half-space slope is greater 1340 than the negative half-space slope.

1341

1342 The linear fit was estimated using an F-statistics, the ratio of the explained variance (due to the 1343 model) and the unexplained variance (residuals). Grid search over the parameter space  $t_n$ ,  $t_n$ 1344 and r was carried out and the values that minimized the mean sum of squared residuals (and 1345 hence maximized the F-statistic) was reported<sup>81</sup>. To avoid edge effects,  $t_n$  and  $t_n$  were set to 1346  $\pm 1.5$  standard deviations<sup>82</sup>. Random intercept linear mixed models were similarly fit to the 1347 transformed data and grid search used to solve for the parameters that minimized the mean 1348 sum of squared residuals for the fixed effects. The autocorrelation function was used to confirm 1349 no residual autocorrelation following model estimation and fit. 1350 1351 1352 Supplemental 3: Physiological basis for electrical impedance spectroscopy change with 1353 glymphatic function. 1354 In normal adult men (women) between the ages of 60-86 years, the GM, WM and total 1355 intracranial volumes (TIV) are  $614.3 \pm 60.1$  ( $562.6 \pm 50.1$  ml),  $534.0 \pm 57.2$  ml ( $476.6 \pm 44.7$  ml)

1356 and 1603.0 ± 133.0 ml (1425.9 ± 109.0 ml)<sup>83</sup>. Average adult cerebral blood flow (CBF) is

1357 approximately 750 ml/min or 12.5 ml/sec. Assuming HR of 60 bpm, 12.5 ml of blood injected

1358 into the brain causes an approximate 50 mΩ decrease in the device IPG sampled at 80 kHz

1359 (see for example Figure 2d, IPG-Impedance Plethysmograph data taken from a female study

1360 participant). At 80 kHz, EIS measures the extracellular compartment and most of the

1361 intracellular compartment. Thus, the 12.5 ml increase in blood volume, representing a

1362 12.5/1425.9 = 0.88% change in TIV, would be measured as a 50 m $\Omega$  decrease in resistance by

1363 EIS.

1364

1365 At low frequencies, EIS measures changes in extracellular volume. The interstitial cortical 1366 volume fraction  $\alpha$  in awake rodents has been shown to be 14.1% and in sleeping rodents 23.4% whereas the tortuosity  $\lambda$  of the interstitial space remained unchanged across sleep and wake<sup>2,84</sup>. 1367 1368 This suggests that in rodents, the sleep-induced volume expansion of the interstitial space 1369 occurs from a change in the cross-sectional area and not length. This is noteworthy because resistance of a conductor is proportional to  $\frac{l}{A}$  where *l* is the length and *A* the cross-sectional 1370 1371 area. Therefore, the increase in interstitial space fluid with glymphatic function will increase the 1372 cross-sectional area of the interstitial space channels and proportionally decrease the transcranial electrical resistance. In humans, the measurements range from 15-20%<sup>85</sup> but 1373 1374 changes with sleep/wake have not been assessed. Using the rodent data as a proxy to what we 1375 might expect in humans, we would expect a 66% increase in interstitial volume with sleep to 1376 occur from of a 66% increase in cross-sectional area of the interstitial channels. The remaining 1377 extracellular compartment volumes contributing to the resistance at low EIS frequencies are 1378 CSF and blood plasma that occupy a total volume comparable to the awake interstitial volume. 1379 Therefore, the net extracellular compartment volume increase, or effective cross-sectional area 1380 increase, with sleep is 33%. Using the IPG relationship between fluid volume change and 1381 transcranial impedance, a 0.88% increase in fluid volume was measured as a 50 m $\Omega$  decrease 1382 in transcranial electrical resistance implying that a 33% volume increase would be measured as 1383 an 1875 m $\Omega$  decrease. This analysis uses the conclusion that the interstitial volume increase of 1384 glymphatic function is an increase in the interstitial channel cross-sectional area and similarly 1385 the assumption that the intravascular volume increase of cardiac output is from an increase in 1386 the intravascular cross-sectional area. The preceding analysis assumed a 66% increase in 1387 interstitial volume fraction as seen in rodents. Assuming a smaller 25% volume fraction increase

and using the same analysis, we would expect a 710 m $\Omega$  decrease in transcranial resistance with sleep.

1390

#### 1391 Supplemental 4: Benchtop and agar phantom characterization of electrodes and device.

1392 Electrodes were characterized according to the ANSI/AAMI EC12 standard for AC impedance,

1393 DC offset voltage, combined offset instability and internal noise, and bias current tolerance<sup>57</sup>.

1394 Defibrillation overload recovery was not tested as it is not relevant to the present application.

1395 Pairs of electrodes were immersed in a 140 mM NaCl solution, facing each other and separated

1396 by 3-4 mm. AC impedance at 10 Hz was measured using a multifunction DAQ module (Analog

1397 Discover 2, Digilent) configured for 2-point impedance measurement. An excitation voltage of

1398 100 millivolts peak-to-peak (mVpp) and a 10 kΩ series resistor guaranteed a maximum current

1399 of 10 microamps peak-to-peak (µApp). DC offset voltage was measured with a Fluke 87V

1400 multimeter. Offset instability and internal noise were measured over five minutes using a 24-bit

1401 digitizer module (ADS1299EVM, Texas Instruments, 67 nV resolution) sampling at 2000

1402 samples per second, calibrated using a Keysight EDU33212A Signal Generator. Recorded data

1403 was subsequently filtered with a 0.15-100 Hz first order bandpass (simulating EC12 filtering) or

1404 the 0.3-50 Hz EEG bandpass filter described in Signal Processing -

1405 **Electroencephalography**. Peak-to-peak values over the 5-minute period are reported. Bias

1406 current tolerance was measured with a multifunction DAQ module using its 14-bit digitizer

1407 (0.32 mV resolution) as data logger (sampling every 10 seconds for 8 hours), and its power

supply to apply 200 nA DC across the pair of electrodes (2 V across a 10 M $\Omega$  resistor in series).

1409 The maximum voltage deviation relative to the initial offset voltage before current application is

reported. All results are found in **Supplemental Table 7**.

1411

Benchtop validation of the investigational device EIS compared the measured to the theoreticalresistance and reactance at each frequency on a circuit model of brain parenchymal impedance

1414 (the load) with separate models for each of the four electrode impedances. The circuit diagram 1415 for these benchtop measurements is shown in Supplemental Figure 2. The load was modelled 1416 using 2R1C parallel circuit and the four electrode-skin interfaces were modeled by individual 1417 2R1C circuits with a charge transfer resistance in parallel to a double layer capacitance that was 1418 in series with a resistor embodying the electrolyte and stratum corneum resistance. The 1419 resistance and capacitance values for the load were based on observed participant resistance 1420 and reactance over the EIS frequencies. Two sets of parameters for the electrode impedance 1421 models were used, a low-impedance model and a high-impedance model. These were selected 1422 to cover the observed range of subject electrode impedances over the range of EIS frequencies. 1423 The parameters for the complete set of benchtop tests are found in **Supplemental Table 8** and 1424 included (i) calibration measurements of purely resistive loads, (ii) calibration of a 2R1C load 1425 varying the parallel resistor  $R_s$  to simulate changes in the interstitial space resistance, and (iii) 1426 calibration of a fixed 2R1C load while varying the electrode impedances at each electrode 1427 between low and high impedance settings to test the sensitivity to expected variations during 1428 use. The absolute error between the measured and theoretical resistance and reactance for the 1429 benchtop tests are reported in **Supplemental Table 9** and in **Supplemental Table 10**, 1430 respectively. The measured impedances reported were rotated by multiplying by the factor 1431  $e^{-j\omega T}$  with the value T chosen so that the reactance at 256kHz was zero<sup>59</sup>. The absolute error of 1432 the resistance reveals a systematic positive bias implicating contributions to the resistance in 1433 the device or benchtop setup that were not fully compensated by the device calibration. For the 1434 measurements of the 2R1C benchtop tests, the resistance bias is 0.278  $\Omega$  and the bias un-1435 adjusted and adjusted RMSE are 0.321  $\Omega$  and 0.144  $\Omega$ , respectively. The reactance did not 1436 show a systematic bias. The RMSE of the reactance for the 2R1C benchtop tests is 0.128  $\Omega$ . 1437 Because we are interested in the dispersion of the resistance over frequencies, or the difference 1438 between the resistance at a low frequency and at a high frequency, the bias cancels out. Using 1439 the signal processing pipeline to fit the Debye model, **Supplemental Table 11** reports the

1440 dispersion prediction error from theoretical value at each frequency relative to 128 kHz. 1441 Reported values are for the 2R1C electrode impedance sensitivity tests. The 1 kHz minus 1442 128kHz dispersion is representative of the parenchymal resistance  $R_P$  computed from the 1443 difference between the extrapolated DC resistance and the infinite frequency resistance. This 1444 dispersion had an RMSE of 0.147  $\Omega$  approaching the bias-adjusted RMSE of the 2R1C 1445 benchtop tests in **Supplemental Table 9**, and represents a 3.1% measurement error in the 1446 theoretical dispersion value of 4.766  $\Omega$ .

1447

1448 The device EIS showed the accuracy needed to reliably measure a single  $R_P$  value but to 1449 evaluate glymphatic function it needs to detect changes in  $R_{\rm P}$ . These changes are small by 1450 comparison to the absolute value of R<sub>P</sub>. As discussed, the overnight decrease ranges between 1451 500 m $\Omega$  and 2000 m $\Omega$ . With the current time-multiplexing settings, the device completes 1452 approximately 84 scans over a 7-hour night of sleep, or 6 to 23 m $\Omega$  average decrease between 1453 scans. The statistical models used in the analysis of the Benchmarking Study and Regression 1454 Study required significance testing of the mean change in R<sub>P</sub> between sleep and wake, and 1455 testing significance of predictors of R<sub>P</sub> in linear mixed models. These tests depend on the SD of 1456 the Debye model dispersion estimate which for the electrode impedance sensitivity tests was 1457 0.113  $\Omega$ , slightly less than the bias-adjusted RMSE. **Supplemental Table 12** shows that the 1458 minimum change in  $R_P$  with 25 and 100 EIS scans that is statistically significant is 44 m $\Omega$  and 1459 22 m $\Omega$ , respectively. Note that during sleep, R<sub>P</sub> decreases with glymphatic function and 1460 therefore each measurement arises from a distribution with a different mean but the same SD 1461  $\sigma$ . Using the linearity of expectation and statistical independence of each R<sub>P</sub> measurement, the standard error of the mean of  $R_P$  is  $\frac{\sigma}{\sqrt{n}}$  for *n* samples. Using the Fisher transform<sup>86</sup> to solve for 1462 1463 the minimum significant correlation detectable at a given sample size. Supplemental Table 11 1464 reports that weak to moderate correlations of R<sub>P</sub> with predictors will be significant at 100 and 25

- 1465 EIS scans, respectively. These estimates are optimistic since not all sources of error are
- 1466 accounted by the electrode impedance sensitivity tests.
- 1467
- Agar phantom testing over 12 hours was used as a final quality check for each fully assembled
- 1469 device. These tests measured the device combined noise level from the electronics,
- 1470 electrochemical interfaces between the electrodes, EEG gel and agar. **Supplemental Figure 3**
- 1471 shows the device periodogram, EEG recording and power spectral density from an agar
- 1472 phantom test.
- 1473

#### 1474 Data availability

- 1475 The data supporting the results in this study are available from the corresponding author with
- 1476 Institutional Review Board approval and Data Use Agreement permitting non-commercial use of
- 1477 data for independent validation, publication and sharing of new findings.
- 1478

#### 1479 **Code availability**

- 1480 Code used for the analysis and to produce figures are available upon reasonable request to the
- 1481 corresponding author.
- 1482
- 1483

#### 1484 Supplemental Table 1. Demographic, genetic and psychometric results of the

1485 Benchmarking Study, Replication Study and Combined Study.

1486

	Benchmarking Study	Replication Study	Combined Study
Ν	30	14	44
Age ± SD (Range)	61.8 ± 2.7 (56, 66)	55.6 ± 4.6 (49, 63)*	59.8 ± 4.4 (49, 66)
Female (Male)	14 (16)	7 (7)	21 (23)
APOEe4 (not APOEe4)	8 (22)	5 (9)	13 (31)
MoCA ± SD (Range)	27.8 ± 1.1 (26, 30)	28.6 ± 1.2 (26, 30)	28.1 ± 1.2 (26, 30)
GDS ± SD (Range)	0.7 ± 1.1 (0, 4)	0.6 ± 1.2 (0, 4)	0.7 ± 1.1 (0, 4)

1487 Montreal Cognitive Assessment, MoCA; Geriatric Depression Scale, GDS. \*P<0.001

1488 Benchmarking vs. Replication Study, unpaired t-test.

1489 Supplemental Table 2. EEG band power, hypnogram, and R<sub>P</sub> as individual predictions of parenchymal contrast 1490 enhancement when added to the null model following overnight sleep.

1491

	Predictor	Estimate	95% CI	P Value	LRT	LRT P Value
	Delta Band Power	19.121	(5.482, 32.760)	0.007	7.50	0.006
	Theta Band Power	-3.755	(-11.982, 4.473)	0.378	0.81	0.368
	Alpha Band Power	-7.279	(-12.264, -2.294)	0.005	8.12	0.004
	Beta Band Power	-5.329	(-7.786, -2.873)	<0.001	17.49	<0.001
Due distance Added	Heart Rate	-21.624	(-49.814, 6.566)	0.139	2.28	0.131
to Null Model	WASO Time	-0.003	(-0.045, 0.038)	0.881	0.02	0.879
to Null Model	N1 Sleep Time	-0.128	(-0.213, -0.042)	0.004	8.46	0.004
	N2 Sleep Time	-0.031	(-0.071, 0.009)	0.139	2.28	0.131
	N3 Sleep Time	0.025	(-0.024, 0.075)	0.322	1.02	0.313
	REM Sleep Time	0.031	(-0.023, 0.086)	0.268	1.28	0.258
	Parenchymal Resistance	-38.080	(-61.348, -14.812)	0.002	10.15	0.001
				-		
	Blood CE	10.29	(5.45, 15.13)	<0.001	-	_
Null Medel	CSF CE	148.48	(123.40, 173.56)	<0.001	-	-
NUII MODEI Fixed Effects	Age	-1.31	(-1.91, -0.71)	<0.001	-	-
	Male Sex	-2.69	(-5.42, 0.063)	0.060	-	-
	ΑΡΟΕ ε4	-3.29	(-6.50, -0.091)	0.048	-	-
Null Model	σ <sup>2</sup>	70.50	-	-	-	-
Random Effects	T00 ROI	12.60	-	-	-	-

1492 Wake After Sleep Onset, WASO; Rapid Eye Movement, REM; Confidence Interval, CI; Likelihood Ratio Test, LRT. **Bolded P values** 

1493 reflect significant associations at P < 0.05. Likelihood ratio test taken between null model and model with predictor.

#### 1495 Supplemental Table 3. Multivariate models of morning brain parenchymal contrast enhancement using overnight and 1496 morning Rp, HR and EEG hypnogram predictors.

1497

			Full Model			Selected Model			Bootstrap Analysis		
Predictor Period	Fixed Effect Predictors	Estimate	СІ	р	Estimate	СІ	р	Bootstrap Inclusion Frequency (%)	RMSD Ratio	Relative Conditional Bias (%)	Bootstrap Median
	Blood CE	0.87	-5.26, 7.00	0.786	-	-	-	11.6	2.14	386.83	0
	CSF CE	221.86	185.38, 258.34	<0.001	225.82	(208.18, 243.47)	<0.001	100.0	0.94	0.01	225.13
	Age	-0.30	-0.82, 0.23	0.286	-	-	-	39.8	1.86	107.95	0
	Male Sex	-2.70	-5.77, 0.36	0.094	-	-	-	41.8	1.07	53.57	0
	APOE ε4	-4.60	-7.86, -1.35	0.008	-5.33	(-8.34, -2.31)	0.001	81.6	0.98	16.33	-4.77
Overnight	RP	-76.16	-99.79, -52.53	<0.001	-67.17	(-87.78, -46.56)	<0.001	100.0	1.16	-5.30	-72.57
Sleep Opportunity	REM Time	0.16	0.08, 0.24	<0.001	0.16	(0.09, 0.23)	<0.001	99.0	1.06	1.30	0.16
	N1 Time	-0.30	-0.43, -0.16	<0.001	-0.32	(-0.43, -0.21)	<0.001	98.8	1.09	0.95	-0.31
	N2 Time	-0.10	-0.14, -0.05	<0.001	-0.10	(-0.15, -0.06)	<0.001	98.0	0.80	-1.01	-0.10
	N3 Time	-0.09	-0.15, -0.03	0.004	-0.07	(-0.12, -0.02)	0.007	86.8	0.72	-1.15	-0.08
	WASO Time	-0.07	-0.13, -0.01	0.037	-0.07	(-0.12, -0.02)	0.006	78.6	0.74	21.00	-0.07
	Heart Rate	-13.08	-44.72, 18.57	0.432	-	-	-	24.2	1.84	133.52	0
	Blood CE	11.33	6.39, 16.28	<0.000	10.84	(5.98,15.71)	<0.001	98.6	0.97	-5.49	10.59
	CSF CE	132.86	101.23, 164.50	<0.000	140.28	(113.86, 166.71)	<0.001	100.0	1.04	1.82	135.82
	Age	-0.81	-1.47, -0.144	0.022	-0.95	(-1.55, -0.34)	0.003	75.8	1.28	38.20	-0.94
	Male Sex	-4.27	-7.73, -0.82	0.020	-3.24	(-5.93, -0.55)	0.023	69.0	0.84	9.25	-3.57
	APOE ε4	-13.22	-23.65, -2.79	0.017	-9.25	(-13.20, -5.29)	<0.001	92.6	1.06	-13.49	-9.74
Morning	R <sub>P</sub>	38.06	7.87, 68.24	0.018	34.42	(5.25, 63.59)	0.025	65.4	0.81	20.18	37.42
Sleep Opportunity	REM Time	0.58	0.10, 1.06	0.024	0.41	(0.20, 0.62)	<0.001	88.2	1.00	-14.04	0.40
	N1 Time	-0.28	-0.59, 0.02	0.080	-0.26	(-0.50, -0.02)	0.040	61.6	0.93	36.23	-0.29
	N2 Time	-0.11	-0.24, 0.022	0.116	-0.13	(-0.26, -0.01)	0.051	41.4	1.30	63.35	0
	N3 Time	-0.18	-0.37, 0.00	0.063	-0.17	(-0.33, -0.021)	0.031	44.2	0.65	15.70	0
	WASO Time	0.19	-0.10, 0.56	0.344	-	-	-	33.4	1.53	57.53	0
	Heart Rate	-23.75	-107.49, 59.98	0.591	-	-	-	18.2	2.01	-28.96	0

1498 Electroencephalography, EEG; Parenchymal Resistance, R<sub>P</sub>; Heart Rate, HR; Contrast Enhancement, CE; 95% Confidence Interval,

1499 CI; Backward Elimination, BE; Root-Mean Square Deviation, RMSD; within ROI variability,  $\sigma^2$ ; inter-ROI variability,  $\tau_{00 \text{ ROI}}$ . Bolded P

1500 values reflect significant associations at P < 0.05. Shaded cells demark the null model that includes blood CE, CSF CE and 1501 potential biological confounders.

# Supplemental Table 4. The change in parenchymal resistance resulting from large changes in EEG band power and heart rate during REM sleep, NREM sleep and wake for each study.

1506

1507

				Fixed Effects Threshold Model Parameters					
Study / Condition	Sleep Stage	Predictors	Estimate	CI	р	DF	Positive Threshold	Negative Threshold	Slope Ratio
		∆delta	-0.42	(-0.62, -0.21)	<0.001	240	1.28	-1.5	2
		∆theta	-0.41	(-0.91, 0.082)	0.105	240	1.5	-1.3	0.5
	REM	∆alpha	-0.05	(-0.21, 0.10)	0.504	240	1.5	-0.08	2
Benchmarking		∆beta	0.54	(0.16, 0.91)	0.006	240	1.5	-1.35	0.5
Study /		ΔHR	0.10	(-0.26, 0.47)	0.588	202	1.5	-0.9	0.5
Sleen On		∆delta	-0.21	(-0.46, 0.039)	0.099	1038	1.5	-1.5	0.95
oleep op		∆theta	-0.12	(-0.33, 0.090)	0.263	1038	1.23	-1.43	0.5
	NREM	∆alpha	-0.14	(-0.30, 0.0063)	0.061	1038	1.5	-1.23	0.98
		∆beta	0.04	(-0.039, 0.12)	0.334	1038	1.3	-1.5	2
		ΔHR	0.13	(0.014, 0.25)	0.029	820	1.5	-0.25	0.5
Benchmarking		∆delta	-0.07	(-0.18, 0.046)	0.243	631	0.75	0	0.5
Study /	WAKE	∆theta	-0.08	(-0.17, 0.0084)	0.076	631	0.73	-1.5	2
Overnight Sleep		∆alpha	0.07	(-0.049, 0.19)	0.245	631	1.5	0	0.5
		∆beta	0.05	(-0.15, 0.26)	0.601	631	1.5	-1	0.83
Deprivation		ΔHR	-0.10	(-0.20, 0.0017)	0.055	596	0.05	0	0.5
		∆delta	-0.69	(-1.1, -0.33)	0.000	78	1.43	-1.38	2
	REM	∆theta	-0.23	(-0.39, -0.074)	0.006	78	0.1	-1.5	2
		∆alpha	-0.19	(-0.46, 0.084)	0.183	78	1.1	-0.1	1.25
Replication		∆beta	0.27	(-0.13, 0.68)	0.196	78	1.48	-0.45	1.08
Study /		ΔHR	1.08	(0.45, 1.7)	0.001	68	1.5	-1.23	0.9
Sleep Op		∆delta	-0.32	(-0.57, -0.064)	0.015	341	1.5	-0.8	0.6
cicch ch		∆theta	0.03	(-0.043, 0.11)	0.379	341	0	-1.5	2
	NREM	∆alpha	0.03	(-0.049,0.11)	0.482	341	0.03	-1.5	2
		∆beta	0.13	(0.045, 0.22)	0.003	341	0.38	-1.5	2
		ΔHR	0.05	(-0.14, 0.25)	0.602	294	0.63	-1.5	1.13
Replication		∆delta	0.04	(-0.075, 0.16)	0.479	505	0.8	-1.5	2
Study /		∆theta	0.03	(-0.043, 0.096)	0.460	505	0	-1.5	2
Overnight	WAKE	∆alpha	0.09	(-0.063, 0.25)	0.247	505	1.15	-1.5	2
Sleep		∆beta	0.18	(0.031, 0.34)	0.019	505	1.48	-1.43	2
Deprivation		ΔHR	-0.11	(-0.27, 0.056)	0.204	405	1	-0.35	0.88

Rapid eye movement, REM; non-REM, NREM; Confidence Interval, CI; Degrees of Freedom,
DF; EEG band power predictor units in percent of total band power; HR predictor units beatsper-minute. Bolded P values reflect significant associations at P < 0.05. Predictor and</li>
parenchymal resistance values in regression models were scaled to zero mean and unit
standard deviation to simplify effect size comparisons across predictors. Positive and negative
thresholds are in units of predictor standard deviation. Models included confounding biological

1514 variables age, gender, and APOE ε4 status.

1515

1516

#### 1518 Supplemental Table 5. The change in parenchymal resistance resulting from large

#### 1519 changes in EEG band power and heart rate at NREM-REM and sleep-wake transitions for 1520 each study.

1520 1521

Threshold Model **Fixed Effects** Parameters Positive Negative Slope Predictors Estimate Ρ DF Study Transition CI Threshold Threshold Ratio ∆alpha 0.86 (-0.05, 1.77)0.073 52 0.725 -1.5 0.5 1.01 (0.18, 1.85) 0.023 52 0.35 -1.5 0.5 ∆beta NREM to ∆delta -0.31 (-0.96, 0.34)0.359 52 1.5 -1.15 2 REM 0.10 37  $\Delta HR$ (-0.27, 0.47) 0.593 1.5 0 2 0.28 52 -1.5 0.5 (-0.37, 0.93)0.405 0 ∆theta ∆alpha -0.17 (-0.46, 0.13)0.276 45 1.5 0 2 -0.08 (-0.29, 0.13) 0.445 45 0.2 -1.5 1.9 ∆beta **REM** to ∆delta -0.43 (-0.74, -0.11) 0.011 45 -0.9 2 1 NREM (-0.13, 0.78) ΔHR 0.32 0.180 34 1.5 -0.625 2 -0.03 (-0.17, 0.1)0.628 45 0 Benchmarking ∆theta 0 2 Study -0.89 (-1.71, -0.08)0.038 53 0.775 -1.5 0.5 ∆alpha ∆beta 0.67 (-0.14, 1.47)0.114 53 0.35 -1.5 0.5 Sleep to 0.03 53 0.025 -1.45 ∆delta (-0.17, 0.23)0.778 2 Wake 0.383 0 -1.4  $\Delta HR$ -0.32 (-1.01, 0.38)39 0.5 -1.5 0.04 (-0.2, 0.29) 0.737 53 0.25 ∆theta 1.75 -0.975 ∆alpha -0.31 (-0.98, 0.37)0.377 89 1.5 0.525 0.45 (-0.07, 0.96)0.095 89 1.5 -1.25 ∆beta 2 Wake to ∆delta -0.22 (-0.6, 0.17) 0.273 89 0.2 -1.5 0.9 Sleep -0.11 (-0.25, 0.03) 0.145 64 0 0 2  $\Delta HR$ -0.20 0.409 89 0.05 -1.3 (-0.68, 0.27)0.5 ∆theta 0.26 -0.1 ∆alpha (-0.46, 0.97)0.493 8 1.5 2 -0.75 (-2.45, 0.94)0.400 0.175 -1.325 0.5 ∆beta 8 REM to ∆delta 2.23 (-0.7, 5.16) 0.167 8 1.15 -1.475 1.8 NREM -0.75  $\Delta HR$ (-2.21, 0.71)0.342 7 0.825 -0.675 0.5 0.11 (-0.73, 0.95)8 -0.675 0.803 1.5 1.9 ∆theta ∆alpha -2.79 (-5.55, -0.04)1.5 -1.5 0.073 12 0.5 0.05 (-0.4, 0.51)0.825 12 0.4 -0.625 2 ∧beta Replication REM to -2.05 1.05 ∆delta (-4.21, 0.12)0.092 12 -1.5 0.5 Study NREM  $\Delta HR$ -0.73 (-6.16, 4.7)0.782 3 0.9 -0.975 0.5 -2.04 0.001 12 0.05 -1.5 0.5 ∆theta (-2.97, -1.11)0.23 (-0.5, 0.96)-0.225 ∆alpha 0.557 17 1.5 2 ∆beta 1.65 (0.54, 2.76)0.011 17 0.1 -1.5 0.5 Wake to ∆delta 2.55 (-3.56, 8.66)0.436 17 1.425 -1.5 0.5 Sleep  $\Delta HR$ 0.36 (-0.2, 0.91)0.236 17 1.5 -0.025 2 ∆theta 0.03 (-0.66, 0.73) 0.931 17 1.5 0 2

1522 Rapid eye movement, REM; non-REM, NREM; Confidence Interval, CI; Degrees of Freedom,

1523 DF; EEG band power predictor units in percent of total band power; HR predictor units beats-

per-minute. Bolded P values reflect significant associations at P < 0.05. Predictor and

1525 parenchymal resistance values in regression models were scaled to zero mean and unit

1526 standard deviation with coefficient estimates representing effect size in standard deviations.

1527 Positive and negative thresholds are in units of predictor standard deviation.

1528 Supplemental Table 6. Comparison of investigational device and polysomnography hypnogram staging to manual scoring. 1529

Manual		Device									
Scoring	w	REM	N1	N2	N3		sensitivity	specificity	precision	accuracy	f1
W	2653	56	256	156	6		0.828	0.959	0.843	0.932	0.835
REM	121	1334	130	127	2		0.801	0.972	0.776	0.954	0.788
N1	162	44	583	250	0		0.367	0.967	0.558	0.905	0.443
N2	224	224	611	4490	20		0.774	0.886	0.804	0.844	0.789
N3	7	5	2	753	877		0.969	0.945	0.525	0.947	0.681
					P	SG (	C3				
	w	REM	N1	N2	N3		sensitivity	specificity	precision	accuracy	f1
w	2922	56	68	79	2		0.892	0.981	0.928	0.962	0.910
REM	40	1563	37	74	0		0.893	0.989	0.910	0.978	0.901
N1	178	54	467	339	1		0.707	0.961	0.447	0.950	0.547
N2	94	76	85	5188	126		0.870	0.958	0.929	0.924	0.899
N3	4	0	1	262	1377		0.914	0.979	0.825	0.973	0.867
					P	SG (	C4				
	w	REM	N1	N2	N3		sensitivity	specificity	precision	accuracy	f1
w	3035	22	31	39	0		0.974	0.991	0.964	0.987	0.969
REM	3	1665	21	25	0		0.965	0.996	0.969	0.993	0.967
N1	27	20	659	333	0		0.885	0.974	0.631	0.969	0.736
N2	10	12	32	5493	22		0.913	0.990	0.984	0.960	0.947
N3	0	5	0	104	1535		0.985	0.990	0.920	0.990	0.951

1530 Polysomnography, PSG; Wake, W; Rapid eye movement, REM

#### Supplemental Table 7: Electrode characterization according to ANSI/AAMI EC12\*. 1531

1532

Electrode Pair #	AC Impedance at 10 Hz [Ω]	DC Offset Voltage [mV]	Combined Offset Internal N	Bias Current Tolerance [mV]	
			EC12 (0.15-100 Hz)	EEG (0.3-50 Hz)	
1	609	0.5	22.9	9.7	11.2
2	759	0.3	126.4	28.2	10.7
3	1023	3.8	13.3	7.9	10.8
4	1035	1.4	19.6	8.0	7.0
5	583	1.4	7.1	1.9	9.5
6	424	1.1	8.1	3.8	9.3

1533 Alternating Current, AC; Direct Current, DC; EC12, ANSI/AAMI EC12:2000/(R)2020.

- 1534 \*ANSI/AAMI EC12 reference values are as follows: AC impedance under 3000 Ω in any pair, under 2000 Ω on average; DC offset
- 1535 under 100 mV; offset instability and internal noise under 150  $\mu$ V; tolerance to bias under 100 mV.

1536

1538 Supplemental Table 8. Benchtop tests for assessing calibration and sensitivity to electrode impedance.

1539

			Load			
		Le	ft	R	ight	101
	Setting	MASTOID	IN-EAR	IN-EAR	MASTOID	ĮΩJ
	Cal R 20	Low	Low	Low	Low	20
	Cal R 40	Low	Low	Low	Low	40.2
	Cal R 60	Low	Low	Low	Low	60.4
	Cal R 80	Low	Low	Low	Low	80.6
	Cal R 100	Low	Low	Low	Low	100
10	Cal 2R1C 20	Low	Low	Low	Low	20 (470 + 22n)
1 2R	Cal 2R1C 40	Low	Low	Low	Low	40.2 (470 + 22n)
tior	Cal 2R1C 60	Low	Low	Low	Low	60.4 (470 + 22n)
ibra	Cal 2R1C 80	Low	Low	Low	Low	80.6 (470 + 22n)
Cal	Cal 2R1C 100	Low	Low	Low	Low	100 (470 + 22n)
Ice	Low All	Low	Low	Low	Low	50 (470 + 22n)
edar	High Right Mastoid	Low	Low	Low	High	50 (470 + 22n)
be	High Right	Low	Low	High	High	50 (470 + 22n)
de l	High Right In-Ear	Low	Low	High	Low	50 (470 + 22n)
stro	High In-Ear	Low	High	High	Low	50 (470 + 22n)
Elec	High Left In-Ear	Low	High	Low	Low	50 (470 + 22n)
to	High Left	High	High	Low	Low	50 (470 + 22n)
vity	High Left Mastoid	High	Low	Low	Low	50 (470 + 22n)
Isiti	High Mastoids	High	Low	Low	High	50 (470 + 22n)
Ser	High All	High	High	High	High	50 (470 + 22n)

Measured Load Components
Measured [Ω]
20.0
40.2
60.3
80.5
100.4
Rs = 20, Rp=468.2, Cp = 23.3n
Rs = 40.2, Rp=468.2, Cp = 23.3n
Rs = 60.3, Rp=468.2, Cp = 23.3n
Rs = 80.5, Rp=468.2, Cp = 23.3n
Rs = 100.4, Rp=468.2, Cp = 23.3n
Rs = 49.9, Rp=468.2, Cp = 23.3n
Rs = 49.9, Rp=468.2, Cp = 23.3n
Rs = 49.9, Rp=468.2, Cp = 23.3n
Rs = 49.9, Rp=468.2, Cp = 23.3n
Rs = 49.9, Rp=468.2, Cp = 23.3n
Rs = 49.9, Rp=468.2, Cp = 23.3n
Rs = 49.9, Rp=468.2, Cp = 23.3n
Rs = 49.9, Rp=468.2, Cp = 23.3n
Rs = 49.9, Rp=468.2, Cp = 23.3n
Rs = 49.9, Rp=468.2, Cp = 23.3n

Element to change from one benchtop test to the next

	Setting	1kHz	1.6kHz	2.28kHz	3.2kHz	4.55kHz	6.4kHz	8.53kHz	12.8kHz	16kHz	25.6kHz	32kHz	51.2kHz	64kHz	85.3kHz	102kHz	128kHz
	Cal R 20	0.125	0.151	0.157	0.119	0.127	0.154	0.182	0.190	0.220	0.308	0.320	0.274	0.094	0.379	0.700	0.702
ration R	Cal R 40	0.220	0.161	0.152	0.192	0.221	0.094	0.164	0.117	0.127	0.151	0.200	0.301	0.134	0.438	0.344	0.396
	Cal R 60	0.333	0.231	0.325	0.307	0.301	0.413	0.411	0.208	0.308	0.326	0.276	0.456	0.327	0.412	0.268	0.301
Calik	Cal R 80	0.104	0.175	0.242	0.205	0.314	0.140	0.154	0.257	0.258	0.332	0.333	0.257	0.284	0.298	0.317	0.230
•	Cal R 100	0.301	0.288	0.268	0.251	0.261	0.323	0.236	0.271	0.458	0.380	0.199	0.157	0.387	0.324	0.196	0.134
10	Cal 2R1C 20	0.232	0.277	0.244	0.105	0.130	0.125	0.141	0.087	0.211	0.247	0.383	0.355	0.228	0.371	0.522	0.756
2R	Cal 2R1C 40	0.191	0.117	0.112	0.305	0.207	0.042	0.207	0.149	0.268	0.157	0.134	0.240	0.314	0.242	0.421	0.311
libration	Cal 2R1C 60	0.372	0.213	0.356	0.292	0.202	0.209	0.263	0.276	0.333	0.475	0.260	0.301	0.522	0.434	0.380	0.318
	Cal 2R1C 80	0.215	0.166	0.249	0.175	0.186	0.252	0.231	0.168	0.348	0.384	0.303	0.211	0.333	0.331	0.280	0.143
ပီ	Cal 2R1C 100	0.384	0.304	0.256	0.295	0.195	0.159	0.294	0.283	0.428	0.423	0.339	0.379	0.208	0.172	0.193	0.021
	Low All	0.284	0.159	0.181	0.318	0.227	0.171	0.280	0.263	0.136	0.152	0.165	0.279	0.237	0.192	0.454	0.330
lance	High Right Mastoid	0.123	0.003	0.165	0.220	0.176	0.210	0.071	0.120	0.128	0.085	0.001	0.300	0.242	0.650	0.362	0.725
nped	High Right	0.131	0.242	0.079	0.279	0.232	0.253	0.274	0.144	0.202	0.186	0.167	-0.022	0.383	0.586	0.620	0.911
de Ir	High Right In-Ear	0.259	0.256	0.249	0.297	0.252	0.347	0.183	0.182	0.279	0.256	0.212	0.315	0.139	0.529	0.457	0.576
ctro	High In-Ear	0.384	0.263	0.109	0.233	0.350	0.236	0.237	0.292	0.266	0.259	0.312	0.327	0.379	0.415	0.446	0.450
Ele	High Left In-Ear	0.210	0.169	0.236	0.313	0.262	0.319	0.229	0.269	0.280	0.332	0.324	0.168	0.303	0.255	0.361	0.310
ty to	High Left	0.266	0.337	0.372	0.241	0.271	0.281	0.252	0.167	0.388	0.501	0.416	0.266	0.128	0.225	0.218	0.006
itivi	High Left Mastoid	0.341	0.325	0.217	0.225	0.222	0.193	0.185	0.242	0.430	0.363	0.269	0.242	0.143	0.097	0.268	0.018
Sens	High Mastoids	0.307	0.227	0.235	0.364	0.286	0.192	0.348	0.363	0.339	0.277	0.238	0.146	0.498	0.455	0.492	0.487
.,	High All	0.517	0.412	0.447	0.374	0.418	0.420	0.342	0.397	0.425	0.461	0.375	0.418	0.527	0.727	0.852	0.843

### 1541 Supplemental Table 9. Absolute error of resistance for benchtop tests (values in ohms).

1544 Supplemental Table 10. Absolute error of reactance for benchtop tests (values in ohms).

1	- A -	
	2/12	
	)4)	
•	~ ~	

	Setting	1kHz	1.6kHz	2.28kHz	3.2kHz	4.55kHz	6.4kHz	8.53kHz	12.8kHz	16kHz	25.6kHz	32kHz	51.2kHz	64kHz	85.3kHz	102kHz	128kHz
	Cal R 20	0.087	-0.031	0.055	-0.046	0.010	-0.016	0.104	-0.030	0.142	0.237	0.172	0.188	0.018	0.250	0.197	0.288
ration R	Cal R 40	0.032	0.042	0.011	0.055	-0.054	-0.057	0.126	0.035	0.018	-0.027	0.027	0.087	-0.070	0.057	0.102	0.040
	Cal R 60	0.103	0.007	-0.025	0.070	-0.052	-0.017	0.025	0.044	0.069	-0.071	0.090	-0.041	-0.032	-0.129	-0.050	-0.107
Calik	Cal R 80	0.036	0.073	0.015	-0.132	-0.042	0.064	0.012	-0.010	0.047	0.072	0.040	-0.010	-0.061	-0.092	-0.162	-0.181
•	Cal R 100	-0.066	-0.054	0.028	-0.019	0.011	0.153	0.057	-0.051	-0.002	0.022	0.045	-0.003	-0.133	-0.024	-0.050	-0.121
c	Cal 2R1C 20	0.044	-0.039	-0.037	0.019	0.043	0.033	0.031	0.051	0.091	0.143	0.210	0.211	0.237	0.285	0.413	0.380
2R1	Cal 2R1C 40	0.001	-0.070	-0.029	0.084	-0.049	0.030	-0.050	-0.033	0.026	0.000	-0.008	0.020	0.117	0.074	0.097	0.114
Calibration	Cal 2R1C 60	0.019	0.006	-0.043	-0.017	0.009	0.032	0.120	-0.120	-0.005	0.034	-0.149	0.089	0.106	0.041	0.204	0.122
	Cal 2R1C 80	0.095	-0.005	0.018	0.145	-0.018	-0.073	0.001	0.017	0.013	0.010	0.145	0.058	0.076	-0.012	-0.028	0.104
	Cal 2R1C 100	-0.030	-0.118	-0.014	0.065	-0.066	0.025	0.070	0.055	0.074	0.037	0.174	0.158	0.012	0.092	0.041	0.105
	Low All	0.015	-0.066	0.047	-0.052	0.046	0.016	0.068	-0.040	-0.032	-0.112	0.006	0.107	0.121	0.006	0.093	0.112
ance	High Right Mastoid	0.113	0.084	0.030	0.095	0.131	-0.034	0.043	0.043	0.103	0.139	0.160	0.251	0.309	0.388	0.389	0.306
pədu	High Right	0.029	0.059	-0.024	0.159	0.000	0.098	0.028	0.016	0.059	0.124	0.186	0.136	0.243	0.204	0.459	0.335
de Im	High Right In-Ear	0.015	-0.074	-0.001	-0.019	0.073	0.044	0.076	0.042	0.011	0.073	0.047	0.131	0.123	-0.009	0.150	0.133
ctroc	High In-Ear	0.071	-0.015	0.000	-0.074	0.026	-0.104	-0.007	0.028	0.087	0.045	0.021	0.103	0.203	0.111	0.043	0.160
Ele	High Left In-Ear	-0.007	0.001	0.015	0.013	-0.042	-0.168	0.045	0.010	-0.049	0.006	-0.032	0.038	0.237	0.150	0.070	0.137
ty to	High Left	-0.150	-0.117	-0.154	-0.178	0.012	-0.104	-0.025	-0.124	-0.172	-0.159	-0.127	-0.253	-0.173	-0.147	-0.124	-0.099
itivi	High Left Mastoid	-0.173	-0.093	-0.169	-0.045	-0.104	-0.073	0.001	-0.104	-0.032	-0.211	-0.271	-0.187	-0.212	-0.076	-0.251	-0.091
Sen	High Mastoids	0.034	-0.002	0.036	-0.023	-0.100	-0.010	-0.054	0.032	-0.042	-0.103	0.008	-0.006	0.083	0.082	0.176	0.058
	High All	-0.041	-0.114	-0.083	-0.109	-0.091	-0.066	-0.051	0.065	0.083	0.103	0.013	0.138	0.278	0.296	0.389	0.401

### 1550 Supplemental Table 11. Debye model absolute prediction error (ohms) of dispersion relative to 128kHz.

	Setting	1kHz	1.6kHz	2.28kHz	3.2kHz	4.55kHz	6.4kHz	8.53kHz	12.8kHz	16kHz	25.6kHz	32kHz	51.2kHz	64kHz	85.3kHz	102kHz
	Low All	-0.037	-0.040	-0.044	-0.051	-0.063	-0.080	-0.093	-0.098	-0.091	-0.058	-0.042	-0.017	-0.010	-0.004	-0.002
ance	High Right Mastoid	-0.243	-0.250	-0.260	-0.278	-0.309	-0.345	-0.368	-0.352	-0.311	-0.187	-0.133	-0.054	-0.032	-0.014	-0.006
pedi	High Right	-0.247	-0.252	-0.261	-0.277	-0.302	-0.332	-0.350	-0.331	-0.291	-0.175	-0.124	-0.050	-0.030	-0.013	-0.006
le Im	High Right In-Ear	-0.109	-0.113	-0.120	-0.132	-0.152	-0.178	-0.197	-0.197	-0.177	-0.110	-0.079	-0.032	-0.019	-0.008	-0.004
ctrod	High In-Ear	-0.128	-0.130	-0.134	-0.140	-0.150	-0.162	-0.168	-0.158	-0.139	-0.084	-0.060	-0.024	-0.015	-0.006	-0.003
Elec	High Left In-Ear	-0.055	-0.053	-0.051	-0.046	-0.039	-0.027	-0.015	0.000	0.005	0.007	0.006	0.003	0.002	0.001	0.000
ity tc	High Left	0.065	0.069	0.074	0.082	0.098	0.119	0.136	0.144	0.133	0.087	0.063	0.026	0.016	0.007	0.003
sitiv	High Left Mastoid	0.067	0.070	0.075	0.084	0.099	0.118	0.135	0.142	0.131	0.085	0.062	0.026	0.015	0.007	0.003
Sen	High Mastoids	-0.119	-0.120	-0.121	-0.124	-0.127	-0.131	-0.130	-0.116	-0.100	-0.059	-0.042	-0.017	-0.010	-0.004	-0.002
	High All	-0.202	-0.209	-0.221	-0.240	-0.271	-0.311	-0.338	-0.329	-0.293	-0.178	-0.127	-0.052	-0.031	-0.013	-0.006
	RMSE	0.147	0.151	0.157	0.168	0.186	0.209	0.224	0.216	0.193	0.117	0.084	0.034	0.020	0.009	0.004
	Load Value	4.766	4.724	4.654	4.526	4.282	3.877	3.374	2.461	1.931	0.995	0.685	0.286	0.183	0.099	0.066
	Error %	3.1%	3.2%	3.4%	3.7%	4.3%	5.4%	6.6%	8.8%	10.0%	11.8%	12.2%	12.0%	11.1%	8.8%	6.1%
## 1553 Supplemental Table 12: Minimum significant change in mean R<sub>P</sub> and correlation with a

1554 predictor using the R<sub>p</sub> standard deviation of the electrode impedance sensitivity tests.

1555

Number of Samples	25	100
Standard Deviation [Ω]	0.113	0.113
Standard Error [Ω]	0.023	0.011
Minimum Significant Change [Ω]	0.044	0.022
Minimum Significant Correlation	0.39	0.20

1556 Brain parenchymal resistance, R<sub>p</sub>.

1557



1560 1561

1562 Supplemental Figure 1. An illustration of the effect of increased CSF influx into the brain parenchyma and clearance from the parenchyma on contrast-enhanced MRI signal intensity in 1563 1564 the Benchmarking study. An increase in CSF influx into the brain parenchyma following 1565 intravenous GBCA leads to greater contrast delivery to the brain parenchyma and a 1566 corresponding increase in MRI signal intensity. MRI signal intensity of the brain parenchyma has been shown to peak at approximately 90 minutes post-injection<sup>15</sup> which occurred at time 1567 0830 in the Benchmarking study. With a terminal half-life of 109 minutes<sup>28</sup>, intravenous contrast 1568 1569 is 60% cleared at 140 minutes post-injection when the morning sleep/wake intervention begins 1570 and is 80% cleared at the end of the morning intervention when the second post-contrast MRI 1571 scan is acquired. During this morning intervention, an increase in CSF clearance from the brain 1572 parenchyma leads to a corresponding decrease in MRI signal intensity.

## Cp $R_p$ 10 ohm 10 ohm $\mathbf{R}_{\mathbf{S}}$ ŝ <u>ل</u> с г RHF **Right Mastoic** Left In-Ear Left Mastoid Right In-Ear b С **Electrode Models Load Models** RHF RLF CLF Rs Rp Cp Low 270 1k 180n **Cal Loads** 0-100 -/470 -/22n 3.3k High 620 82n **Realistic Load** 50\* 470 22n \* 50 realized with a 49.9 ohm resistor 1000 H 00000 Hz 50 4000 50||(470+22n) 270+(180n||1000) 620+(82n||3300) 300 48 R [ohm] Mag [oh 2000 46 1000 44 1269 ohm 3915 ohm 865 ohm 2058 ohm 270 ohm 620 ohm 10<sup>2</sup> 10<sup>3</sup> 10<sup>5</sup> 10<sup>1</sup> 10<sup>4</sup> 106 -0.5 -10 [6ap] -20 [<sup>ш</sup>чо] × -1.5 Angle -30 10<sup>3</sup>10<sup>7</sup> Frequency [Hz] 10 105 10 $10^{3}$ $10^{4}$ 10 10<sup>2</sup> 10<sup>4</sup> 10<sup>5</sup> 106 Frequency [Hz]

1574

1573

а

Supplemental Figure 2.

1575 Supplemental Figure 2. a, Circuit model of transcranial measurements using four-point 1576 electrical impedance spectroscopy and models for each of the four electrode contact 1577 impedances. b, Electrode impedance models comprised a low impedance and a high 1578 impedance model, representing the range of in-human impedances. c, Calibration loads varied 1579 the resistance  $\mathbf{R}_{s}$  of the free fluid or interstitial fluid compartment from 20 to 100  $\Omega$  in increments of 20 Ω, with and additional R<sub>p</sub>C<sub>p</sub> in parallel to simulate complex loads. The realistic load 1580 1581 parameters were chosen to create a frequency dispersion that approximated the in-human 1582 measured dispersions. d. Electrode impedance dispersion over the measured frequencies for 1583 the low and high impedance model. e, Load impedance dispersion over the measured 1584 frequencies using the Real Load model.





1587

1588

Supplemental Figure 3. a, Periodogram of a device over a 12 hour test using four Ag/AgCl
 sintered disk electrodes on an Agar phantom with EEG gel. For reference, human EEG beta
 power during NREM sleep is above -10dB on the device. b, EEG recording over an epoch
 shows 0.5 µV peak-to-peak noise. c, Power spectral density shows a noise floor at
 -150dB/Hz with a 1/f increase to -140db/Hz below 10Hz.

## 1595 **REFERENCES**

1596 Iliff, J. J. et al. A paravascular pathway facilitates CSF flow through the brain 1 1597 parenchyma and the clearance of interstitial solutes, including amyloid  $\beta$ . Sci Transl Med 1598 4, 147ra111 (2012). https://doi.org/10.1126/scitranslmed.3003748 1599 2 Xie, L. et al. Sleep drives metabolite clearance from the adult brain. Science 342, 373-1600 377 (2013). https://doi.org/10.1126/science.1241224 Iliff, J. J. et al. Impairment of glymphatic pathway function promotes tau pathology after 1601 3 traumatic brain injury. J Neurosci 34, 16180-16193 (2014). 1602 1603 https://doi.org/10.1523/JNEUROSCI.3020-14.2014 Harrison, I. F. et al. Impaired glymphatic function and clearance of tau in an Alzheimer's 1604 4 1605 disease model. Brain 143, 2576-2593 (2020). https://doi.org/10.1093/brain/awaa179 1606 5 Ishida, K. et al. Glymphatic system clears extracellular tau and protects from tau 1607 aggregation and neurodegeneration. J Exp Med 219 (2022). 1608 https://doi.org/10.1084/jem.20211275 1609 Cui, H. et al. Decreased AQP4 Expression Aggravates a-Synuclein Pathology in 6 1610 Parkinson's Disease Mice, Possibly via Impaired Glymphatic Clearance. J Mol Neurosci 1611 71, 2500-2513 (2021). https://doi.org/10.1007/s12031-021-01836-4 1612 Zou, W. et al. Blocking meningeal lymphatic drainage aggravates Parkinson's disease-7 1613 like pathology in mice overexpressing mutated  $\alpha$ -synuclein. Transl Neurodegener 8, 7 1614 (2019). https://doi.org/10.1186/s40035-019-0147-v 1615 Hablitz, L. M. & Nedergaard, M. The Glymphatic System: A Novel Component of 8 1616 Fundamental Neurobiology. J Neurosci 41, 7698-7711 (2021). https://doi.org/10.1523/JNEUROSCI.0619-21.2021 1617 1618 9 Klostranec, J. M. et al. Current Concepts in Intracranial Interstitial Fluid Transport and 1619 the Glymphatic System: Part II-Imaging Techniques and Clinical Applications. 1620 Radiology 301, 516-532 (2021). https://doi.org/10.1148/radiol.2021204088 Hablitz, L. M. et al. Circadian control of brain glymphatic and lymphatic fluid flow. Nat 1621 10 1622 Commun 11, 4411 (2020). https://doi.org/10.1038/s41467-020-18115-2 Hablitz, L. M. et al. Increased glymphatic influx is correlated with high EEG delta power 1623 11 1624 and low heart rate in mice under anesthesia. Sci Adv 5, eaav5447 (2019). 1625 https://doi.org/10.1126/sciadv.aav5447 1626 Eide, P. K., Vinje, V., Pripp, A. H., Mardal, K. A. & Ringstad, G. Sleep deprivation 12 1627 impairs molecular clearance from the human brain. Brain 144, 863-874 (2021). 1628 https://doi.org/10.1093/brain/awaa443 Ringstad, G. et al. Brain-wide glymphatic enhancement and clearance in humans 1629 13 1630 assessed with MRI. JCI Insight 3 (2018). https://doi.org/10.1172/jci.insight.121537 1631 14 Deike-Hofmann, K. et al. Glymphatic Pathway of Gadolinium-Based Contrast Agents 1632 Through the Brain: Overlooked and Misinterpreted. Invest Radiol 54, 229-237 (2019). 1633 https://doi.org/10.1097/RLI.000000000000533 1634 Richmond, S. B. et al. Quantification approaches for magnetic resonance imaging 15 1635 following intravenous gadolinium injection: A window into brain-wide glymphatic 1636 function. Eur J Neurosci 57, 1689-1704 (2023). https://doi.org/10.1111/ejn.15974 1637 16 Bera, T. K. Bioelectrical Impedance Methods for Noninvasive Health Monitoring: A 1638 Review. J Med Eng 2014, 381251 (2014). https://doi.org/10.1155/2014/381251 1639 17 Abasi, S., Aggas, J. R., Garayar-Leyva, G. G., Walther, B. K. & Guiseppi-Elie, A. 1640 Bioelectrical Impedance Spectroscopy for Monitoring Mammalian Cells and Tissues

1641		under Different Frequency Domains: A Review. ACS Meas Sci Au 2, 495-516 (2022).
1642		https://doi.org/10.1021/acsmeasuresciau.2c00033
1643	18	Stupin, D. D. et al. Bioimpedance Spectroscopy: Basics and Applications. ACS Biomater
1644		Sci Eng 7, 1962-1986 (2021). https://doi.org/10.1021/acsbiomaterials.0c01570
1645	19	Gabriel, S., Lau, R. W. & Gabriel, C. The dielectric properties of biological tissues: II.
1646		Measurements in the frequency range 10 Hz to 20 GHz. Phys Med Biol 41, 2251-2269
1647		(1996). https://doi.org/10.1088/0031-9155/41/11/002
1648	20	Gabriel, C. Dielectric properties of biological tissue: variation with age.
1649		Bioelectromagnetics Suppl 7, S12-18 (2005). https://doi.org/10.1002/bem.20147
1650	21	Jessen, N. A., Munk, A. S., Lundgaard, I. & Nedergaard, M. The Glymphatic System: A
1651		Beginner's Guide. Neurochem Res 40, 2583-2599 (2015). https://doi.org/10.1007/s11064-
1652		<u>015-1581-6</u>
1653	22	Nakamura, K. et al. Diurnal fluctuations in brain volume: Statistical analyses of MRI
1654		from large populations. Neuroimage 118, 126-132 (2015).
1655		https://doi.org/10.1016/j.neuroimage.2015.05.077
1656	23	Elvsåshagen, T. <i>et al.</i> Cerebral blood flow changes after a day of wake, sleep, and sleep
1657		deprivation. Neuroimage 186, 497-509 (2019).
1658		https://doi.org/10.1016/j.neuroimage.2018.11.032
1659	24	Dagum, P. Non-invasive assessment of glymphatic flow and neurodegeneration from a
1660		wearable device. (2022).
1661	25	Dagum, P. Non-invasive assessment of glymphatic flow and neurodegeneration from a
1662		wearable device. (2022).
1663	26	Nasreddine, Z. S. et al. The Montreal Cognitive Assessment, MoCA: a brief screening
1664		tool for mild cognitive impairment. J Am Geriatr Soc 53, 695-699 (2005).
1665		https://doi.org/10.1111/j.1532-5415.2005.53221.x
1666	27	Brown, L. M. & Schinka, J. A. Development and initial validation of a 15-item informant
1667		version of the Geriatric Depression Scale. Int J Geriatr Psychiatry 20, 911-918 (2005).
1668		https://doi.org/10.1002/gps.1375
1669	28	Administration., U. F. a. D. Gadavist (gadobutrol) injection, for intravenous use,
1670		< <u>https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201277s000lb1.pdf</u> >
1671		(2011).
1672	29	Heinze, G., Wallisch, C. & Dunkler, D. Variable selection - A review and
1673		recommendations for the practicing statistician. Biom J 60, 431-449 (2018).
1674		https://doi.org/10.1002/bimj.201700067
1675	30	Iliff, J. J. et al. Brain-wide pathway for waste clearance captured by contrast-enhanced
1676		MRI. J Clin Invest 123, 1299-1309 (2013). https://doi.org/10.1172/JCI67677
1677	31	Boukamp, B. A. A Linear Kronig-Kramers Transform Test for Immittance Data
1678		Validation. Journal of The Electrochemical Society 142, 1885 (1995).
1679	32	Schonleber, M., Klotz, D. & Ivers-Tiffee, E. A Method for Improving the Robustness of
1680		linear Kramers-Kronig Validity Tests. Electrochimica Acta 131, 20-27 (2014).
1681	33	Song, J. et al. Electrical Impedance Changes at Different Phases of Cerebral Edema in
1682		Rats with Ischemic Brain Injury. Biomed Res Int 2018, 9765174 (2018).
1683		https://doi.org/10.1155/2018/9765174
1684	34	Abboud, T., Mielke, D. & Rohde, V. Mini Review: Impedance Measurement in
1685		Neuroscience and Its Prospective Application in the Field of Surgical Neurooncology.
1686		Front Neurol 12, 825012 (2021). https://doi.org/10.3389/fneur.2021.825012

Witkowska-Wrobel, A., Aristovich, K., Crawford, A., Perkins, J. D. & Holder, D. 1687 35 1688 Imaging of focal seizures with Electrical Impedance Tomography and depth electrodes in 1689 real time. Neuroimage 234, 117972 (2021). 1690 https://doi.org/10.1016/j.neuroimage.2021.117972 Romsauerova, A. et al. Multi-frequency electrical impedance tomography (EIT) of the 1691 36 1692 adult human head: initial findings in brain tumours, arteriovenous malformations and 1693 chronic stroke, development of an analysis method and calibration. *Physiol Meas* 27, 1694 S147-161 (2006). https://doi.org/10.1088/0967-3334/27/5/S13 1695 37 Iliff, J. J. et al. Cerebral arterial pulsation drives paravascular CSF-interstitial fluid 1696 exchange in the murine brain. J Neurosci 33, 18190-18199 (2013). 1697 https://doi.org/10.1523/JNEUROSCI.1592-13.2013 1698 38 Ringstad, G., Vatnehol, S. A. S. & Eide, P. K. Glymphatic MRI in idiopathic normal 1699 pressure hydrocephalus. Brain 140, 2691-2705 (2017). 1700 https://doi.org/10.1093/brain/awx191 Mestre, H. et al. Aquaporin-4-dependent glymphatic solute transport in the rodent brain. 1701 39 1702 Elife 7 (2018). https://doi.org/10.7554/eLife.40070 1703 Mestre, H. et al. Flow of cerebrospinal fluid is driven by arterial pulsations and is 40 1704 reduced in hypertension. Nat Commun 9, 4878 (2018). https://doi.org/10.1038/s41467-1705 018-07318-3 1706 Jiang-Xie, L. F. et al. Neuronal dynamics direct cerebrospinal fluid perfusion and brain 41 1707 clearance. Nature 627, 157-164 (2024). https://doi.org/10.1038/s41586-024-07108-6 1708 42 Piantino, J., Lim, M. M., Newgard, C. D. & Iliff, J. Linking Traumatic Brain Injury, 1709 Sleep Disruption and Post-Traumatic Headache: a Potential Role for Glymphatic 1710 Pathway Dysfunction. Curr Pain Headache Rep 23, 62 (2019). 1711 https://doi.org/10.1007/s11916-019-0799-4 Nedergaard, M. & Goldman, S. A. Glymphatic failure as a final common pathway to 1712 43 1713 dementia. Science 370, 50-56 (2020). https://doi.org/10.1126/science.abb8739 Goldman, N., Hablitz, L. M., Mori, Y. & Nedergaard, M. The Glymphatic System and 1714 44 1715 Pain. Med Acupunct 32, 373-376 (2020). https://doi.org/10.1089/acu.2020.1489 1716 Braun, M. & Iliff, J. J. The impact of neurovascular, blood-brain barrier, and glymphatic 45 1717 dysfunction in neurodegenerative and metabolic diseases. Int Rev Neurobiol 154, 413-1718 436 (2020). https://doi.org/10.1016/bs.irn.2020.02.006 1719 Gakuba, C. et al. General Anesthesia Inhibits the Activity of the "Glymphatic System". 46 1720 Theranostics 8, 710-722 (2018). https://doi.org/10.7150/thno.19154 1721 Miao, A. et al. Brain clearance is reduced during sleep and anesthesia. Nat Neurosci 27, 47 1046-1050 (2024). https://doi.org/10.1038/s41593-024-01638-v 1722 1723 Kress, B. T. et al. Impairment of paravascular clearance pathways in the aging brain. Ann 48 1724 Neurol 76, 845-861 (2014). https://doi.org/10.1002/ana.24271 Wang, M. et al. Focal Solute Trapping and Global Glymphatic Pathway Impairment in a 1725 49 1726 Murine Model of Multiple Microinfarcts. J Neurosci 37, 2870-2877 (2017). https://doi.org/10.1523/JNEUROSCI.2112-16.2017 1727 1728 Li, M. et al. Impaired Glymphatic Function and Pulsation Alterations in a Mouse Model 50 1729 of Vascular Cognitive Impairment. Front Aging Neurosci 13, 788519 (2021). 1730 https://doi.org/10.3389/fnagi.2021.788519

<ul> <li>accumulation and memory deficits. <i>Mol Neurodegener</i> 10, 58 (2015). https://doi.org/10.1186/s13024-015-0056-1</li> <li>Simon, M. <i>et al.</i> Loss of perivascular aquaporin-4 localization impairs glymphatic exchange and promotes amyloid β plaque formation in mice. <i>Alcheimers Res Ther</i> 14, 59 (2022). https://doi.org/10.1186/s13195-022-00999-5</li> <li>Pedersen, T. J., Keil, S. A., Han, W., Wang, M. X. &amp; lliff, J. J. The effect of aquaporin-4 mis-localization on Aβ deposition in mice. <i>Neurobiol Dis</i> 181, 106100 (2023). https://doi.org/10.1016/j.nbd.2023.106100</li> <li>Burfeind, K. G. <i>et al.</i> The effects of noncoding aquaporin-4 single-nucleotide polymorphisms on cognition and functional progression of Alzheimer's disease. <i>Alcheimers Dement (N Y)</i> 3, 348-359 (2017). https://doi.org/10.1016/j.trci.2017.05.001</li> <li>Zeppenfeld, D. M. <i>et al.</i> Association of Perivascular Localization of Aquaporin-4 With Cognition and Alzheimer Disease in Aging Brains. <i>JAMA Neurol</i> 74, 91-99 (2017). https://doi.org/10.1001/jamaneurol.2016.4370</li> <li>Simon, M. J. <i>et al.</i> Transcriptional network analysis of human astrocytic endfoot genes reveals region-specific associations with dementia status and tau pathology. <i>Sci Rep</i> 8, 12389 (2018). https://doi.org/10.1038/s41598-018-30779-x</li> <li>Instrumentation, A. N. S. I. A. f. A. o. M. Vol. EC12:2000/(R)2020 (2020).</li> <li>Ayllon, D., Seoane, F. &amp; Gil-Pita, R. Cole equation and parameter estimation from electrical bioimpedance spectroscopy measurements - A comparative study. <i>Annu Int Conf IEEE Eng Med Biol Soc</i> 2009, 3779-3782 (2009). https://doi.org/10.1109/IEMIBS.2009.5334494</li> <li>De Lorenzo, A., Andreoli, A., Matthie, J. &amp; Withers, P. Predicting body cell mass with bioimpedance by using theoretical methods: a technological review. <i>J Appl Physiol</i> (1983) 82, 1542-1558 (1997). https://doi.org/10.1152/jappl.1977.85, 1542</li> <li>Gabriel, S., Lau, R. W. &amp; Gabriel, C. The dielectric properties of biological itsues: III. Par</li></ul>	1731	51	Xu, Z. et al. Deletion of aquaporin-4 in APP/PS1 mice exacerbates brain Aβ
<ul> <li>https://doi.org/10.1186/s13024-015-0056-1</li> <li>Simon, M. <i>et al.</i> Loss of perivascular aquaporin-4 localization impairs glymphatic exchange and promotes amyloid b plaque formation in mice. <i>Alcheimers Res Ther</i> 14, 59 (2022). https://doi.org/10.1186/s13195-022-00999-5</li> <li>Pedersen, T. J., Kcil, S. A., Han, W., Wang, M. X. &amp; Iliff, J. J. The effect of aquaporin-4 mis-localization on Aβ deposition in mice. <i>Neurobiol Dis</i> 181, 106100 (2023). https://doi.org/10.1016/j.mbd.2023.106100</li> <li>Burfeind, K. G. <i>et al.</i> The effects of noncoding aquaporin-4 single-nucleotide polymorphisms on cognition and functional progression of Alzheimer's disease. <i>Alcheimers Dement (N Y)</i> 3, 348-359 (2017). https://doi.org/10.1016/j.trci.2017.05.001</li> <li>Zeppenfeld, D. M. <i>et al.</i> Association of Perivascular Localization of Aquaporin-4 With Cognition and Alzheimer Disease: in Aging Brains. <i>JAMA Neurol</i> 74, 91-99 (2017). https://doi.org/10.1001/jamaneurol.2016.4370</li> <li>Simon, M. J. <i>et al.</i> Transcriptional network analysis of human astrocytic endfoot genes reveals region-specific associations with dementia status and tau pathology. <i>Sci Rep</i> 8, 12389 (2018). https://doi.org/10.1038/s41598-018-30779-x</li> <li>Instrumentation, A. N. S. I. A. f. A. o. M. Vol. EC12:2000/(R)2020 (2020).</li> <li>Ayllon, D., Seoane, F. &amp; Gil-Pita, R. Cole equation and parameter estimation from electrical bioimpedance spectroscopy measurements - A comparative study. <i>Annu Int Conf IEEE Eng Med Biol Soc</i> 2009, 3779-3782 (2009). https://doi.org/10.1016/IEEE Sign 4010/1019/IS1953541494</li> <li>De Lorenzo, A., Andreoli, A., Matthie, J. &amp; Withers, P. Predicting body cell mass with bioimpedance by using theoretical methods: a technological review. J <i>Appl Physiol (1985)</i> 82, 1542-1558 (1997). https://doi.org/10.1152/jappl.1997.82.5.1542</li> <li>Gabriel, S., Lau, R. W. &amp; Gabriel, C. The dielectric properties of biological tissues: III. Parametric models for the dielectric spectrum of tissue</li></ul>	1732		accumulation and memory deficits. Mol Neurodegener 10, 58 (2015).
<ul> <li>Simon, M. <i>et al.</i> Loss of perivascular aquaporin-4 localization impairs glymphatic exchange and promotes amyloid β plaque formation in mice. <i>Al. heimers Res Ther</i> 14, 59 (2022). https://doi.org/10.1186/s13195-022-00999-5</li> <li>Pedersen, T. J., Keil, S. A., Han, W., Wang, M. X. &amp; Iliff, J. J. The effect of aquaporin-4 mis-localization on Aβ deposition in mice. <i>Neurobiol Dis</i> 181, 106100 (2023). https://doi.org/10.1016/j.inbd.2023.106100</li> <li>Burfeind, K. G. <i>et al.</i> The effects of noncoding aquaporin-4 single-nucleotide polymorphisms on cognition and functional progression of Alzheimer's disease. <i>Al. heimers Dement (N Y)</i> 3, 348-359 (2017). https://doi.org/10.1016/j.trci.2017.05.001</li> <li>Zeppenfeld, D. M. <i>et al.</i> Association of Perivascular Localization of Aquaporin-4 With Cognition and Alzheimer Disease in Aging Brains. <i>JAMA Neurol</i> 74, 91-99 (2017). https://doi.org/10.1016/j.tmci.2017.05.001</li> <li>Simon, M. J. <i>et al.</i> Transcriptional network analysis of human astrocytic endfoot genes reveals region-specific associations with dementia status and tau pathology. <i>Sci Rep</i> 8, 12389 (2018). https://doi.org/10.1038/s41598-018-30779-x</li> <li>Instrumentation, A. N. S. I. A. f. A. o. M. Vol. EC12:2000/(R)2020 (2020).</li> <li>Ayllon, D., Seoane, F. &amp; Gil-Pita, R. Cole equation and parameter estimation from electrical bioimpedance spectroscopy measurements - A comparative study. <i>Annu Int Conf IEEE Eng Med Biol Soc</i> 2009, 3779-3782 (2009). https://doi.org/10.1109/IEMBS.2009.5334494</li> <li>De Lorenzo, A., Andreoli, A., Matthie, J. &amp; Withers, P. Predicting body cell mass with bioimpedance by using theoretical methods: a technological review. <i>J Appl Physiol (1985)</i> 82, 1542-1558 (1997). https://doi.org/10.1152/jappl.1997.82.5.1542</li> <li>Gabriel, S., Lau, R. W. &amp; Gabriel, C. The dielectric properties of biological tissues: III. Parametric models for the dielectric spectrum of tissues. <i>Phys Med Biol</i> 41, 2271-2293 (1996). https://doi.org/10.1088/031-</li></ul>	1733		https://doi.org/10.1186/s13024-015-0056-1
<ul> <li>exchange and promotes amyloid β plaque formation in mice. <i>Alzheimers Res Ther</i> 14, 59 (2022). https://doi.org/10.1186/s13195-022-00999-5</li> <li>Pedersen, T. J., Keil, S. A., Han, W., Wang, M. X. &amp; Iliff, J. J. The effect of aquaporin-4 mis-localization on Aβ deposition in mice. <i>Neurobiol Dis</i> 181, 106100 (2023). https://doi.org/10.1016/j.tbd.2023.106100</li> <li>Burfeind, K. G. <i>et al.</i> Association of Perivascular Localization of Alzheimer's disease. <i>Alzheimers Dement</i> (N Y) 3, 348-359 (2017). https://doi.org/10.1016/j.trci.2017.05.001</li> <li>Zeppenfeld, D. M. <i>et al.</i> Association of Perivascular Localization of Aquaporin-4 With Cognition and Alzheimer Disease in Aging Brains. <i>JAMA Neurol</i> 74, 91-99 (2017). https://doi.org/10.1001/jamaneurol.2016.4370</li> <li>Simon, M. J. <i>et al.</i> Transcriptional network analysis of human astrocytic endfoot genes reveals region-specific associations with dementia status and tau pathology. <i>Sci Rep</i> 8, 12389 (2018). https://doi.org/10.1038/s41598-018-30779-x</li> <li>Instrumentation, A. N. S. I. A. f. A. o. M. Vol. EC12:2000/(R)2020 (2020).</li> <li>Ayllon, D., Seoane, F. &amp; Gil-Pita, R. Cole equation and parameter estimation from electrical bioimpedance spectroscopy measurements - A comparative study. <i>Annu Int Conf IEEE Eng Med Biol Soc</i> 2009, 3779-3782 (2009). https://doi.org/10.1109/IEMBS.2009.5334494</li> <li>De Lorenzo, A., Andreoli, A., Matthie, J. &amp; Withers, P. Predicting body cell mass with bioimpedance by using theoretical methods: a technological review. <i>J Appl Physiol (1985)</i> 82, 1542-1558 (1977). https://doi.org/10.1152/jappl.1997.82.5.1542</li> <li>Gabriel, S., Lau, R. W. &amp; Gabriel, C. The dielectric properties of biological tissues: III. Parametric models for the dielectric spectrum of tissues. <i>Phys Med Biol</i> 41, 2271-2293 (1996). https://doi.org/10.108/s40031-9155/4/11/1003</li> <li>Welch, P. The use of the fast Fourier transform for the estimation of power spectra: A method based on time averaging over</li></ul>	1734	52	Simon, M. et al. Loss of perivascular aquaporin-4 localization impairs glymphatic
<ul> <li>(2022). https://doi.org/10.1186/s13195-022-00999-5</li> <li>Pedersen, T. J., Keil, S. A., Han, W., Wang, M. X. &amp; Iliff, J. J. The effect of aquaporin-4 mis-localization on Aß deposition in mice. <i>Neurobiol Dis</i> 181, 106100 (2023). https://doi.org/10.1016/j.nbd.2023.106100</li> <li>Burfeind, K. G. <i>et al.</i> The effects of noncoding aquaporin-4 single-nucleotide polymorphisms on cognition and functional progression of Alzheimer's disease. <i>Alzheimers Dement (N Y)</i> 3, 348-359 (2017). https://doi.org/10.1016/j.trci.2017.05.001</li> <li>Zeppenfeld, D. M. <i>et al.</i> Association of Perivascular Localization of Aquaporin-4 With Cognition and Alzheimer Disease in Aging Brains. <i>JAMA Neurol</i> 74, 91-99 (2017). https://doi.org/10.1001/jamaneurol.2016.4370</li> <li>Simon, M. J. <i>et al.</i> Transcriptional network analysis of human astrocytic endfoot genes reveals region-specific associations with dementia status and tau pathology. <i>Sci Rep</i> 8, 12389 (2018). https://doi.org/10.1038/s41598-018-30779-x</li> <li>Instrumentation, A. N. S. I. A. f. A. o. M. Vol. EC12:2000/(R)2020 (2020).</li> <li>Ayllon, D., Seoane, F. &amp; Gil-Pita, R. Cole equation and parameter estimation from electrical bioimpedance spectroscopy measurements - A comparative study. <i>Annu Int Conf IEEE Eng Med Biol Soc</i> 2009, 3779-3782 (2009). https://doi.org/10.1109/IEMBS.2009.5334494</li> <li>De Lorenzo, A., Andreoli, A., Mathie, J. &amp; Withers, P. Predicting body cell mass with bioimpedance by using theoretical methods: a technological review. <i>J Appl Physiol (1985)</i> 82, 1542-1558 (1997). https://doi.org/10.1152/jappl.1997.82.5.1542</li> <li>Gabriel, S., Lau, R. W. &amp; Gabriel, C. The dielectric properties of biological tissues: III. Parametric models for the dielectric spectrum of tissues. <i>Phys Med Biol</i> 141, 2271-2293 (1996). https://doi.org/10.1088/0031-9155/41/11/003</li> <li>Welch, P. The use of the fast Fourier transform for the estimation of power spectra: A method based on time averaging over short, modified perio</li></ul>	1735		exchange and promotes amyloid $\beta$ plaque formation in mice. Alzheimers Res Ther 14, 59
<ul> <li>Pedersen, T. J., Keil, S. A., Han, W., Wang, M. X. &amp; Iliff, J. J. The effect of aquaporin-4 mis-localization on Aβ deposition in mice. Neurobiol Dis 181, 106100 (2023). https://doi.org/10.1016/j.nbd.2023.106100</li> <li>Burfeind, K. G. et al. The effects of noncoding aquaporin-4 single-nucleotide polymorphisms on cognition and functional progression of Alzheimer's disease. Alzheimers Dement (N Y) 3, 348-359 (2017). https://doi.org/10.1016/j.trei.2017.05.001</li> <li>Zeppenfeld, D. M. et al. Association of Perivascular Localization of Aquaporin-4 With Cognition and Alzheimer Disease in Aging Brains. JAMA Neurol 74, 91-99 (2017). https://doi.org/10.1001/jamancurol.2016.4370</li> <li>Simon, M. J. et al. Transcriptional network analysis of human astrocytic endfoot genes reveals region-specific associations with dementia status and tau pathology. Sci Rep 8, 12389 (2018). https://doi.org/10.1038/s41598-018-30779-x</li> <li>Instrumentation, A. N. S. I. A. f. A. o. M. Vol. EC12:2000/(R)2020 (2020).</li> <li>Ayllon, D., Seoane, F. &amp; Gil-Pita, R. Cole equation and parameter estimation from electrical bioimpedance spectroscopy measurements - A comparative study. Annu Int Conf IEEE Eng Med Biol Soc 2009, 3779-3782 (2009).</li> <li>https://doi.org/10.1109/IEMIBS.2009.5334494</li> <li>De Lorenzo, A., Andreoli, A., Matthie, J. &amp; Withers, P. Predicting body cell mass with bioimpedance by using theoretical methods: a technological review. J Appl Physiol (1985) 82, 1542-1558 (1997). https://doi.org/10.1152/jappl.1982.5.1542</li> <li>Gabriel, S., Lau, R. W. &amp; Gabriel, C. The dielectric properties of biological tissues: III. Parametric models for the dielectric spectrum of tissues. Phys Med Biol 41, 2271-2293 (1996). https://doi.org/10.1088/0031-9155/41/11/1003</li> <li>Welch, P. The use of the fast Fourier transform for the estimation of power spectra: A method based on time averaging over short, modified periodograms. IEEE Trans. Audio Electroacoust 15, 70-73 (1967).</li> <li></li></ul>	1736		(2022). https://doi.org/10.1186/s13195-022-00999-5
<ul> <li>mis-localization on Aβ deposition in mice. Neurobiol Dis 181, 106100 (2023). https://doi.org/10.1016/j.nbd.2023.106100</li> <li>Burfeind, K. G. <i>et al.</i> The effects of noncoding aquaporin-4 single-nucleotide polymorphisms on cognition and functional progression of Alzheimer's disease. <i>Alzheimers Dement (N Y)</i> 3, 348-359 (2017). https://doi.org/10.1016/j.trci.2017.05.001</li> <li>Zeppenfeld, D. M. <i>et al.</i> Association of Perivascular Localization of Aquaporin-4 With Cognition and Alzheimer Disease in Aging Brains. <i>JAMA Neurol</i> 74, 91-99 (2017). https://doi.org/10.1001/jamaneurol.2016.4370</li> <li>Simon, M. J. <i>et al.</i> Transcriptional network analysis of human astrocytic endfoot genes reveals region-specific associations with dementia status and tau pathology. <i>Sci Rep</i> 8, 12389 (2018). https://doi.org/10.1038/s41598-018-30779-x</li> <li>Instrumentation, A. N. S. I. A. f. A. o. M. Vol. EC12:2000(R)2020 (2020).</li> <li>Ayllon, D., Scoane, F. &amp; Gil-Pita, R. Cole equation and parameter estimation from electrical bioimpedance spectroscopy measurements - A comparative study. <i>Annu Int Conf IEEE Eng Med Biol Soc</i> 2009, 3779-3782 (2009). https://doi.org/10.1109/IEMBS.2009.5334494</li> <li>De Lorenzo, A., Andreoli, A., Matthic, J. &amp; Withers, P. Predicting body cell mass with bioimpedance by using theoretical methods: a technological review. <i>J Appl Physiol</i> (<i>1935</i>) 82, 1542-1558 (1997). https://doi.org/10.1152/jappl.1997.82.5.1542</li> <li>Gabriel, S., Lau, R. W. &amp; Gabriel, C. The dielectric properties of biological tissues: III. Parametric models for the dielectric spectrum of tissues. <i>Phys Med Biol</i> 41, 2271-2293 (1996). https://doi.org/10.1088/031-9155/41/11/003</li> <li>Welch, P. The use of the fast Fourier transform for the estimation of power spectra: A method based on time averaging over short, modified periodograms. <i>IEEE Trans. Audio</i> <i>Electroacoust</i> 15, 70-73 (1967).</li> <li>Vallat, R. &amp; Walker, M. P. An open-source, high-performance tool for automated sl</li></ul>	1737	53	Pedersen, T. J., Keil, S. A., Han, W., Wang, M. X. & Iliff, J. J. The effect of aquaporin-4
<ul> <li>https://doi.org/10.1016/j.nbd.2023.106100</li> <li>Burfeind, K. G. et al. The effects of noncoding aquaporin-4 single-nucleotide polymorphisms on cognition and functional progression of Alzheimer's disease. Alzheimers Dement (N Y) 3, 348-359 (2017). https://doi.org/10.1016/j.trci.2017.05.001</li> <li>Zeppenfeld, D. M. et al. Association of Perivascular Localization of Aquaporin-4 With Cognition and Alzheimer Disease in Aging Brains. JAMA Neurol 74, 91-99 (2017). https://doi.org/10.1001/jamaneurol.2016.4370</li> <li>Simon, M. J. et al. Transcriptional network analysis of human astrocytic endfoot genes reveals region-specific associations with dementia status and tau pathology. Sci Rep 8, 12389 (2018). https://doi.org/10.1038/s41598-018-30779-x</li> <li>Instrumentation, A. N. S. I. A. f. A. o. M. Vol. EC12:2000/(R)2020 (2020).</li> <li>Ayllon, D., Seoane, F. &amp; Gil-Pita, R. Cole equation and parameter estimation from electrical bioimpedance spectroscopy measurements - A comparative study. Annu Int Conf IEEE Eng Med Biol Soc 2009, 3779-3782 (2009). https://doi.org/10.1109/IEMBS.2009.5334494</li> <li>De Lorenzo, A., Andreoli, A., Matthie, J. &amp; Withers, P. Predicting body cell mass with bioimpedance by using theoretical methods: a technological review. J Appl Physiol (1985) 82, 1542-1558 (1997). https://doi.org/10.1152/jappl.1997.82.5.1542</li> <li>Gabriel, S., Lau, R. W. &amp; Gabriel, C. The dielectric properties of biological tissues: III. Parametric models for the dielectric spectrum of tissues. Phys Med Biol 41, 2271-2293 (1996). https://doi.org/10.1088/0031-9155/41/11/003</li> <li>Welch, P. The use of the fast Fourier transform for the estimation of power spectra: A method based on time averaging over short, modified periodograms. IEEE Trans. Audio Electroacoust 15, 70-73 (1967).</li> <li>Vallat, R. &amp; Walker, M. P. An open-source, high-performance tool for automated sleep staging. Elife 10 (2021). https://doi.org/10.7554/eLife.70092</li> <li>Vullat, R. &amp; Walker,</li></ul>	1738		mis-localization on Aβ deposition in mice. Neurobiol Dis 181, 106100 (2023).
<ul> <li>S4 Burfeind, K. G. <i>et al.</i> The effects of noncoding aquaporin-4 single-nucleotide polymorphisms on cognition and functional progression of Alzheimer's disease. <i>Alzheimers Dement (N Y)</i> 3, 348-359 (2017). https://doi.org/10.1016/j.trci.2017.05.001</li> <li>Zeppenfeld, D. M. <i>et al.</i> Association of Perivascular Localization of Aquaporin-4 With Cognition and Alzheimer Disease in Aging Brains. <i>JAMA Neurol</i> 74, 91-99 (2017). https://doi.org/10.1001/jamaneurol.2016.4370</li> <li>Simon, M. J. <i>et al.</i> Transcriptional network analysis of human astrocytic endfoot genes reveals region-specific associations with dementia status and tau pathology. <i>Sci Rep</i> 8, 12389 (2018). https://doi.org/10.1038/s41598-018-30779-x</li> <li>Instrumentation, A. N. S. I. A. F. A. o. M. Vol. EC12:2000/(R)2020 (2020).</li> <li>Ayllon, D., Seoane, F. &amp; Gil-Pita, R. Cole equation and parameter estimation from electrical bioimpedance spectroscopy measurements - A comparative study. <i>Annu Int Conf IEEE Eng Med Biol Soc</i> 2009, 3779-3782 (2009). https://doi.org/10.1109/IEMBS.2009.5334494</li> <li>De Lorenzo, A., Andreoli, A., Matthie, J. &amp; Withers, P. Predicting body cell mass with bioimpedance by using theoretical methods: a technological review. <i>J Appl Physiol (1985)</i> 82, 1542-1558 (1997). https://doi.org/10.1152/jappl.1997.82.5.1542</li> <li>Gabriel, S., Lau, R. W. &amp; Gabriel, C. The dielectric properties of biological tissues: III. Parametric models for the dielectric spectrum of tissues. <i>Phys Med Biol</i> 41, 2271-2293 (1996). https://doi.org/10.1088/0319-155/41/11/003</li> <li>Welch, P. The use of the fast Fourier transform for the estimation of power spectra: A method based on time averaging over short, modified periodograms. <i>IEEE Trans. Audio Electroacoust</i> 15, 70-73 (1967).</li> <li>Vallat, R. &amp; Walker, M. P. An open-source, high-performance tool for automated sleep staging. <i>Elife</i> 10 (2021). https://doi.org/10.21055/a/2Life.70092</li> <li>Quinn, A. J., Lopes-Dos-Santos, V., Dupret, D., N</li></ul>	1739		https://doi.org/10.1016/j.nbd.2023.106100
<ul> <li>polymorphisms on cognition and functional progression of Alzheimer's disease. <i>Alzheimers Dement (N Y)</i> <b>3</b>, 348-359 (2017). https://doi.org/10.1016/j.trci.2017.05.001</li> <li>Zeppenfeld, D. M. et al. Association of Perivascular Localization of Aquaporin-4 With Cognition and Alzheimer Disease in Aging Brains. <i>JAMA Neurol</i> <b>74</b>, 91-99 (2017). https://doi.org/10.1001/jamaneurol.2016.4370</li> <li>Simon, M. J. et al. Transcriptional network analysis of human astrocytic endfoot genes reveals region-specific associations with dementia status and tau pathology. <i>Sci Rep</i> <b>8</b>, 12389 (2018). https://doi.org/10.1038/s41598-018-30779-x</li> <li>Instrumentation, A. N. S. I. A. f. A. o. M. Vol. EC12:2000/(R)2020 (2020).</li> <li>Ayllon, D., Scoane, F. &amp; Gil-Pita, R. Cole equation and parameter estimation from electrical bioimpedance spectroscopy measurements - A comparative study. <i>Annu Int</i> <i>Conf IEEE Eng Med Biol Soc</i> <b>2009</b>, 3779-3782 (2009).</li> <li>https://doi.org/10.1109/IEMBS.2009.5334494</li> <li>De Lorenzo, A., Andreoli, A., Matthie, J. &amp; Withers, P. Predicting body cell mass with bioimpedance by using theoretical methods: a technological review. <i>J Appl Physiol</i> (<i>1985</i>) <b>82</b>, 1542-1558 (1997). https://doi.org/10.1152/jappl.1997.82.5.1542</li> <li>Gabriel, S., Lau, R. W. &amp; Gabriel, C. The dielectric properties of biological tissues: III. Parametric models for the dielectric spectrum of tissues. <i>Phys Med Biol</i> <b>41</b>, 2271-2293 (1996). https://doi.org/10.1088/0031-9155/41/11/003</li> <li>Welch, P. The use of the fast Fourier transform for the estimation of power spectra: A method based on time averaging over short, modified periodograms. <i>IEEE Trans. Audio</i> <i>Electroacoust</i> <b>15</b>, 70-73 (1967).</li> <li>Vallat, R. &amp; Walker, M. P. An open-source, high-performance tool for automated sleep staging. <i>Elife</i> <b>10</b> (2021). https://doi.org/10.21105/joss.02977</li> <li>Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task</li></ul>	1740	54	Burfeind, K. G. et al. The effects of noncoding aquaporin-4 single-nucleotide
<ul> <li><i>Alzheimers Dement (Ñ Y)</i> <b>3</b>, 348-359 (2017). https://doi.org/10.1016/j.trci.2017.05.001</li> <li><i>Zeppenfeld</i>, D. M. <i>et al.</i> Association of Perivascular Localization of Aquaporin-4 With</li> <li>Cognition and Alzheimer Disease in Aging Brains. <i>JAMA Neurol</i> <b>74</b>, 91-99 (2017).</li> <li>https://doi.org/10.1001/jamaneurol.2016.4370</li> <li>Simon, M. J. <i>et al.</i> Transcriptional network analysis of human astrocytic endfoot genes</li> <li>reveals region-specific associations with dementia status and tau pathology. <i>Sci Rep</i> <b>8</b>,</li> <li>12389 (2018). https://doi.org/10.1038/s41598-018-30779-x</li> <li>Instrumentation, A. N. S. I. A. f. A. o. M. Vol. EC12:2000(R)2020 (2020).</li> <li>Ayllon, D., Seoane, F. &amp; Gil-Pita, R. Cole equation and parameter estimation from</li> <li>electrical bioimpedance spectroscopy measurements - A comparative study. <i>Annu Int</i></li> <li><i>Conf IEEE Eng Med Biol Soc</i> <b>2009</b>, 3779-3782 (2009).</li> <li>https://doi.org/10.1109/IEMBS.2009.5334494</li> <li>De Lorenzo, A., Andreoli, A., Matthie, J. &amp; Withers, P. Predicting body cell mass with</li> <li>bioimpedance by using theoretical methods: a technological review. <i>J Appl Physiol</i></li> <li>(<i>1985</i>) <b>82</b>, 1542-1558 (1997). https://doi.org/10.1152/jappl.1997.82.5.1542</li> <li>Gabriel, S., Lau, R. W. &amp; Gabriel, C. The dielectric properties of biological tissues: III.</li> <li>Parametric models for the dielectric spectrum of tissues. <i>Phys Med Biol</i> <b>41</b>, 2271-2293</li> <li>(1996). https://doi.org/10.1088/0031-9155/41/11/003</li> <li>Welch, P. The use of the fast Fourier transform for the estimation of power spectra: A</li> <li>method based on time averaging over short, modified periodograms. <i>IEEE Trans. Audio</i></li> <li><i>Eletroacoust</i> <b>15</b>, 70-73 (1967).</li> <li>Vallat, R. &amp; Walker, M. P. An open-source, high-performance tool for automated sleep</li> <li>staging. <i>Elife</i> <b>10</b> (2021). https://doi.org/10.21105/joss.02977</li> <li>Heart r</li></ul>	1741		polymorphisms on cognition and functional progression of Alzheimer's disease.
<ul> <li>1743 55 Zeppenfeld, D. M. <i>et al.</i> Association of Perivascular Localization of Aquaporin-4 With Cognition and Alzheimer Disease in Aging Brains. <i>JAMA Neurol</i> 74, 91-99 (2017). https://doi.org/10.1001/jamaneurol.2016.4370</li> <li>1746 56 Simon, M. J. <i>et al.</i> Transcriptional network analysis of human astrocytic endfoot genes reveals region-specific associations with dementia status and tau pathology. <i>Sci Rep</i> 8, 12389 (2018). https://doi.org/10.1038/s41598-018-30779-x</li> <li>1747 10101111111111111111111111111111111</li></ul>	1742		Alzheimers Dement (N Y) 3, 348-359 (2017). https://doi.org/10.1016/j.trci.2017.05.001
<ul> <li>Cognition and Alzheimer Disease in Aging Brains. JAMA Neurol 74, 91-99 (2017). https://doi.org/10.1001/jamaneurol.2016.4370</li> <li>Simon, M. J. et al. Transcriptional network analysis of human astrocytic endfoot genes reveals region-specific associations with dementia status and tau pathology. Sci Rep 8, 12389 (2018). https://doi.org/10.1038/s41598-018-30779-x</li> <li>Instrumentation, A. N. S. I. A. f. A. o. M. Vol. EC12:2000/(R)2020 (2020).</li> <li>Ayllon, D., Seoane, F. &amp; Gil-Pita, R. Cole equation and parameter estimation from electrical bioimpedance spectroscopy measurements - A comparative study. Annu Int Conf IEEE Eng Med Biol Soc 2009, 3779-3782 (2009).</li> <li>https://doi.org/10.1109/IEMBS.2009.5334494</li> <li>De Lorenzo, A., Andreoli, A., Matthie, J. &amp; Withers, P. Predicting body cell mass with bioimpedance by using theoretical methods: a technological review. J Appl Physiol (1985) 82, 1542-1558 (1997). https://doi.org/10.1152/jappl.1997.82.5.1542</li> <li>Gabriel, S., Lau, R. W. &amp; Gabriel, C. The dielectric properties of biological tissues: III. Parametric models for the dielectric spectrum of tissues. Phys Med Biol 41, 2271-2293 (1996). https://doi.org/10.1088/0031-9155/41/11/003</li> <li>Welch, P. The use of the fast Fourier transform for the estimation of power spectra: A method based on time averaging over short, modified periodograms. IEEE Trans. Audio Electroacoust 15, 70-73 (1967).</li> <li>Vallat, R. &amp; Walker, M. P. An open-source, high-performance tool for automated sleep staging. Elife 10 (2021). https://doi.org/10.7554/cLife.70092</li> <li>Guin, A. J., Lopes-Dos-Santos, V., Dupret, D., Nobre, A. C. &amp; Woolrich, M. W. EMD: Empirical Mode Decomposition and Hilbert-Huag Spectral Analyses in Python. J Open Source Softw 6 (2021). https://doi.org/10.21105/joss.02977</li> <li>Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North Americ</li></ul>	1743	55	Zeppenfeld, D. M. et al. Association of Perivascular Localization of Aquaporin-4 With
<ul> <li>https://doi.org/10.1001/jamaneurol.2016.4370</li> <li>Simon, M. J. et al. Transcriptional network analysis of human astrocytic endfoot genes reveals region-specific associations with dementia status and tau pathology. Sci Rep 8, 12389 (2018). https://doi.org/10.1038/s41598-018-30779-x</li> <li>Instrumentation, A. N. S. I. A. f. A. o. M. Vol. EC12:2000/(R)2020 (2020).</li> <li>Ayllon, D., Seoane, F. &amp; Gil-Pita, R. Cole equation and parameter estimation from electrical bioimpedance spectroscopy measurements - A comparative study. Annu Int Conf IEEE Eng Med Biol Soc 2009, 3779-3782 (2009).</li> <li>https://doi.org/10.1109/IEMBS.2009.5334494</li> <li>De Lorenzo, A., Andreoli, A., Matthie, J. &amp; Withers, P. Predicting body cell mass with bioimpedance by using theoretical methods: a technological review. J Appl Physiol (1985) 82, 1542-1558 (1997). https://doi.org/10.1152/jappl.1997.82.5.1542</li> <li>Gabriel, S., Lau, R. W. &amp; Gabriel, C. The dielectric properties of biological tissues: III. Parametric models for the dielectric spectrum of tissues. Phys Med Biol 41, 2271-2293 (1996). https://doi.org/10.1088/0031-9155/41/11/003</li> <li>Welch, P. The use of the fast Fourier transform for the estimation of power spectra: A method based on time averaging over short, modified periodograms. IEEE Trans. Audio Electroacoust 15, 70-73 (1967).</li> <li>Vallat, R. &amp; Walker, M. P. An open-source, high-performance tool for automated sleep staging. Elife 10 (2021). https://doi.org/10.2155/4/Life.70092</li> <li>Vallat, R. &amp; Walker, M. P. An open-source, high-performance tool for automated sleep staging. Elife 10 (2021). https://doi.org/10.21105/joss.02977</li> <li>Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 93, 1043-1065 (1996).</li> <li>Janelidze, S. et al. Head-to-Head Comparison of 8 Plasma Amyloid</li></ul>	1744		Cognition and Alzheimer Disease in Aging Brains. JAMA Neurol 74, 91-99 (2017).
<ul> <li>Simon, M. J. <i>et al.</i> Transcriptional network analysis of human astrocytic endfoot genes reveals region-specific associations with dementia status and tau pathology. <i>Sci Rep</i> 8, 12389 (2018). https://doi.org/10.1038/s41598-018-30779-x</li> <li>Instrumentation, A. N. S. I. A. f. A. o. M. Vol. EC12:2000/(R)2020 (2020).</li> <li>Ayllon, D., Seoane, F. &amp; Gil-Pita, R. Cole equation and parameter estimation from electrical bioimpedance spectroscopy measurements - A comparative study. <i>Annu Int</i> <i>Conf IEEE Eng Med Biol Soc</i> 2009, 3779-3782 (2009).</li> <li>https://doi.org/10.1109/IEMBS.2009.5334494</li> <li>De Lorenzo, A., Andreoli, A., Matthie, J. &amp; Withers, P. Predicting body cell mass with bioimpedance by using theoretical methods: a technological review. <i>J Appl Physiol</i> (<i>1985</i>) 82, 1542-1558 (1997). https://doi.org/10.1152/jappl.1997.82.5.1542</li> <li>Gabriel, S., Lau, R. W. &amp; Gabriel, C. The dielectric properties of biological tissues: III.</li> <li>Parametric models for the dielectric spectrum of tissues. <i>Phys Med Biol</i> 41, 2271-2293 (1996). https://doi.org/10.1088/0031-9155/4/1/11/003</li> <li>Welch, P. The use of the fast Fourier transform for the estimation of power spectra: A method based on time averaging over short, modified periodograms. <i>IEEE Trans. Audio</i> <i>Electroacoust</i> 15, 70-73 (1967).</li> <li>Vallat, R. &amp; Walker, M. P. An open-source, high-performance tool for automated sleep staging. <i>Elife</i> 10 (2021). https://doi.org/10.7554/eLife.70092</li> <li>Quinn, A. J., Lopes-Dos-Santos, V., Dupret, D., Nobre, A. C. &amp; Woolrich, M. W. EMD: Empirical Mode Decomposition and Hilbert-Huang Spectral Analyses in Python. <i>J Open</i> <i>Source Softw</i> 6 (2021). https://doi.org/10.21105/joss.02977</li> <li>Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. <i>Circulation</i> 93, 1043-1065 (1996).</li> <li>Janelidze, S. <i>et al.</i> Head-to-Head Comparison of 8</li></ul>	1745		https://doi.org/10.1001/jamaneurol.2016.4370
<ul> <li>reveals region-specific associations with dementia status and tau pathology. <i>Sci Rep</i> 8, 12389 (2018). https://doi.org/10.1038/s41598-018-30779-x</li> <li>Instrumentation, A. N. S. I. A. f. A. o. M. Vol. EC12:2000(R)2020 (2020).</li> <li>Ayllon, D., Seoane, F. &amp; Gil-Pita, R. Cole equation and parameter estimation from electrical bioimpedance spectroscopy measurements - A comparative study. <i>Annu Int Conf IEEE Eng Med Biol Soc</i> 2009, 3779-3782 (2009).</li> <li>https://doi.org/10.1109/IEMBS.2009.5334494</li> <li>De Lorenzo, A., Andreoli, A., Matthie, J. &amp; Withers, P. Predicting body cell mass with bioimpedance by using theoretical methods: a technological review. <i>J Appl Physiol</i> (<i>1985</i>) 82, 1542-1558 (1997). https://doi.org/10.1152/jappl.1997.82.5.1542</li> <li>Gabriel, S., Lau, R. W. &amp; Gabriel, C. The dielectric properties of biological tissues: III. Parametric models for the dielectric spectrum of tissues. <i>Phys Med Biol</i> 41, 2271-2293 (1996). https://doi.org/10.1088/0031-9155/41/11/003</li> <li>Welch, P. The use of the fast Fourier transform for the estimation of power spectra: A method based on time averaging over short, modified periodograms. <i>IEEE Trans. Audio Electroacoust</i> 15, 70-73 (1967).</li> <li>Vallat, R. &amp; Walker, M. P. An open-source, high-performance tool for automated sleep staging. <i>Elife</i> 10 (2021). https://doi.org/10.7554/eLife.70092</li> <li>Quinn, A. J., Lopes-Dos-Santos, V., Dupret, D., Nobre, A. C. &amp; Woolrich, M. W. EMD: Empirical Mode Decomposition and Hilbert-Huang Spectral Analyses in Python. <i>J Open Source Softw</i> 6 (2021). https://doi.org/10.21105/joss.02977</li> <li>Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. <i>Circulation</i> 93, 1043-1065 (1996).</li> <li>Janelidze, S. <i>et al.</i> Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease. <i>JAMA Neurol</i> 78, 1375-1382 (2021).</li> <li>https://d</li></ul>	1746	56	Simon, M. J. et al. Transcriptional network analysis of human astrocytic endfoot genes
<ul> <li>12389 (2018). https://doi.org/10.1038/s41598-018-30779-x</li> <li>1749 57 Instrumentation, A. N. S. I. A. f. A. o. M. Vol. EC12:2000/(R)2020 (2020).</li> <li>1750 58 Ayllon, D., Seoane, F. &amp; Gil-Pita, R. Cole equation and parameter estimation from electrical bioimpedance spectroscopy measurements - A comparative study. <i>Annu Int Conf IEEE Eng Med Biol Soc</i> 2009, 3779-3782 (2009).</li> <li>1751 https://doi.org/10.1109/IEMBS.2009.5334494</li> <li>1754 59 De Lorenzo, A., Andreoli, A., Matthie, J. &amp; Withers, P. Predicting body cell mass with bioimpedance by using theoretical methods: a technological review. <i>J Appl Physiol</i> (<i>1985)</i> 82, 1542-1558 (1997). https://doi.org/10.1152/jappl.1997.82.5.1542</li> <li>1756 Gabriel, S., Lau, R. W. &amp; Gabriel, C. The dielectric properties of biological tissues: III. Parametric models for the dielectric spectrum of tissues. <i>Phys Med Biol</i> 41, 2271-2293 (1996). https://doi.org/10.1088/0031-9155/41/11/003</li> <li>1760 61 Welch, P. The use of the fast Fourier transform for the estimation of power spectra: A method based on time averaging over short, modified periodograms. <i>IEEE Trans. Audio Electroacoust</i> 15, 70-73 (1967).</li> <li>1763 62 Vallat, R. &amp; Walker, M. P. An open-source, high-performance tool for automated sleep staging. <i>Elife</i> 10 (2021). https://doi.org/10.21105/joss.02977</li> <li>1768 63 Quinn, A. J., Lopes-Dos-Santos, V., Dupret, D., Nobre, A. C. &amp; Woolrich, M. W. EMD: Empirical Mode Decomposition and Hilbert-Huang Spectral Analyses in Python. J Open Source Softw 6 (2021). https://doi.org/10.21105/joss.02977</li> <li>1768 64 Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. <i>Circulation</i> 93, 1043-1065 (1996).</li> <li>1771 65 Janelidze, S. <i>et al.</i> Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease. <i>JAMA Neurol</i> 78, 1375-1382 (2021).</li> <li>https://doi.org/10.100</li></ul>	1747		reveals region-specific associations with dementia status and tau pathology. Sci Rep 8,
<ul> <li>1749 57 Instrumentation, A. N. S. I. A. f. A. o. M. Vol. EC12:2000/(R)2020 (2020).</li> <li>1750 58 Ayllon, D., Seoane, F. &amp; Gil-Pita, R. Cole equation and parameter estimation from</li> <li>1751 electrical bioimpedance spectroscopy measurements - A comparative study. <i>Annu Int</i></li> <li>1752 <i>Conf IEEE Eng Med Biol Soc</i> 2009, 3779-3782 (2009).</li> <li>1753 https://doi.org/10.1109/IEMBS.2009.5334494</li> <li>1754 59 De Lorenzo, A., Andreoli, A., Matthie, J. &amp; Withers, P. Predicting body cell mass with</li> <li>1756 bioimpedance by using theoretical methods: a technological review. <i>J Appl Physiol</i></li> <li>1756 (<i>1985</i>) 82, 1542-1558 (1997). https://doi.org/10.1152/jappl.1997.82.5.1542</li> <li>1757 60 Gabriel, S., Lau, R. W. &amp; Gabriel, C. The dielectric properties of biological tissues: III.</li> <li>1758 Parametric models for the dielectric spectrum of tissues. <i>Phys Med Biol</i> 41, 2271-2293</li> <li>(1996). https://doi.org/10.1088/0031-9155/41/11/003</li> <li>1760 61 Welch, P. The use of the fast Fourier transform for the estimation of power spectra: A</li> <li>1761 method based on time averaging over short, modified periodograms. <i>IEEE Trans. Audio</i></li> <li>1762 <i>Electroacoust</i> 15, 70-73 (1967).</li> <li>1763 62 Vallat, R. &amp; Walker, M. P. An open-source, high-performance tool for automated sleep</li> <li>1764 staging. <i>Elife</i> 10 (2021). https://doi.org/10.7554/cLife.70092</li> <li>1765 63 Quinn, A. J., Lopes-Dos-Santos, V., Dupret, D., Nobre, A. C. &amp; Woolrich, M. W. EMD:</li> <li>1766 Empirical Mode Decomposition and Hilbert-Huang Spectral Analyses in Python. <i>J Open</i></li> <li>1769 <i>Source Softw</i> 6 (2021). https://doi.org/10.21105/joss.02977</li> <li>1768 64 Heart rate variability: standards of measurement, physiological interpretation and clinical</li> <li>1769 use. Task Force of the European Society of Cardiology and the North American Society</li> <li>1770 of Pacing and Electrophysiology. <i>Circulation</i> 93, 1043-1065 (1996).</li> <li>1771 Alzheimer Disease. <i>JAMA Neurol</i> 78, 1375-1382 (2021).<!--</td--><td>1748</td><td></td><td>12389 (2018). https://doi.org/10.1038/s41598-018-30779-x</td></li></ul>	1748		12389 (2018). https://doi.org/10.1038/s41598-018-30779-x
<ul> <li>Ayllon, D., Seoane, F. &amp; Gil-Pita, R. Cole equation and parameter estimation from electrical bioimpedance spectroscopy measurements - A comparative study. <i>Annu Int</i> <i>Conf IEEE Eng Med Biol Soc</i> 2009, 3779-3782 (2009).</li> <li>https://doi.org/10.1109/IEMBS.2009.5334494</li> <li>De Lorenzo, A., Andreoli, A., Matthie, J. &amp; Withers, P. Predicting body cell mass with bioimpedance by using theoretical methods: a technological review. <i>J Appl Physiol</i> <i>(1985)</i> 82, 1542-1558 (1997). https://doi.org/10.1152/jappl.1997.82.5.1542</li> <li>Gabriel, S., Lau, R. W. &amp; Gabriel, C. The dielectric properties of biological tissues: III. Parametric models for the dielectric spectrum of tissues. <i>Phys Med Biol</i> 41, 2271-2293 (1996). https://doi.org/10.1088/0031-9155/41/11/003</li> <li>Welch, P. The use of the fast Fourier transform for the estimation of power spectra: A method based on time averaging over short, modified periodograms. <i>IEEE Trans. Audio</i> <i>Electroacoust</i> 15, 70-73 (1967).</li> <li>Vallat, R. &amp; Walker, M. P. An open-source, high-performance tool for automated sleep staging. <i>Elife</i> 10 (2021). https://doi.org/10.7554/eLife.70092</li> <li>Quinn, A. J., Lopes-Dos-Santos, V., Dupret, D., Nobre, A. C. &amp; Woolrich, M. W. EMD: Empirical Mode Decomposition and Hilbert-Huang Spectral Analyses in Python. <i>J Open</i> <i>Source Softw</i> 6 (2021). https://doi.org/10.21105/joss.02977</li> <li>Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. <i>Circulation</i> 93, 1043-1065 (1996).</li> <li>Janelidze, S. <i>et al.</i> Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease. <i>JAMA Neurol</i> 78, 1375-1382 (2021). https://doi.org/10.1001/jamaneurol.2021.3180</li> <li>Roberts, K. F. <i>et al.</i> Amyloid-8 fflux from the central nervous system into the plasma</li> </ul>	1749	57	Instrumentation, A. N. S. I. A. f. A. o. M. Vol. EC12:2000/(R)2020 (2020).
<ul> <li>lectrical bioimpedance spectroscopy measurements - A comparative study. Annu Int Conf IEEE Eng Med Biol Soc 2009, 3779-3782 (2009).</li> <li>https://doi.org/10.1109/IEMBS.2009.5334494</li> <li>S9 De Lorenzo, A., Andreoli, A., Matthie, J. &amp; Withers, P. Predicting body cell mass with bioimpedance by using theoretical methods: a technological review. J Appl Physiol (1985) 82, 1542-1558 (1997). https://doi.org/10.1152/jappl.1997.82.5.1542</li> <li>Gabriel, S., Lau, R. W. &amp; Gabriel, C. The dielectric properties of biological tissues: III. Parametric models for the dielectric spectrum of tissues. Phys Med Biol 41, 2271-2293 (1996). https://doi.org/10.1088/0031-9155/41/11/003</li> <li>Welch, P. The use of the fast Fourier transform for the estimation of power spectra: A method based on time averaging over short, modified periodograms. IEEE Trans. Audio Electroacoust 15, 70-73 (1967).</li> <li>Vallat, R. &amp; Walker, M. P. An open-source, high-performance tool for automated sleep staging. Elife 10 (2021). https://doi.org/10.7554/eLife.70092</li> <li>Quinn, A. J., Lopes-Dos-Santos, V., Dupret, D., Nobre, A. C. &amp; Woolrich, M. W. EMD: Empirical Mode Decomposition and Hilbert-Huang Spectral Analyses in Python. J Open Source Softw 6 (2021). https://doi.org/10.21105/joss.02977</li> <li>Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 93, 1043-1065 (1996).</li> <li>Janelidze, S. et al. Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease. JAMA Neurol 78, 1375-1382 (2021). https://doi.org/10.1001/jamaneurol.2021.3180</li> <li>https://doi.org/10.1001/jamaneurol.2021.3180</li> </ul>	1750	58	Ayllon, D., Seoane, F. & Gil-Pita, R. Cole equation and parameter estimation from
<ul> <li><i>Conf IEEE Eng Med Biol Soc</i> 2009, 3779-3782 (2009).</li> <li>https://doi.org/10.1109/IEMBS.2009.5334494</li> <li>De Lorenzo, A., Andreoli, A., Matthie, J. &amp; Withers, P. Predicting body cell mass with bioimpedance by using theoretical methods: a technological review. J Appl Physiol (1985) 82, 1542-1558 (1997). https://doi.org/10.1152/jappl.1997.82.5.1542</li> <li>Gabriel, S., Lau, R. W. &amp; Gabriel, C. The dielectric properties of biological tissues: III. Parametric models for the dielectric spectrum of tissues. <i>Phys Med Biol</i> 41, 2271-2293 (1996). https://doi.org/10.1088/0031-9155/41/11/003</li> <li>Welch, P. The use of the fast Fourier transform for the estimation of power spectra: A method based on time averaging over short, modified periodograms. <i>IEEE Trans. Audio Electroacoust</i> 15, 70-73 (1967).</li> <li>Vallat, R. &amp; Walker, M. P. An open-source, high-performance tool for automated sleep staging. <i>Elife</i> 10 (2021). https://doi.org/10.7554/eLife.70092</li> <li>Quinn, A. J., Lopes-Dos-Santos, V., Dupret, D., Nobre, A. C. &amp; Woolrich, M. W. EMD: Empirical Mode Decomposition and Hilbert-Huang Spectral Analyses in Python. <i>J Open Source Softw</i> 6 (2021). https://doi.org/10.21105/joss.02977</li> <li>Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. <i>Circulation</i> 93, 1043-1065 (1996).</li> <li>Janelidze, S. <i>et al.</i> Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease. <i>JAMA Neurol</i> 78, 1375-1382 (2021).</li> <li>https://doi.org/10.101/jamaneurol.2021.3180</li> <li>Boetts, K. F. <i>et al.</i> Amyloid-β efflux from the central nervous system into the plasma</li> </ul>	1751		electrical bioimpedance spectroscopy measurements - A comparative study. Annu Int
<ul> <li>https://doi.org/10.1109/IEMBS.2009.5334494</li> <li>De Lorenzo, A., Andreoli, A., Matthie, J. &amp; Withers, P. Predicting body cell mass with bioimpedance by using theoretical methods: a technological review. <i>J Appl Physiol</i> (<i>1985</i>) 82, 1542-1558 (1997). https://doi.org/10.1152/jappl.1997.82.5.1542</li> <li>Gabriel, S., Lau, R. W. &amp; Gabriel, C. The dielectric properties of biological tissues: III. Parametric models for the dielectric spectrum of tissues. <i>Phys Med Biol</i> 41, 2271-2293 (1996). https://doi.org/10.1088/0031-9155/41/11/003</li> <li>Welch, P. The use of the fast Fourier transform for the estimation of power spectra: A method based on time averaging over short, modified periodograms. <i>IEEE Trans. Audio</i> <i>Electroacoust</i> 15, 70-73 (1967).</li> <li>Vallat, R. &amp; Walker, M. P. An open-source, high-performance tool for automated sleep staging. <i>Elife</i> 10 (2021). https://doi.org/10.7554/eLife.70092</li> <li>Quinn, A. J., Lopes-Dos-Santos, V., Dupret, D., Nobre, A. C. &amp; Woolrich, M. W. EMD: Empirical Mode Decomposition and Hilbert-Huang Spectral Analyses in Python. <i>J Open</i> <i>Source Softw</i> 6 (2021). https://doi.org/10.21105/joss.02977</li> <li>Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. <i>Circulation</i> 93, 1043-1065 (1996).</li> <li>Janelidze, S. <i>et al.</i> Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease. <i>JAMA Neurol</i> 78, 1375-1382 (2021). https://doi.org/10.101/jamaneurol.2021.3180</li> <li>Boerts, K. F. <i>et al.</i> Amyloid-β efflux from the central nervous system into the plasma</li> </ul>	1752		Conf IEEE Eng Med Biol Soc 2009, 3779-3782 (2009).
<ul> <li>De Lorenzo, A., Andreoli, A., Matthie, J. &amp; Withers, P. Predicting body cell mass with bioimpedance by using theoretical methods: a technological review. <i>J Appl Physiol</i> (<i>1985</i>) 82, 1542-1558 (1997). https://doi.org/10.1152/jappl.1997.82.5.1542</li> <li>Gabriel, S., Lau, R. W. &amp; Gabriel, C. The dielectric properties of biological tissues: III.</li> <li>Parametric models for the dielectric spectrum of tissues. <i>Phys Med Biol</i> 41, 2271-2293 (1996). https://doi.org/10.1088/0031-9155/41/11/003</li> <li>Welch, P. The use of the fast Fourier transform for the estimation of power spectra: A method based on time averaging over short, modified periodograms. <i>IEEE Trans. Audio</i> <i>Electroacoust</i> 15, 70-73 (1967).</li> <li>Vallat, R. &amp; Walker, M. P. An open-source, high-performance tool for automated sleep staging. <i>Elife</i> 10 (2021). https://doi.org/10.7554/eLife.70092</li> <li>Quinn, A. J., Lopes-Dos-Santos, V., Dupret, D., Nobre, A. C. &amp; Woolrich, M. W. EMD: Empirical Mode Decomposition and Hilbert-Huang Spectral Analyses in Python. <i>J Open</i> <i>Source Softw</i> 6 (2021). https://doi.org/10.21105/joss.02977</li> <li>Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. <i>Circulation</i> 93, 1043-1065 (1996).</li> <li>Janelidze, S. <i>et al.</i> Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease. <i>JAMA Neurol</i> 78, 1375-1382 (2021). https://doi.org/10.1001/jamaneurol.2021.3180</li> <li>Roberts, K. F. <i>et al.</i> Amyloid-β efflux from the central nervous system into the plasma</li> </ul>	1753		https://doi.org/10.1109/IEMBS.2009.5334494
<ul> <li>bioimpedance by using theoretical methods: a technological review. J Appl Physiol (1985) 82, 1542-1558 (1997). https://doi.org/10.1152/jappl.1997.82.5.1542</li> <li>Gabriel, S., Lau, R. W. &amp; Gabriel, C. The dielectric properties of biological tissues: III.</li> <li>Parametric models for the dielectric spectrum of tissues. Phys Med Biol 41, 2271-2293 (1996). https://doi.org/10.1088/0031-9155/41/11/003</li> <li>Welch, P. The use of the fast Fourier transform for the estimation of power spectra: A method based on time averaging over short, modified periodograms. IEEE Trans. Audio Electroacoust 15, 70-73 (1967).</li> <li>Vallat, R. &amp; Walker, M. P. An open-source, high-performance tool for automated sleep staging. Elife 10 (2021). https://doi.org/10.7554/eLife.70092</li> <li>Quinn, A. J., Lopes-Dos-Santos, V., Dupret, D., Nobre, A. C. &amp; Woolrich, M. W. EMD: Empirical Mode Decomposition and Hilbert-Huang Spectral Analyses in Python. J Open Source Softw 6 (2021). https://doi.org/10.21105/joss.02977</li> <li>Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 93, 1043-1065 (1996).</li> <li>Janelidze, S. et al. Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease. JAMA Neurol 78, 1375-1382 (2021). https://doi.org/10.211.3180</li> <li>Roberts, K. F. et al. Amyloid-β flux from the central nervous system into the plasma</li> </ul>	1754	59	De Lorenzo, A., Andreoli, A., Matthie, J. & Withers, P. Predicting body cell mass with
<ul> <li>(1985) 82, 1542-1558 (1997). https://doi.org/10.1152/jappl.1997.82.5.1542</li> <li>Gabriel, S., Lau, R. W. &amp; Gabriel, C. The dielectric properties of biological tissues: III.</li> <li>Parametric models for the dielectric spectrum of tissues. <i>Phys Med Biol</i> 41, 2271-2293</li> <li>(1996). https://doi.org/10.1088/0031-9155/41/11/003</li> <li>Welch, P. The use of the fast Fourier transform for the estimation of power spectra: A</li> <li>method based on time averaging over short, modified periodograms. <i>IEEE Trans. Audio</i></li> <li><i>Electroacoust</i> 15, 70-73 (1967).</li> <li>Vallat, R. &amp; Walker, M. P. An open-source, high-performance tool for automated sleep</li> <li>staging. <i>Elife</i> 10 (2021). https://doi.org/10.7554/eLife.70092</li> <li>Quinn, A. J., Lopes-Dos-Santos, V., Dupret, D., Nobre, A. C. &amp; Woolrich, M. W. EMD:</li> <li>Empirical Mode Decomposition and Hilbert-Huang Spectral Analyses in Python. <i>J Open</i></li> <li><i>Source Softw</i> 6 (2021). https://doi.org/10.21105/joss.02977</li> <li>Heart rate variability: standards of measurement, physiological interpretation and clinical</li> <li>use. Task Force of the European Society of Cardiology and the North American Society</li> <li>of Pacing and Electrophysiology. <i>Circulation</i> 93, 1043-1065 (1996).</li> <li>Janelidze, S. et al. Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in</li> <li>Alzheimer Disease. <i>JAMA Neurol</i> 78, 1375-1382 (2021).</li> <li>https://doi.org/10.1001/jamaneurol.2021.3180</li> <li>Roberts, K. F. et al. Amyloid-β efflux from the central nervous system into the plasma</li> </ul>	1755		bioimpedance by using theoretical methods: a technological review. J Appl Physiol
<ul> <li>Gabriel, S., Lau, R. W. &amp; Gabriel, C. The dielectric properties of biological tissues: III.</li> <li>Parametric models for the dielectric spectrum of tissues. <i>Phys Med Biol</i> 41, 2271-2293 (1996). <a href="https://doi.org/10.1088/0031-9155/41/11/003">https://doi.org/10.1088/0031-9155/41/11/003</a></li> <li>Welch, P. The use of the fast Fourier transform for the estimation of power spectra: A method based on time averaging over short, modified periodograms. <i>IEEE Trans. Audio Electroacoust</i> 15, 70-73 (1967).</li> <li>Vallat, R. &amp; Walker, M. P. An open-source, high-performance tool for automated sleep staging. <i>Elife</i> 10 (2021). <a href="https://doi.org/10.7554/eLife.70092">https://doi.org/10.7554/eLife.70092</a></li> <li>Quinn, A. J., Lopes-Dos-Santos, V., Dupret, D., Nobre, A. C. &amp; Woolrich, M. W. EMD: Empirical Mode Decomposition and Hilbert-Huang Spectral Analyses in Python. <i>J Open Source Softw</i> 6 (2021). <a href="https://doi.org/10.21105/joss.02977">https://doi.org/10.21105/joss.02977</a></li> <li>Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. <i>Circulation</i> 93, 1043-1065 (1996).</li> <li>Janelidze, S. <i>et al.</i> Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease. <i>JAMA Neurol</i> 78, 1375-1382 (2021). <a href="https://doi.org/10.1001/jamaneurol.2021.3180">https://doi.org/10.1001/jamaneurol.2021.3180</a></li> </ul>	1756		(1985) 82, 1542-1558 (1997). https://doi.org/10.1152/jappl.1997.82.5.1542
<ul> <li>Parametric models for the dielectric spectrum of tissues. <i>Phys Med Biol</i> 41, 2271-2293 (1996). https://doi.org/10.1088/0031-9155/41/11/003</li> <li>Welch, P. The use of the fast Fourier transform for the estimation of power spectra: A method based on time averaging over short, modified periodograms. <i>IEEE Trans. Audio Electroacoust</i> 15, 70-73 (1967).</li> <li>Vallat, R. &amp; Walker, M. P. An open-source, high-performance tool for automated sleep staging. <i>Elife</i> 10 (2021). https://doi.org/10.7554/eLife.70092</li> <li>Quinn, A. J., Lopes-Dos-Santos, V., Dupret, D., Nobre, A. C. &amp; Woolrich, M. W. EMD: Empirical Mode Decomposition and Hilbert-Huang Spectral Analyses in Python. <i>J Open Source Softw</i> 6 (2021). https://doi.org/10.21105/joss.02977</li> <li>Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. <i>Circulation</i> 93, 1043-1065 (1996).</li> <li>Janelidze, S. <i>et al.</i> Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease. <i>JAMA Neurol</i> 78, 1375-1382 (2021). https://doi.org/10.1001/jamaneurol.2021.3180</li> </ul>	1757	60	Gabriel, S., Lau, R. W. & Gabriel, C. The dielectric properties of biological tissues: III.
<ul> <li>(1996). https://doi.org/10.1088/0031-9155/41/11/003</li> <li>Welch, P. The use of the fast Fourier transform for the estimation of power spectra: A method based on time averaging over short, modified periodograms. <i>IEEE Trans. Audio Electroacoust</i> 15, 70-73 (1967).</li> <li>Vallat, R. &amp; Walker, M. P. An open-source, high-performance tool for automated sleep staging. <i>Elife</i> 10 (2021). https://doi.org/10.7554/eLife.70092</li> <li>Quinn, A. J., Lopes-Dos-Santos, V., Dupret, D., Nobre, A. C. &amp; Woolrich, M. W. EMD: Empirical Mode Decomposition and Hilbert-Huang Spectral Analyses in Python. <i>J Open Source Softw</i> 6 (2021). https://doi.org/10.21105/joss.02977</li> <li>Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. <i>Circulation</i> 93, 1043-1065 (1996).</li> <li>Janelidze, S. <i>et al.</i> Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease. <i>JAMA Neurol</i> 78, 1375-1382 (2021). https://doi.org/10.1001/jamaneurol.2021.3180</li> <li>Roberts, K. F. <i>et al.</i> Amyloid-β efflux from the central nervous system into the plasma</li> </ul>	1758		Parametric models for the dielectric spectrum of tissues. Phys Med Biol 41, 2271-2293
<ul> <li>Welch, P. The use of the fast Fourier transform for the estimation of power spectra: A method based on time averaging over short, modified periodograms. <i>IEEE Trans. Audio Electroacoust</i> 15, 70-73 (1967).</li> <li>Vallat, R. &amp; Walker, M. P. An open-source, high-performance tool for automated sleep staging. <i>Elife</i> 10 (2021). https://doi.org/10.7554/eLife.70092</li> <li>Quinn, A. J., Lopes-Dos-Santos, V., Dupret, D., Nobre, A. C. &amp; Woolrich, M. W. EMD: Empirical Mode Decomposition and Hilbert-Huang Spectral Analyses in Python. <i>J Open Source Softw</i> 6 (2021). https://doi.org/10.21105/joss.02977</li> <li>Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. <i>Circulation</i> 93, 1043-1065 (1996).</li> <li>Janelidze, S. <i>et al.</i> Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease. <i>JAMA Neurol</i> 78, 1375-1382 (2021). https://doi.org/10.1001/jamaneurol.2021.3180</li> <li>Roberts, K. F. <i>et al.</i> Amyloid-β efflux from the central nervous system into the plasma</li> </ul>	1759		(1996). https://doi.org/10.1088/0031-9155/41/11/003
<ul> <li>method based on time averaging over short, modified periodograms. <i>IEEE Trans. Audio</i> <i>Electroacoust</i> 15, 70-73 (1967).</li> <li>Vallat, R. &amp; Walker, M. P. An open-source, high-performance tool for automated sleep staging. <i>Elife</i> 10 (2021). <u>https://doi.org/10.7554/eLife.70092</u></li> <li>Quinn, A. J., Lopes-Dos-Santos, V., Dupret, D., Nobre, A. C. &amp; Woolrich, M. W. EMD: Empirical Mode Decomposition and Hilbert-Huang Spectral Analyses in Python. <i>J Open</i> <i>Source Softw</i> 6 (2021). <u>https://doi.org/10.21105/joss.02977</u></li> <li>Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. <i>Circulation</i> 93, 1043-1065 (1996).</li> <li>Janelidze, S. <i>et al.</i> Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease. <i>JAMA Neurol</i> 78, 1375-1382 (2021). <u>https://doi.org/10.1001/jamaneurol.2021.3180</u></li> <li>Roberts, K. F. <i>et al.</i> Amyloid-β efflux from the central nervous system into the plasma</li> </ul>	1760	61	Welch, P. The use of the fast Fourier transform for the estimation of power spectra: A
<ul> <li><i>Electroacoust</i> 15, 70-73 (1967).</li> <li>Vallat, R. &amp; Walker, M. P. An open-source, high-performance tool for automated sleep</li> <li>staging. <i>Elife</i> 10 (2021). https://doi.org/10.7554/eLife.70092</li> <li>Quinn, A. J., Lopes-Dos-Santos, V., Dupret, D., Nobre, A. C. &amp; Woolrich, M. W. EMD:</li> <li>Empirical Mode Decomposition and Hilbert-Huang Spectral Analyses in Python. <i>J Open</i></li> <li><i>Source Softw</i> 6 (2021). https://doi.org/10.21105/joss.02977</li> <li>Heart rate variability: standards of measurement, physiological interpretation and clinical</li> <li>use. Task Force of the European Society of Cardiology and the North American Society</li> <li>of Pacing and Electrophysiology. <i>Circulation</i> 93, 1043-1065 (1996).</li> <li>Janelidze, S. <i>et al.</i> Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in</li> <li>Alzheimer Disease. <i>JAMA Neurol</i> 78, 1375-1382 (2021).</li> <li>https://doi.org/10.1001/jamaneurol.2021.3180</li> <li>Roberts, K. F. <i>et al.</i> Amyloid-β efflux from the central nervous system into the plasma</li> </ul>	1761		method based on time averaging over short, modified periodograms. <i>IEEE Trans. Audio</i>
<ul> <li>Vallat, R. &amp; Walker, M. P. An open-source, high-performance tool for automated sleep</li> <li>staging. <i>Elife</i> 10 (2021). https://doi.org/10.7554/eLife.70092</li> <li>Quinn, A. J., Lopes-Dos-Santos, V., Dupret, D., Nobre, A. C. &amp; Woolrich, M. W. EMD:</li> <li>Empirical Mode Decomposition and Hilbert-Huang Spectral Analyses in Python. <i>J Open</i></li> <li><i>Source Softw</i> 6 (2021). https://doi.org/10.21105/joss.02977</li> <li>Heart rate variability: standards of measurement, physiological interpretation and clinical</li> <li>use. Task Force of the European Society of Cardiology and the North American Society</li> <li>of Pacing and Electrophysiology. <i>Circulation</i> 93, 1043-1065 (1996).</li> <li>Janelidze, S. <i>et al.</i> Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in</li> <li>Alzheimer Disease. <i>JAMA Neurol</i> 78, 1375-1382 (2021).</li> <li>https://doi.org/10.1001/jamaneurol.2021.3180</li> <li>Roberts, K. F. <i>et al.</i> Amyloid-β efflux from the central nervous system into the plasma</li> </ul>	1762		<i>Electroacoust</i> <b>15</b> , 70-73 (1967).
<ul> <li>staging. <i>Elife</i> 10 (2021). <u>https://doi.org/10.7554/eLife.70092</u></li> <li>Quinn, A. J., Lopes-Dos-Santos, V., Dupret, D., Nobre, A. C. &amp; Woolrich, M. W. EMD: Empirical Mode Decomposition and Hilbert-Huang Spectral Analyses in Python. <i>J Open</i> <i>Source Softw</i> 6 (2021). <u>https://doi.org/10.21105/joss.02977</u></li> <li>Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. <i>Circulation</i> 93, 1043-1065 (1996).</li> <li>Janelidze, S. <i>et al.</i> Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease. <i>JAMA Neurol</i> 78, 1375-1382 (2021).</li> <li>https://doi.org/10.1001/jamaneurol.2021.3180</li> <li>Roberts, K. F. <i>et al.</i> Amyloid-β efflux from the central nervous system into the plasma</li> </ul>	1763	62	Vallat, R. & Walker, M. P. An open-source, high-performance tool for automated sleep
<ul> <li>Quinn, A. J., Lopes-Dos-Santos, V., Dupret, D., Nobre, A. C. &amp; Woolrich, M. W. EMD: Empirical Mode Decomposition and Hilbert-Huang Spectral Analyses in Python. <i>J Open</i> <i>Source Softw</i> 6 (2021). <u>https://doi.org/10.21105/joss.02977</u></li> <li>Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. <i>Circulation</i> 93, 1043-1065 (1996).</li> <li>Janelidze, S. <i>et al.</i> Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease. <i>JAMA Neurol</i> 78, 1375-1382 (2021). <u>https://doi.org/10.1001/jamaneurol.2021.3180</u></li> <li>Roberts, K. F. <i>et al.</i> Amyloid-β efflux from the central nervous system into the plasma</li> </ul>	1764		staging. <i>Elife</i> <b>10</b> (2021). https://doi.org/10.7554/eLife.70092
<ul> <li>Empirical Mode Decomposition and Hilbert-Huang Spectral Analyses in Python. <i>J Open</i> <i>Source Softw</i> 6 (2021). <u>https://doi.org/10.21105/joss.02977</u></li> <li>Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. <i>Circulation</i> 93, 1043-1065 (1996).</li> <li>Janelidze, S. <i>et al.</i> Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease. <i>JAMA Neurol</i> 78, 1375-1382 (2021).</li> <li><u>https://doi.org/10.1001/jamaneurol.2021.3180</u></li> <li>Roberts, K. F. <i>et al.</i> Amyloid-β efflux from the central nervous system into the plasma</li> </ul>	1765	63	Quinn, A. J., Lopes-Dos-Santos, V., Dupret, D., Nobre, A. C. & Woolrich, M. W. EMD:
<ul> <li>Source Softw 6 (2021). https://doi.org/10.21105/joss.02977</li> <li>Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. <i>Circulation</i> 93, 1043-1065 (1996).</li> <li>Janelidze, S. <i>et al.</i> Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease. <i>JAMA Neurol</i> 78, 1375-1382 (2021).</li> <li>https://doi.org/10.1001/jamaneurol.2021.3180</li> <li>Roberts, K. F. <i>et al.</i> Amyloid-β efflux from the central nervous system into the plasma</li> </ul>	1766		Empirical Mode Decomposition and Hilbert-Huang Spectral Analyses in Python. J Open
<ul> <li>Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. <i>Circulation</i> 93, 1043-1065 (1996).</li> <li>Janelidze, S. <i>et al.</i> Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease. <i>JAMA Neurol</i> 78, 1375-1382 (2021).</li> <li>https://doi.org/10.1001/jamaneurol.2021.3180</li> <li>Roberts, K. F. <i>et al.</i> Amyloid-β efflux from the central nervous system into the plasma</li> </ul>	1767		Source Softw 6 (2021). https://doi.org/10.21105/joss.02977
<ul> <li>use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. <i>Circulation</i> 93, 1043-1065 (1996).</li> <li>Janelidze, S. <i>et al.</i> Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease. <i>JAMA Neurol</i> 78, 1375-1382 (2021).</li> <li>https://doi.org/10.1001/jamaneurol.2021.3180</li> <li>Roberts, K. F. <i>et al.</i> Amyloid-β efflux from the central nervous system into the plasma</li> </ul>	1768	64	Heart rate variability: standards of measurement, physiological interpretation and clinical
<ul> <li>of Pacing and Electrophysiology. <i>Circulation</i> 93, 1043-1065 (1996).</li> <li>Janelidze, S. <i>et al.</i> Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in</li> <li>Alzheimer Disease. <i>JAMA Neurol</i> 78, 1375-1382 (2021).</li> <li><u>https://doi.org/10.1001/jamaneurol.2021.3180</u></li> <li>Roberts, K. F. <i>et al.</i> Amyloid-β efflux from the central nervous system into the plasma</li> </ul>	1769		use. Task Force of the European Society of Cardiology and the North American Society
<ul> <li>1771 65 Janelidze, S. <i>et al.</i> Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in</li> <li>1772 Alzheimer Disease. <i>JAMA Neurol</i> 78, 1375-1382 (2021).</li> <li>1773 <u>https://doi.org/10.1001/jamaneurol.2021.3180</u></li> <li>1774 66 Roberts, K. F. <i>et al.</i> Amyloid-β efflux from the central nervous system into the plasma</li> </ul>	1770		of Pacing and Electrophysiology. Circulation 93, 1043-1065 (1996).
<ul> <li>Alzheimer Disease. JAMA Neurol 78, 1375-1382 (2021).</li> <li>https://doi.org/10.1001/jamaneurol.2021.3180</li> <li>Roberts, K. F. et al. Amyloid-β efflux from the central nervous system into the plasma</li> </ul>	1771	65	Janelidze, S. <i>et al.</i> Head-to-Head Comparison of 8 Plasma Amyloid-B 42/40 Assays in
<ul> <li>1773 <u>https://doi.org/10.1001/jamaneurol.2021.3180</u></li> <li>1774 66 Roberts, K. F. <i>et al.</i> Amyloid-β efflux from the central nervous system into the plasma</li> </ul>	1772		Alzheimer Disease. JAMA Neurol 78, 1375-1382 (2021).
1774 66 Roberts, K. F. <i>et al.</i> Amyloid-B efflux from the central nervous system into the plasma	1773		https://doi.org/10.1001/jamaneurol.2021.3180
1, $1$ $0$ $1$ $1000100, 10, 100000, 10000000000000000$	1774	66	Roberts, K. F. <i>et al.</i> Amyloid- $\beta$ efflux from the central nervous system into the plasma.
1775 Ann Neurol <b>76</b> , 837-844 (2014). <u>https://doi.org/10.1002/ana.24270</u>	1775		Ann Neurol 76, 837-844 (2014). https://doi.org/10.1002/ana.24270

1776	67	Liu, H. et al. Acute sleep loss decreases CSF-to-blood clearance of Alzheimer's disease
1777		biomarkers. Alzheimers Dement (2023). https://doi.org/10.1002/alz.12930
1778	68	Loh, S., Lamond, N., Dorrian, J., Roach, G. & Dawson, D. The validity of psychomotor
1779		vigilance tasks of less than 10-minute duration. Behav Res Methods Instrum Comput 36,
1780		339-346 (2004). https://doi.org/10.3758/bf03195580
1781	69	Arsintescu, L. et al. Validation of a touchscreen psychomotor vigilance task. Accid Anal
1782		Prev 126, 173-176 (2019). https://doi.org/10.1016/j.aap.2017.11.041
1783	70	Arbuthnott, K. & Frank, J. Trail making test, part B as a measure of executive control:
1784		validation using a set-switching paradigm. J Clin Exp Neuropsychol 22, 518-528 (2000).
1785		https://doi.org/10.1076/1380-3395(200008)22:4;1-0;FT518
1786	71	Digit Span (DGS), <https: cambridgecognition.com="" digit-span-dgs=""></https:> (
1787	72	<i>PVT Research Tool</i> , < <u>https://apps.apple.com/tr/app/pvt-research-tool/id1475726298&gt;(</u>
1788	73	Smith, A. Symbol Digit Modalities Test. (Western Psychological Association, 1992).
1789	74	Reitan, R. Trail Making Test: Manual for Administration and Scoring. (1992).
1790	75	Diagnostics, C. N. < <u>https://c2n.com/</u> > (
1791	76	Piantino, J. et al. Link between Mild Traumatic Brain Injury, Poor Sleep, and Magnetic
1792		Resonance Imaging: Visible Perivascular Spaces in Veterans. J Neurotrauma 38, 2391-
1793		2399 (2021), https://doi.org/10.1089/neu.2020.7447
1794	77	Boespflug, E. L. <i>et al.</i> MR Imaging-based Multimodal Autoidentification of Perivascular
1795		Spaces (mMAPS): Automated Morphologic Segmentation of Enlarged Perivascular
1796		Spaces at Clinical Field Strength. <i>Radiology</i> <b>286</b> , 632-642 (2018).
1797		https://doi.org/10.1148/radiol.2017170205
1798	78	Levendovszky, S. R. <i>et al.</i> Preliminary cross-sectional investigations into the human
1799		glymphatic system using multiple novel non-contrast MRI methods. <i>bioRxiv</i> (2023).
1800		https://doi.org/10.1101/2023.08.28.555150
1801	79	Ohene, Y. <i>et al.</i> Non-invasive MRI of brain clearance pathways using multiple echo time
1802		arterial spin labelling: an aquaporin-4 study. <i>Neuroimage</i> <b>188</b> , 515-523 (2019).
1803		https://doi.org/10.1016/i.neuroimage.2018.12.026
1804	80	Fultz, N. E. <i>et al.</i> Coupled electrophysiological, hemodynamic, and cerebrospinal fluid
1805		oscillations in human sleep. Science <b>366</b> , 628-631 (2019).
1806		https://doi.org/10.1126/science.aax5440
1807	81	Fong, Y., Huang, Y., Gilbert, P. B. & Permar, S. R. chngpt: threshold regression model
1808		estimation and inference. BMC Bioinformatics 18, 454 (2017).
1809		https://doi.org/10.1186/s12859-017-1863-x
1810	82	Fong, Y., Di, C. & Permar, S. Change point testing in logistic regression models with
1811		interaction term. Stat Med <b>34</b> , 1483-1494 (2015). https://doi.org/10.1002/sim.6419
1812	83	Farokhian, F., Yang, C., Beheshti, I., Matsuda, H. & Wu, S. Age-Related Gray and White
1813		Matter Changes in Normal Adult Brains. Aging Dis 8, 899-909 (2017).
1814		https://doi.org/10.14336/AD.2017.0502
1815	84	Ding, F. et al. Changes in the composition of brain interstitial ions control the sleep-wake
1816		cycle. Science <b>352</b> , 550-555 (2016). https://doi.org/10.1126/science.aad4821
1817	85	Sun, Y. & Sun, X. Exploring the interstitial system in the brain: the last mile of drug
1818	-	delivery. Rev Neurosci 32, 363-377 (2021). https://doi.org/10.1515/revneuro-2020-0057
1819	86	Hotelling, H. New light on the correlation coefficient and its transforms. <i>Journal of the</i>
1820		Royal Statistical Society. Series B (Methodological) <b>15.2</b> . 193-232 (1953).
1821		,